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1.1 Pathogenesis of atherosclerosis 
 
Cardiovascular diseases, including myocardial infarction and stroke, are the 
main cause of death in the Western world1. The main underlying pathology 
leading to these clinical manifestations is atherosclerosis. It is a progressive 
disease of the middle and large arteries characterized by lipid deposition, 
inflammation, cell death and fibrosis2-5. Atherosclerotic plaque development 
will lead to narrowing of the vessel, eventually resulting in downstream hypoxia 
and nutrient deprivation.  Finally, the rupture of a destabilized atherosclerotic 
plaque leads to more dramatic clinical events, and may induce sudden arterial 
occlusion due to thrombus formation. Depending on the affected artery, the 
ischemia resulting from the thrombus formation will lead to myocardial 
infarction, stroke or peripheral artery diseases such as intermittent claudication. 
In the last decades several risk factors for atherosclerosis have been identified 
including smoking, hyperlipidemia, hypertension, physical inactivity, diabetes 
and male sex6. Today, treatments are mostly based on the elimination of these 
identified risk factors and consist of lowering of serum lipid levels by statins, 
reduction of blood pressure and changes in life style.   
 
Adhesion and transmigration of leukocytes 
 
A healthy arterial wall consists of a tight endothelial cell layer covering the 
inner surface, elastic lamina and a surrounding layer of smooth muscle cells. 
Atherosclerotic lesion formation is initiated by increased adhesiveness of the 
endothelial cell layer7. Normally functioning healthy endothelium produces 
anti-inflammatory and anti-thrombotic agents that prevent large scale 
infiltration of leukocytes and thrombus formation8, 9. So-called “injury” of the 
endothelium due to risk factors discussed above, results in an increased 
permeability and adhesiveness of the vessel wall9. Endothelial cells enhance the 
expression of adhesion molecules and produce pro-inflammatory mediators 
including chemokines and interleukins10. 
The attracted leukocytes transmigrate though the endothelial layer in a multi-
step process in which the following stages can be identified; rolling on the 
endothelium, firm adhesion and transmigration to the sub-endothelial space11, 12. 
A schematic overview of this process is shown in figure 1.  
Deceleration of leukocyte rolling on the vessel wall is mediated by the selectin 
family, mainly E- and P-selectin13. The expression of these molecules is induced 
after vascular stress, and is the result of NFκB induced activation14-16. Firm 
adhesion of the now slowly rolling leukocyte is facilitated by intercellular 
adhesion molecule (ICAM)-1 and -2 and vascular adhesion molecule (VECAM)-
117, 18. Due to release of chemo-attractants and pro-inflammatory molecules, the 
attracted leukocytes get activated and upregulate the surface expression of 
integrins such as very late antigen (VLA)-4 and lymphocyte function associated 
antigen (LFA)-1.  These integrins function as counter-ligands for ICAM-1 and 
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VCAM-119-21. Additional molecules with adhesive properties on leukocytes are 
L-selectin, CD14 and P-selectin glycoprotein ligand (PSGL)-122. Shortly after 
firm adhesion, passage of the leukocyte through the endothelial junction is 
facilitated by the expression of platelet/endothelial cell adhesion molecule 
(PECAM)-1, junctional adhesion molecule (JAM)-1 and CD9923-27.  This process 
is also known as diapedesis. 
The process of leukocyte infiltration is accompanied by the release of 
chemokines and interleukins that modulate the activation state of both the 
endothelium as well as the entering leukocyte. The complex function and 
regulation of interleukins and chemokines is addressed in separate chapters 
below. 
 
Figure 1: schematic overview of leukocyte egress during atherogenesis 
Upon activation, the vascular wall increases the expression of proteins with adhesive properties such 
as E- and P-selectin and cell adhesion molecules (CAM’s). Transmigration of the leukocytes is 
mediated by endothelial junction proteins such as PECAM-1, junctional adhesion proteins (JAM’s) 




A high serum cholesterol level is one of the predominant risk factors associated 
with atherosclerosis and lipid deposition within the arterial wall is a 
characteristic of atherosclerotic plaques. As mentioned, leukocytes and in 
particular monocytes enter the sub-endothelial space after endothelial 
activation due to “injury”. Once invaded, they differentiate into macrophages 
and consistent with their role as scavenging cells, start to take up the modified 
lipoproteins present in the neo-intima28. In normal cells, cholesterol 
homeostasis is a tightly regulated process mainly controlled by feedback 
regulation of low density lipoprotein (LDL) receptor to balance cholesterol 
intake, and intracellular cholesterol level sensors in combination with sterol-
regulatory binding proteins (SREBP’s)29-31.  Scavenger receptor mediated uptake 





























cholesterol within a high cholesterol environment28. This excessive 
accumulation of cholesterol esters (CE) eventually leads to foam cell for-
mation32. 
These foamy macrophages are the primary constituents of the initial (non-
obstructive) atherosclerotic plaque, also called fatty streak. Next to macro-
phages, T lymphocytes, that further drive the inflammatory response, are also 
present. 
After the formation of a fatty streak, a more complex lesion can form. This 
process involves the additional influx of more leukocytes, small extra-cellular 
lipid deposits, and proliferation of vascular smooth muscle cells. Vascular 
smooth muscle cells migrate to form a fibrous cap on top of the growing lipid 
core33. The lipid core and fibrous cap are hallmarks of the so-called advanced 
atherosclerotic lesion. Ultimately, plaques form complex lesions that are 
partially necrotic, contain cholesterol crystals and calcified material. These 
advanced plaques are prone to rupture due to increased expression of matrix 
metalloproteinases and other cathepsins that are able to destabilize the fibrous 
cap. The increasing amount of apoptosis and necrosis within the plaque also 
contributes to destabilization34-37. Plaque rupture and the subsequent release of 
the pro-thrombogenic plaque content is the direct underlying cause of the 
majority of acute clinical manifestations such as MI and stroke. 
 
1.2 Finding new biological targets using genomics 
 
The genome of mammals consists of thousands of genes, and these genes result 
in a vast amount of RNA molecules (20000-25000) and their related proteins. 
The regulation of this important machinery is a complex and multi-factorial 
process, as the eventual expression level of the functional protein can depend on 
transcription rate, translation rate, and post translational modification such as 
phosphorylation.  
Common experiments in molecular biology are based on the “one gene, one 
experiment” design. This setup severely limits the amount of information 
generated per experiment as it only addresses the regulation of a chosen target. 
In the past decade, micro-arrays were developed that enabled the simultaneous 
monitoring of several genes at a time by spotting of cDNA or RNA probes on 
glass slides. Unravelling the total mouse and human genome facilitated the 
construction of whole genome arrays that were able to visualize the expression 
of thousands of genes in one experiment (for a schematic overview, see figure 
2).   
 
Expression profiles of different metabolic situations can be easily compared, 
leading to insight in the underlying mechanisms. These experiments however 
produce vast amounts of data that have to be analyzed in a reliable and orderly 
fashion, and generate new and complex statistical challenges.  
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In the field of atherosclerosis, several micro-array analyses have been performed 
to identify signature gene expression patterns for different disease stages. In the 
majority of these studies, entire vessels from animal models of atherogenesis 
were used to compare diseased to healthy vessel wall38-42. Clearly, this approach 
has a drawback with respect to the fact that the tissue used does contain 
multiple cell types, especially when comparing the healthy vessel wall with 
advanced atherosclerotic plaques with large leukocyte infiltrates. The observed 
regulatory profile is therefore hard to address, as it may predominantly result 
from the difference in sample composition only.  
 
Figure 2: Basic design of a micro-array study 
RNA is isolated from target tissue and labelled with fluorescent dyes. Samples from two different 
situations or 1 sample and a common reference are hybridized and subsequently the expression 
levels of all the transcripts present on the array can be determined. 
 
 
Laser capture micro-dissection (LCM) can be used to isolated specific cell types 
or specific regions from an atherosclerotic plaque. In this way, the transciptome 
of distinct cells can be compared in different situations, limiting the amount of 
variables in the equation. This method has been used to isolate RNA from the 
smooth muscle cell rich cap, macrophages and endothelial cells from both 
human and mouse atherosclerotic plaques43-45.  
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In general, micro-array studies provide an attractive and fast method to detect 
transciptome differences between healthy and diseased phenotypes. However, 
attention must be paid to the experimental setup, the sample isolation and 




1.3 Immunity in atherosclerosis 
 
Immune cells such as T cells were already discovered in the atherosclerotic 
plaque in 198646 and certainly during the last decade it has become clear that 
atherosclerosis is an inflammatory disease47-50. Normally, an inflammatory 
reaction is evoked against a pathogen or chemical toxin, in order to facilitate the 
eventual removal of the harmful agent. During this inflammatory response, 
blood flow is increased and vascular permeability is induced, leading to 
leukocyte migration to the damaged or infected site. After the initial infiltration 
of leukocytes, the inflammatory reaction is enhanced by secretion of 
interleukins, growth factors and chemokines by the now resident immune cells. 
This in turn attracts more leukocytes, leads to activation of the adjacent tissue 
and results in a pro-inflammatory feedback loop. The immune reaction ends 
when the pathogen or stimulus is removed by scavenging cells and the tissue 
returns to its non-activated state.  
The immune system is able to distinguish self from non-self, resulting in 
tolerance for self-proteins. A problem arises when the harmful agent is not a 
removable pathogen, but an endogenous stimulus. This will result in the break- 
down of tolerance and an auto-immune reaction against self-peptides. The 
inflammatory reaction then has no clearly defined end point because removal of 
the stimulus is impossible as it is constitutively expressed in the body.  
Atherosclerosis is considered an auto-immune disease since it has features of 
auto-immune diseases such as rheumatoid arthritis (RA) and multiple sclerosis 
(MS). The inflammatory reaction is most likely to be directed against antigens 
such as oxidized lipoproteins and heat shock proteins that are presented in the 
atherosclerotic plaque. An immune response against these antigens is 
demonstrated by the elevated levels of (auto-) antibodies against these epitopes 
in patients with severe atherosclerotic lesions51, 52. As elevated cholesterol levels 
and increased vascular permeability continuously lead to the deposition and 
modification of LDL, total removal of the inflammatory component by 
scavenging cells is never achieved. Macrophages and dendritic cells take up the 
oxidized LDL, but due to the constant supply, they end up as foam cells and 
further contribute to the growing lesion. The immune system has developed 
ways to repress an ongoing inflammatory response by specific regulatory 
mechanisms, for example by specific anti-inflammatory cytokines and T cell 




In this section, the role of leukocyte activation and migration in the initiation 
and progression of atherosclerosis is addressed. Firstly, the role of chemokines 
and other molecules associated with leukocyte migration will be discussed. 
Secondly, molecules with a role in activation and differentiation functions 
(mostly interleukins) are addressed, followed by a section on co-stimulatory 





Chemokines are small proteins with chemoattractant properties and are secreted 
to induce leukocyte growth and regulation of leukocyte trafficking. Next to 
these effects on leukocytes, chemokines also mediate platelet activation and 
aggregation. Chemokines are classified in four sub-families based on the 
structural arrangement of the N-terminal conserved cystein residues, being C, 
CC, CXC, and CX3C. The receptors for chemokines contain  7 transmembrane 
loops coupled to heterotrimeric G-proteins and ligand binding to the receptor 
generally induces cAMP mediated calcium release and subsequent activation of 
downstream signalling cascades53. An overview of the chemokine receptors and 
their ligands is shown in figure 3. Chemokine and chemokine receptor 
expression within the atherosclerotic plaque has been well documented12, 54.  
The following section will focus on the chemokine families that have a role in 
atherogenesis and therefore the C-family is not discussed.  
 
CC family 
Until now, 28 member of the CC chemokine family have been identified. MCP-
1 (CCL2) was the first chemokine whose function in the formation of 
atherosclerotic lesions was addressed. It is expressed in atherosclerotic plaques 
and can be released by all vascular cells. The receptor for CCL2 is CCR2, which 
is present on monocytes, immature dendritic cells and T cells55-57. Studies with 
CCR2 and MCP-1 deficient and transgenic animals have shown the pivotal role 
of this interaction in the formation of atherosclerotic plaques58-61. Other 
chemokines with affinity for CCR2 are MCP-2 (CCL8), -3 (CCL7), -4 (CCL13), 
and -5 (CCL12).  Lutgens et al. showed that antibody mediated blockade of 
MCP-1/5 resulted in attenuated atherosclerotic plaque formation39. 
A second well documented CC receptor/chemokine signalling axis in 
atherogenesis consists of CCR5 and its T cell derived ligands CCL3 (MIP-1α), 
CCL-4 (MIP-1β) and CCL-5 (RANTES). Expression of CCL3, -4 and -5 was 
shown in atherosclerotic plaques62 and antagonizing CCL-5 results in decreased 
plaque formation63,64. CCL5 has, next to CCR5, high affinity for two other 
chemokine receptors, CCR1 and CCR3.  Reports on the role of CCR1 in the 
formation of atherosclerotic plaques are controversial. Two recent papers show 
that neo-intima formation and diet-induced lesion formation are not affected by 
CCR1 deficiency, but  a protective role for bone marrow derived CCR1 is 
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suggested by Potteaux and colleagues65-67.  CCR3 expression is associated with 
macrophage rich lesions and its main ligand, eotaxin (CCL11) is produced by 
vascular smooth muscle cells68. As CCL11 mainly attracts eosinofils and these 
cells are not commonly observed in atherosclerotic plaques, more research is 
needed to address the function of CCR3/CCL11 expression in atheroma.   
 
Figure 3: Chemokine receptors and their ligands 
 
 
The expression of CCR7 and its ligands CCL19 and CCL21 is increased within 
atherosclerotic lesions of ApoE-/- mice and in human atherosclerotic carotid 
plaques, and in plasma of patients with coronary artery disease69. Furthermore, 
CCR7 expression is essential in the regression of atherosclerotic plaques due to a 
decrease in serum lipids, as antibodies against CCR7 and its ligands abolish 
plaque regression70.  
A theoretical role for CCR4 and CCR8 signalling has been proposed in 
literature. Expression of the CCR4 ligands CCL17 (TARK) and CCL22 (MDC) 
has been established in atheroma and is associated with macrophage rich areas 
and sites of neo-vascularization71. CCR8 has a potential role in atherogenesis as 
it mediates monocyte migration via its ligand CCL1 (I-309) in ApoAI activated 




The CCR6 ligand CCL20 (LARC) is not detected in atherosclerotic plaques on 
mRNA or protein level indicating that this molecule is not involved in lesion 
formation or progression75. Finally, no clearly defined role for CCR9 and CCR10 




The CXC chemokine family has 17 members and several of these molecules 
have been shown to contribute to atherosclerotic plaque formation.   
Confusingly, some interleukins have been directed into the chemokine 
nomenclature due to their function and molecular structure. One of these 
molecules is IL-8, also known as CXCL8 (or in mice, KC). CXCR2 is the receptor 
for IL-8 and is upregulated on monocytes when they are exposed to oxidized 
LDL76. A pathological function for this increased expression was shown by 
Boisvert et al, who showed that deficiency in CXCR2 or (murine) IL-8 decreases 
plaque formation in apoE deficient mice. They show that CXCR2 is essential for 
cells to be retained in the advanced plaque77-79. A complicating factor is the 
rather large number of other CXCL molecules with affinity for CXCR2. These 
include CXCL1 (GROα), -2(GROβ), -3(GROγ), -5 (ENA-78) and -6(GCP-2), and 
on the other side, the affinity of CXCL6 and -8 for CXCR1. The observed effects 
in experimental models for atherosclerosis are therefore difficult to interpret. 
CXCR3 is expressed on various types of leukocytes and its expression is highly 
induced upon T cell activation80, 81. CXCR3 has 3 known ligands; CXCL9 (MIG), 
CXCL10 (IP-10) and CXCL11 (ITAC) and the expression of these ligands is 
highly inducible by interferon-γ (IFN-γ)82. Recent publications point towards a 
prominent role for CXCR3 mediated migration of inflammatory cells in 
atherosclerosis. Human atherosclerotic lesions express high levels  of all three 
CXCR3 ligands83. Targeted deletion of CXCR3 in ApoE deficient (ApoE-/-) mice 
results in decreased lesion formation in the abdominal aorta84. Furthermore, 
deletion of the CXCR3 ligand CXCL10 in ApoE-/- mice results in decreased 
lesion formation by reducing the migration of CD4 effector T cells to the 
atherosclerotic plaque85.  
A splice variant of the CXCR3 receptor, called CXCR3B is the receptor for 
CXCL4, also known as Platelet Factor 4 (PF-4). Elevated serum levels of PF4 are 
correlated to CAD and peripheral vascular disease and PF-4 release by platelets 
induced monocyte arrest and oxLDL binding on vascular endothelium86, 87.   
CXCL12 (SDF-1) is a chemokine that is a potent inducer of  pro-thrombotic 
events and it is highly expressed by all cell types in the atherosclerotic plaque88. 
In turn, reduced CXCL12 plasma levels have been associated with unstable 
coronary artery disease, suggesting anti-inflammatory or plaque-stabilizing 
properties for CXCL12 in atherosclerosis89. The receptor for SDF-1 is CXCR4. 
CXCR4 was shown to be abundantly expressed by atherosclerotic plaque 
endothelium that is exposed to low/absent shear stress, while it is poorly 
expressed by healthy endothelium. It is associated with atherogenesis by 
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favouring the integrity of the endothelial barrier and by inhibiting MCP-1 and 
IL-8 expression90. 
Neither CXCR5 nor its ligand CXCL13 is reported to be expressed or 
differentially regulated during atherosclerotic lesion formation. 
CXCRL-16, also known as SR-PSOX is a rather peculiar member of the 
chemokine family. It is membrane bound, and is available for its receptor, 
CXCR6 upon cleavage by ADAM-1091. Interestingly the transmembrane form 
functions as a scavenger receptor and as such mediates the uptake of oxLDL by 
macrophages92-94. It is expressed in human atherosclerotic plaques by all vascular 
cells, and not in healthy tissue. Furthermore, it mediates the adhesion of CXCR6 
expressing cells95. Recently it was shown that a polymorphism of CXCL16 is 




Only one member of the CX3C family is described, CX3CL1, and this molecule 
was only identified in 199797. Like CXCL16, it is expressed as a membrane 
bound chemokine, and is accessible for its receptor CX3CR1 only after cleavage 
by ADAM-1798. Despite its recent discovery, a vast amount of evidence exists on 
the pro-atherogenic role of this chemokine and receptor. It is expressed in 
macrophages and smooth muscle cells in the advanced human atherosclerotic 
plaque and provides chemotactic signals to these cells and mediates cell 
adhesion71. CX3CR1 deficient mice reduce less atherosclerosis. Cross breeding 
with apoE and LDLr deficient mice resulted in a decrease in lesion formation in 
the bracheocephalic artery, but not in the aortic root99-101.  Next to these 
findings in animal models, genetic polymorphisms (SNP’s) in the gene for 





Interleukins are messenger molecules that are used in the communication 
between (=inter) leukocytes and inflamed tissue to induce or attenuate immune 
responses (hence the name interleukin). Interleukins are key players in the 
inflammatory reaction observed in atherogenesis. Both pro-atherogenic as well 
as anti-atherogenic interleukins have been identified and for most of these 
factors the expression within the plaque or circulation has been shown. In 
figure 4 the regulation and expression of these interleukins is shown. In this 
section, the function and effects of both pro- and anti-inflammatory 
interleukins will be discussed in respect to their role in atherogenesis. As 
specific cell types are mostly associated with the specific sub-set of interleukins 





Pro-atherogenic signalling routes 
 
A number of cytokines have a clear function in plaque initiation/formation and 
progression. The first pro-atherogenic interleukins to be studied in detail were 
IL-1 and IL-6. A strong correlation is observed between the prevalence of CAD, 
MI and carotid atherosclerosis and the expression of IL-6108-110. The profound 
effects in patients are attributable to the pro-inflammatory effects of IL-6 on 
monocytes111, smooth muscle cell proliferation112 and endothelial cells113. 
IL-1β has  pro-inflammatory effects on endothelial cells114, 115, vascular smooth 
muscle cells116 and macrophages, all detrimental in the formation of 
atherosclerotic lesions117. Increased levels of IL-1 lead to an upregulation of 
adhesion molecules and induce leukocyte migration to the growing lesion118. 
Numerous studies in IL-1 or IL-1 receptor knock outs and transgenic mice 
underlined these findings119-121. The other member of the IL-1 family is IL-18 
and the activity of both molecules is dependent on cleavage by caspase-1 (ICE). 
Binding of IL-18 to its receptor on leukocytes, smooth muscle cells and 
endothelial cells induces a pro-inflammatory response by the secretion of IFNγ, 
IL-6 and vascular adhesion molecules122, 123. Furthermore, IL-18 has been shown 
to decrease plaque stability by the induction of matrix metalloproteinases 
(MMP’s) that degrade the stabilizing collagen content of the plaque124.  
Interestingly, combined stimulation of T and NK cells with IL-18 and IL-12 
leads to activation of Th1 cells and subsequent  IFNγ production125.  The absence 
or selective blockade of this differentiation route by inhibition of IL-12126-129 or 
IFNγ130-132  profoundly inhibits atherosclerosis. 
IFNγ is the predominant cytokine produced by T helper type 1 (Th1) cells and 
the pro-atherogenic role of IFNγ and IL-12/IL-18 indicates that this cell type 
induces and accelerates atherosclerotic lesion formation. Buono et al. under-
lined this hypothesis by showing severe attenuation of atherogenesis in mice 
deficient in the Th1 specific transcription factor T-bet133.  
The IL-12 family was recently supplemented with 2 new members; IL-23 and 
IL-27 (see anti-inflammatory section). IL-23 shares the p40 molecule with IL-12 
and has p19 as the IL-23 specific subunit134. Similar to IL-12, Il-23 is 
predominantly produced by activated antigen presenting cells (APC’s).  IL-23 
promotes the development of a specific T cell subset that produces high levels of 
IL-17, the Th17 cell135. IL-17 has clearly defined possible pro-atherogenic effects 
on various atheroma-associated cell types136, 137. In vitro stimulation with IL-23 
induces the release of pro-inflammatory cytokines such as IL-6, IL-1, IL-8 and 
MCP-1 and increases the activity of MMP’s that contribute to plaque 
destabilisation138, 139.  
A separate group of interleukins that share a common subunit (in this case of 
their receptor) is the γc IL-2 family, comprising of IL-2, IL-4, IL-7, IL-9, IL-13, 
IL-15 and IL-21. This interleukin family is less well studied in the context of 
atherosclerosis, but 2 members are reported to be pro-atherogenic.  Although 
IL-4 is a characteristic Th2 cytokine (thus repressing the above described pro-
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atherogenic Th1 pathway), several reports have indicated a pro-atherogenic role 
for this interleukin126, 140.  The unexpected pro-atherogenic effects are possibly 
mediated by the induction of adhesion molecules such as VCAM-1 and the pro-
inflammatory messenger MCP-1 by IL-4141, 142. 
 
IL-15 is expressed in atherosclerotic plaques and autocrine regulation of 
macrophage cytokine production, such as TNF-α, IL-6 and IL-1 is reported for 
IL-15143-145. For another member of the IL-2 family, IL-7 a pro-atherogenic role 
was suggested by Damas et al. The authors showed that a high levels of IL-7 are 
associated with unstable angina pectoris146. However, lower levels of IL-7 
mRNA were shown in unstable coronary atherosclerotic plaques147. These 











Figure 4: Schematic overview of pro-and anti-atherogenic cytokines 
Upon activation of APC’s such as macrophages and B cells, these cells secrete cytokines that in turn 
activate specific subsets of T cells. Activation of T helper cells (Th1 and Th2) can be suppressed by 
activation of regulatory T cells that secrete IL-10 and TGFβ. 
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Anti-atherogenic signalling routes 
 
In contrast to the rather long list of pro-atherogenic signalling molecules, only a 
short list of suppressive molecules is reported.  
IL-10 is a pleiotropic molecule that has several athero-protective properties. IL-
10 decreases the expression of adhesion molecules in monocytes and reduces 
antigen presentation and pro-inflammatory cytokine production by macro-
phages148, 149. It induces a shift towards a protective Th2 phenotype as it inhibits 
Th1 proliferation of T cells150. A number of papers provide  direct evidence for a 
link between a decrease in serum IL-10 levels and unstable angina and CAD151, 
152 and have addressed the protective effects of IL-10 on atherosclerotic lesion 
formation153-155. Next to this direct function of IL-10, adaptive regulatory T cells 
(Tr1) mainly produce IL-10 upon activation by which  they exert an anti-
atherogenic effect156. A similar function is postulated for the Th2 associated 
cytokine IL-9. This molecule is able to reduce TNFα, IFNγ and IL-12 secretion 
and induce IL-10 expression after LPS injection157.  
As discussed, Th1 associated interleukins such as IL-12 and IFNγ induce 
atherosclerotic lesion formation, and the inhibitory effect of the Th2 cytokine 
IL-10 perfectly fits this hypothesis.  
A second Th2 associated interleukin is IL-5. The athero-protective properties of 
IL-5 were demonstrated by Binder and colleagues158. They however found that 
its protective effects were mainly due to increased production of oxLDL specific 
naturally occurring IgM antibodies, and not per se by the inhibition of Th1 
differentiation. That IL-5 is able to induce an anti-atherogenic effect without an 
accompanying Th2 response was demonstrated by the administration of an 
OX40L antibody during atherogenesis. This antibody repressed Th2 
differentiation, but due to increased IL-5 and IgM levels, atherosclerosis was 
attenuated159. 
The potent anti-inflammatory molecule TGFβ was linked to atherogenesis in a 
study that showed reduced serum levels of active TGFβ in patients with 
advanced atherosclerosis160. TGFβ has anti-inflammatory properties on 
macrophages, smooth muscle cells and endothelial cells by reducing the 
production of pro-inflammatory cytokines, and by increasing IL-10 
production161, 162.  Interestingly, naturally occurring regulatory T cells identified 
as   CD4+CD25+FOXP3+ positive, exert their protective effects via the release of 
IL-10 and TGFß163,164. This is also observed for the Th3 cells that mediate 
tolerance and subsequent suppression of inflammation after oral administration 
of antigens165. 
The most recent addition to the anti-atherogenic cytokine family is IL-27, a 
member of the IL-12 family. IL-27 is encoded by the Epstein Barr virus (EBV)-
induced gene 3 (EBI3) and IL12p35 like protein named IL-27p28166. Effects on 
both Th1 and Th2 subsets have been described for IL-27166-173. In addition, IL-27 
is a suppressor of pro-atherogenic Th17 cells and in this way can provide 
protection against atherosclerotic lesion formation174.  
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T cell activation  
 
Next to chemokines and interleukins, an additional route exists for the 
modulation of the activity of leukocytes. This route is part of the adaptive 
immune system and involves the direct cellular contact of T cells with antigen 
presenting cells such as macrophages, B cells or dendritic cells. Antigen specific 
T cell activation is mediated via MHC-II presentation by antigen presenting 
cells. Next to this signalling route, additional signals are required to activate the 
T cells and induce expansion of the antigen specific T cell subset. 
Communication via co-stimulatory molecules provides this essential stimulus. 
The activated T cell subsequently is able to give B cell help and this B-T cell 
cooperation leads to an antigen specific antibody response. (Schematic overview 
figure 4). Most of the co-stimulatory molecules described are members of the 
TNF receptor superfamily (TNFRSF). In this section the known co-stimulatory 
molecules and their role in the adaptive immunity during atherogenesis are 
discussed. 
 
One of the best characterized co-stimulatory molecules expressed by T cells is 
CD28, which interacts with CD80 (B7.1) and CD86 (B7.2) on the membrane of 
APC’s. This pathway is essential in isotype switching to IgG1 and IgG2a in B 
cells, and formation of germinal centers175.  It is the first stimulatory signal after 
antigen presentation that is received by T cells and facilitates their survival. 
Deficiency in both CD80 and CD86 resulted in decreased lesion formation in 
LDLr-/- mice due to deceased levels of MHCII and IFNγ in the lesion176. 
Interestingly, bone marrow transplantation with CD80/CD86 deficient cells to 
LDLr-/- mice markedly increased lesion formation as shown by Ait-Oufella et al. 
and this was the result of abrogated regulatory T cell differentiation. Also 
transplantation with CD28-/- bone marrow resulted in an increased lesion area, 
and this was reversible by the administration of regulatory T cells164. 
CD80 and CD86 have very high affinity for CTLA-4, another co-stimulatory 
molecule mainly expressed on CD4+ T cells. Its functions are however opposite 
of that of CD28, as CTLA-4 signaling prevents activation and subsequent pro-
inflammatory processes177-181. CTLA-4 expression is furthermore increased in T 
cells with a regulatory phenotype, and in this way can suppress the ongoing 
inflammatory response. As both CTLA-4 with its inhibitory effects and the pro-
inflammatory CD28 are able to regulate the activation and expansion of Tregs, 
this signaling axis needs further research to delineate the exact role in 
atherogenesis182. 
After initial activation of T cells via CD28/CD80-CD86 interaction, other signals 
are provided by the APC. The role of the co-stimulatory couple CD40-CD154 
(CD40L) has been well documented in inflammatory disorders and 
atherogenesis and follows shortly after initial activation. Interaction of CD40 on 
the APC with CD40L on the T cell results in the expansion and priming of CD4+ 
T cells183. The combined exposure of CD40 to CD40L and MHCII to the T cell 
General Introduction 
 23 
receptor (TCR) leads to further activation of the APC and secretion of pro-
inflammatory cytokines such as IL-12184,185. As expected, blockade of CD40-
CD40L signaling markedly decreased atherosclerotic lesion formation and 
enhanced plaque stability as shown by numerous authors186-189.  
 
Approximately three days after the primary activation, T cells induce the 
expression of the co-stimulatory molecule CD134 (OX40, TNFRSF4) on their 
surface. A correlation with the expression of OX40 and severity of several auto-
immune diseases has been established190,191. The ligand for OX40 (OX40L, 
TNFSF4) is expressed by APC’s and by vascular endothelium192, 193. In this way 
OX40/OX40L binding leads to activation and migration of OX40 positive 
activated T cells. Recently, a role for the co-stimulatory molecule CD134 and its 
ligand in atherogenesis was established by the group of Paigen et al. They 
showed that a specific locus associated with atherosclerosis susceptibility in 
C57/Bl6 mice contained the OX40L gene, and a that a specific allele of this gene 
in humans leads to enhanced incidence of MI. Furthermore, mice with targeted 
mutations of OX40L had significantly smaller atherosclerotic lesions than did 
control mice, and mice over-expressing OX40L had significantly larger 
atherosclerotic lesions194,195. In the present thesis, chapter 8 describes the athero-
protective effects of OX40L antibody administration. 
CD30, another member of the TNF superfamily, is expressed by activated T cells 
and is induced in a CD28 dependent activation pathway. CD30L is reported on 
B cells as well as T cells resulting in reverse signalling. Expression of CD30 is 
reported in inflamed unstable coronary plaques196.   
 
GITR (TNFRSF18) in mice, and AITR in humans is a surface receptor molecule 
that is upregulated upon T cell stimulation via CD28197. It has been shown to be 
constitutively expressed in T-regulatory cells and extending the survival of T-
effector cells198. Recently, Kim et al demonstrated that GITR and its ligand are 
expressed mainly in lipid-rich macrophages within atherosclerotic plaques199. 
Furthermore they showed that GITR stimulation increased TNFα and MMP-9 
secretion by macrophages, and thus postulated a role for GITR in plaque 
destabilization. How these effects are to be seen in combination with enhanced 
expression of GITR on Tregs needs to be clarified. The lymphotoxin ß receptor 
(LTßR), a tumour necrosis factor receptor superfamily member has two 
identified ligands, Lymphotoxin (LT) and LIGHT. These ligands are expressed 
on T cells and both provide potent pro-inflammatory signals. For lymphotoxin, 
expression was detected in smooth muscle cells and macrophages in 
atherosclerotic lesions. Furthermore it was shown that functional variations in 
this gene are associated with susceptibility to MI and lymphotoxin deficiency 
reduced atherosclerosis in an experimental model for atherosclerosis200, 201. For 
LIGHT, a role in lipid metabolism was described very recently by Lo et al and a 




Two members of the TNFRSF that are well described in the activation and 
regulation of T cell immunity are 4-1BB  and CD27 but no direct evidence links 
these co-activation markers to atherogenesis. Interestingly, both molecules were 




Figure 5: Schematic overview of T cell activation via MHC-II and co-stimulatory molecules 
Macrophages process antigens and present fragments of these antigens to T cells via MHC molecules. 
Additional stimulatory signals are generated by the ligation of CD80/CD86 with CD28 on the T cell. 
Other co-stimulatory pathways are comprised of CD40/CD40L and OX40/OX40L. 
 
 
1.4 Treatment strategies 
 
The current treatment of atherosclerosis is based on the reduction of risk factors 
such as high circulating cholesterol levels or hypertension. Statins are currently 
clinically the most used drug and exert their effect by lowering cholesterol 
levels by inhibition of HMGCoA reductase, a rate limiting enzyme in 
cholesterol sythesis203 204.  
Although a role for inflammation has been extensively shown, no treatment 
directly modulating the inflammatory response that drives atherosclerotic 
plaque formation has been described. Formulating an ideal strategy to reach 





In general, pharmaceutically active compounds are relatively small, hydrophilic 
compounds that show high affinity for a receptor or enzyme. In this way, the 
interaction of a ligand with the targeted receptor is inhibited, or the enzymatic 
activity is decreased. The generation of such compounds is a time consuming 
and costly process that needs structural knowledge of the target protein. Next to 
this, functional dosing of these pharmaceutically active compounds mostly 
requires daily intake by the patient and in the case of atherosclerosis this will 
result in (life) long dependency due to the progressive nature of the disease.    
 
Vaccination can provide an alternative for the treatment of atherosclerosis. The 
onset of lesion formation starts already at a very young age (<20) and removal or 
blockade of pro-atherogenic factors in childhood could be very effective in the 
prevention of lesion formation. Active immunization using a vaccine results in 
the life long immunity against a chosen endogenous factor by inducing an 
antibody or cytotoxic response and is currently used in the prevention of 
numerous diseases such as diphtheria, chicken pocks and tetanus. In 
atherosclerosis, several strategies can be defined to attenuate the formation of 
lesions by using vaccination.  
The most ideal strategy would be to develop a vaccine against the actual protein 
or sugar moiety that induces the immune response in atherogenesis. However, 
this molecule has not been defined yet. Interesting candidates are indicated by 
the presence of antibodies against oxLDL of heat shock proteins in patients with 
CAD or carotid artery occlusion. Furthermore, it was shown that antibodies 
against modified apoB-100, a protein moiety in LDL correlate with the extend of 
carotid artery disease and that these antibodies show protective inhibitory 
effects on atherogenesis205-207. Another approach would be to specifically block 
the signalling of pro-atherogenic molecules that are identified, such as pro-
inflammatory interleukins and subsets of chemokines. 
 
In normal vaccination protocols, immunity is raised against a part of, or a 
complete attenuated pathogen. This method has some practical drawbacks when 
vaccinating against a protein and not an efficiently multiplying pathogen.  Large 
quantities of protein (antigen) have to be synthesized or isolated, and its storage 
and production are rather expensive processes. 
An attractive way to induce immunity is provided by DNA vaccination. This 
method uses isolated eukaryotic expression vectors that encode the antigen and 
administrate this DNA into the body by injection208.  Recent studies using this 
method in patients have shown that the administration of naked DNA alone 
sometimes does not result in an immune response that is strong enough to 
induce protection209.  
 
The addition of immuno-modulatory components provides a way to increase the 
chance that DNA vaccination will result in protection. Examples of this 
technique are the addition of bacterial motifs, coding regions for interleukins, or 
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co-stimulatory molecules and the addition of other adjutants during 
immunization210. Furthermore, the plasmid can be administered to the body 
inside an attenuated pathogen that will induce an immune response and thus 
functions both as an adjuvant and a carrier at the same time. An example of 
such a bacterium is an attenuated strain of Salmonella Typhimurium that has 
been described for vaccination purposes211. An advantage of Salmonella is that it 
egresses from the gut lumen via the M cells to Peyers patches, and in this way 
the vector (via the pathogen) is efficiently transported to the immune system for 
translation and processing212-214. 
DNA vaccination by using oral administration of Salmonella can lead to 
different immune responses, based on the T cell subset that is activated by 
APC’s present in the Peyers patch215. By activation of CD8+ cells, a cellular 
immune response is initiated. This leads to the specific killing of cells that 
express and present the antigen via MHCI. A humoral response is characterized 
by the production of antibodies against the chosen antigen. This is the result of 
specific T cell help from activated CD4+ T cells to antigen specific B cells. The 
following two paragraphs will discuss the mechanisms leading to cellular or 
humoral immunity. 
 
Cellular immunity  
Atherosclerosis is a multi-factorial disease and numerous cell types contribute to 
the growing lesion. The specific removal of pro-atherogenic cell types that drive 
the atherogenic response could be a potential way to attenuate lesion formation. 
Vaccination strategies using S. Typhimurium transformed with plasmid DNA 
encoding pathogen proteins have been shown to result in cytotoxic responses to 
the live pathogens upon infection. This strategy induces protection against a 
lethal challenge with several bacterial strains216, 217. Not only bacterial strains can 
be the target of CTL mediated apoptosis, also eukaryotic cells expressing high 
levels of the protein via MHCI can be targeted via vaccination. This was 
elegantly shown by Niethammer and colleagues, who used this technique to 
target tumour associated proteins that enhanced angiogenesis. They induced 
cellular immunity against vascular endothelial growth factor (VEGF) receptor 2 
and carcinoembryonic antigen (CEA). In this way they attenuated tumour growth 
and prolonged survival in mouse models for cancer218-221.  
This experimental setup can also be used in the treatment of atherosclerosis as 
several cell types show clear pro-atherogenic effects. Most likely, removal of these 
cells would lead to attenuation of disease progression. Our lab has demonstrated 
that vaccination against VEGFR2 inhibits lesion formation in LDL receptor 
deficient mice by the generation of CD8+ VEGF specific CTL’s that remove 








Vaccination against membrane bound proteins is mediated via the above described 
cellular vaccination. A problem arises when the pro-atherogenic moiety is not a 
cell, but a secreted protein. As there is no cell type that will be targeted, a different 
vaccination strategy is needed. Induction of antibody secretion is an attractive 
strategy, because antibodies are highly efficient in mediating removal of the 
unwanted proteins from the circulation and at sites of infection. Studies that used 
Salmonella mediated DNA vaccination in C57/Bl6 mice showed that without any 
additional stimulants the antibody production in this animal was negligible upon 
DNA vaccination215. This indicates that a moiety has to be inserted that drives 
activation of the T helper subset, instead of the activation of the CD8+ cytotoxic 
response mediated by the Salmonella alone.  
Several peptides and DNA sequences have shown to induce a profound T cell 
help to B cells, and when these epitopes are coupled to the protein or DNA 
sequence in a vaccination strategy, a robust antibody production is the result. 
Examples of these sequences are Hen Egg Lysosyme (HEL), PanDRepitope 
(PADRE) and ovalbumine (OVA)223. The mechanism by which these epitopes 
break tolerance against the attached protein/DNA sequence is as follows. After 
administration of the plasmid by using oral administration of transformed 
attenuated Salmonella, or injection of the plasmid DNA, the fusion protein is 
sythesized. B cells process the complex after binding to the B cell receptor. As 
the complex encodes a self-protein, no T cell help is available to start antibody 
production. This essential T cell help, and the resulting loss of tolerance, is 
generated by the inserted epitope (HEL/PADRE) by HMC-II restricted T cell 
activation. In this way, antibodies can be generated against identified pro-
atherogenic factors and an attractive therapeutic possibility for the treatment of 
atherosclerosis is generated. 
 
 
1.5 Scope of the thesis 
 
The research described in this thesis has two major focus points. Firstly, we used 
micro-array experiments to find new molecules or genes that provide attractive 
therapeutic possibilities to treat or prevent atherogenesis. This is described in 
the first two research chapters. Chapter 2 shows a study in which the 
transciptome of vascular tissue from LDL receptor deficient mice on a Western 
type diet is compared to healthy mice. In this way, new genes and transcription 
factors are identified that have a possible role in atherogenesis. Chapter 3 
focuses on CD4 positive T cells during atherosclerotic lesion formation, as this 
cell type is identified as the predominant T cell type in atherosclerosis. CD4 
positive T cells are isolated from mice on a Western type diet at two different 
time points. The transcriptional regulation in these cells is compared to cells 
from healthy mice and relevant pathways and genes are identified. 
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The second part of this thesis illustrates several novel therapeutic strategies to 
affect atherosclerotic lesion formation. A number of these chapters is based on 
the targets identified in the above described micro-array experiments. Both the 
migration (chapters 4-7) and activation (chapters 7-8) of leukocytes are subject 
of research. 
Chapter 4 identifies the HIV entry inhibitor TAK-779 as a CCR5/CXCR3 
antagonist that reduces atherosclerotic lesion formation in LDLr-/- mice. 
Attenuated lesion formation is the result of reduced migration of Th1 cells into 
the atherosclerotic plaque. In Chapter 5 it is shown that that atherogenesis is 
inhibited by administration of the selective CXCR3 inhibitor NBI-74330. The 
observed reduction in plaque formation is the result of increased migration of 
regulatory T cells to the plaque and the draining lymph nodes. Chapter 6 
focuses on the functional role of the recently identified molecule CD99 during 
atherosclerotic lesion formation. This molecule, which is expressed both in the 
endothelial junction as well as on leukocytes, has a pro-atherogenic role, as 
vaccination against CD99 results in reduction of lesion formation in LDLr-/- 
mice. Chapter 7 shows for the first time that IL-16 has anti-atherogenic 
properties. This interleukin is the first described chemotactic factor for T cells. 
Vaccination against interleukin-16 results in accelerated lesion formation, 
especially after longer periods of high fat diet feeding. 
Next to the above described interference in leukocyte migration, 2 chapters are 
incorporated that indicate the possible therapeutic possibility of leukocyte 
activation modulation. Chapter 8 describes the antibody mediated blockade of 
CD134 (OX40 ligand) during atherogenesis. This molecule is the ligand for 
OX40, a T cell activation marker. Blockade of OX40/OX40 ligand signalling 
results in reduced lesion formation by the generation of protective OxLDL 
specific IgM antibodies due to inhibited Th2 mediated isotype switching. 
Chapter 9 shows that CD127 is essential for macrophage and regulatory T cell 
function in atherosclerotic lesion formation. Vaccination against this receptor 
for IL-7 severely increases the lesion burden in LDLr-/- mice by inducing 
macrophage apoptosis and decreasing the locally present regulatory T cell 
number. Chapter 10 reviews the combined results of the earlier chapters. 
Clinical implications of the described novel therapeutic candidates and 
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Atherosclerosis is a multi-factorial disease associated with elevated plasma 
cholesterol levels, lipid deposition and inflammation within the vessel wall. 
Several molecules and transcriptional pathways have been identified in 
established atheroma, but initial factors contributing to the onset of disease are 
less well described.  
In this study, we compared the transciptome of the aortic arch of LDL receptor 
deficient mice that were fed a Western type diet with chow fed mice by using 
two different statistical approaches. We identified transcription factor binding 
sites overrepresented within similarly regulated gene clusters and found that 
FOXO1 mediated transcription is enhanced during Western type diet feeding. 
This was further demonstrated by the significant upregulation of the FOXO1 
downstream gene HMG-CoA reductase. In addition, we used Gene Set 
Enrichment Analysis to identify genes and pathways enriched in initial and 
early atherogenesis. We confirmed the specific upregulation of ABCB10 in 
initial lesion formation, and CCL8 in early lesion formation. 
This study identifies new transcriptional regulators and genes associated with 
very early changes in the vascular wall that precede the large scale influx of 
leukocytes leading to atherosclerotic plaque formation. These new molecules 





Atherosclerosis is a progressive disease of the medium to large arteries that is 
characterized by lipid deposition and a subsequent influx of leukocytes into the 
vessel wall1. It is the primary cause of myocardial infarction (MI) and stroke, and 
a major cause of death in the Western world2. Several risk factors have been 
identified over the past decade, including hyperlipidemia, smoking, hyper-
tension, obesity and diabetes3. To increase the understanding of the disease, 
numerous studies have been performed that focused mostly on single genes, for 
example by using knockout animals, SNP analysis of a single gene or gene 
silencing via siRNA.  Due to the multi-factorial and complex nature of 
atherosclerosis, a broad, non-biased approach will be highly informative, leading 
to a better understanding and insight in the biological processes that underlie 
the disease. Furthermore, not only genes that have previously been associated 
with atherosclerosis are included, but also unexpected genes that have never 
been linked to this disease can be identified. 
Along this line, efforts have been made to identify disease related gene 
expression patterns in atherosclerosis via transcriptional profiling using micro-
arrays4. Several studies are performed to define the transciptome of human 
atherosclerosis, but the identified genes were mostly linked to atherogenesis 
already5-6. They include genes involved in inflammation, lipid metabolism, 
matrix degradation as well as cell proliferation and differentiation. Due to the 
difficulties in human sample incorporation and isolation, mouse models for 
atherosclerosis provide an attractive alternative. The commonly used animal 
model for these studies is the ApoE deficient mouse. Array studies were 
performed to identify differentially expressed genes in mice of different ages, 
and mice fed with different atherogenic diets7-11.  Functional gene groups that 
have been reported to be differentially expressed are chemokines and 
chemokine receptors, cathepsins and general pro-inflammatory markers.  
The aim of the present study was to identify new genes and/or gene clusters that 
are differentially expressed during very early lesion formation in the aorta. For 
this purpose we used LDL receptor deficient (LDLr-/-) animals, which unlike 
ApoE deficient animals, only develop atherosclerotic lesions when fed an 
atherogenic diet12. This provides the possibility to time the onset of disease, and 
identify very early changes in gene expression in the aortic wall.  We used 
whole mount tissue from the aortic arch of animals at 0-1.5-3-4.5-9 weeks of 
Western type diet feeding and compared the transciptome to aortic tissue from 
mice on chow. By using advanced statistical analyses both on single transcript 
levels as well as on functional level we identified genes and pathways that are 
specific for changes in the vessel wall during the initiation of lesion formation. 
Transcriptional Profiling in Early Atherogenesis 
 45 
Material and methods 
 
Animal experiments 
Female LDLr-/- mice (n=6 per group) were fed an atherogenic Western type diet 
containing 0.25% cholesterol and 15% cocoa butter (Special Diet Service, UK) 
for 0-1.5-3-4.5 and 9 weeks. After the indicated diet feeding periods, mice were 
anaesthetized, flushed with PBS and the aortic arch (thoracic) was prepared free 
of peri-adventitial fat tissue and snap frozen in liquid nitrogen. All animal 
experiments were approved by the Leiden University animal welfare committee 
and in concordance with Dutch law. Concentration of serum cholesterol was 
determined using enzymatic colorimetric procedures (Roche/Hitachi, 
Mannheim, Germany). Precipath (Roche/Hitachi) was used as a standard. 
 
Micro-array protocol 
RNA was isolated from aortic tissue using the GTC method and DNAse treated. 
The RNA was linearly amplified for 1 round (starting material 1 μg total RNA) 
synthesizing anti-sense cRNAs with an average base length of 500 nucleotides 
using the Message-Amp kit from Ambion. Aminoallyl-UTP was incorporated 
with a molar ration of 1:1 to rUTP. Cy3 or Cy5 mono-reactive dyes were 
coupled according to the manufacturers’ instructions (Amersham Bioscience, 
Piscataway, New Jersey). Labeled cRNA was purified using the RNeasy 
purification kit (Qiagen, Germany). All aortic RNA samples were hybridized 
against a common reference containing (in equal amounts and amplified one 
round); liver, spleen and aorta of LDLr-/- mice 6 weeks on western type diet and 
LDLr-/- mice treated with LPS, RAW cells treated with LPS, H5V cells treated 
with TNFα and Strategene universal mouse reference RNA.  
Hybridization was performed on glass based micro-arrays representing 22.056 
unique murine oligonucleotide sequences (Micro Array Department, University 
of Amsterdam, The Netherlands (http://www.microarray.nl/libraries.html).  
Microarray data were acquired and imported in Rosetta Resolver database and 
Loess normalized (limma package, Bioconductor). Significant differences in time 
were calculated by using one-way Bayesian ANOVA with Benjamini-Hochberg 
multiple testing correction (Cyber-T, R script, UCLA) with genes detectable in 
all arrays and FDR < 25%.  
Data were grouped into control (0 weeks of diet), no lesion formation, 1.5 and 3 
weeks of diet), and initial lesion formation (4.5 and 9 weeks of diet). 
Hierarchical clustering of significant genes was performed using Cluster (Eisen 
Lab, UCB, http://rana.lbl.gov/EisenSoftware.htm)13. Conserved transcription 
factor binding sites in the region of 500 base pairs from ATG of genes 
overrepresented within the clusters were analyzed with whole genome rVista by 
using the 2004 mouse/human conserved genome database14.   
Genome wide analysis at group level was performed using GSEA after 
conversion of mouse to human signature15. The molecular signature database 
that was used was a modified version of the original named c2.symbols.gmt 
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(http://www.broad.mit.edu/gsea/msigdb/msigdb_index.html) set and earlier de-
scribed by Volger et al16. The dataset contained 594 gene sets. Analysis was 
performed with the following settings: 100 permutations on phenotype, gene 
sets with more that 10 genes were included in the analysis.   
 
Validation of candidate genes by RT-PCR 
Quantitative gene expression analysis was performed on an ABI PRISM 7700 
machine (Applied Biosystems, Foster City, CA) using SYBR Green technology. 
PCR primers (appendix I) were designed using Primer Express software with the 
manufacturer's default settings (Applied Biosystems). Acidic ribosomal 
phosphoprotein PO (36B4) and hypoxanthine phosphoribosyl transferase 
(HPRT) were used as housekeeping genes.  
 
Statistical analysis  
Values are expressed as mean ± SEM. Two-tailed student’s T-test was used to 
compare normally distributed data. Mann-Whitney test was used to compare 
lesion area data and other not normally distributed data. A probability value of 




Figure 1: Diet induced lesion formation in LDLr-/- mice. Female LDLr-/- mice (n=6 per group) were 
placed on a Western type diet for 0-1.5-3-4.5 and 9 weeks. Total serum cholesterol was determined 
during the experiment and a significant increase is observed at 1.5 weeks of Western type diet 
feeding that is maintained throughout the experiment. Representative pictures of lesion formation in 
the aortic root at the indicated time points are visualized in the power panels. Oil red o staining is 
used to visualize lipids. 
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Animal and tissue phenotype 
We designed this experiment to identify genes and genetic pathways that are 
specific for very early atherosclerotic lesion formation. We used LDLr-/- mice as 
a model for atherosclerosis as in this animal, the onset of lesion formation can be 
specifically timed by feeding a Western type diet. Female LDLr-/- mice 
(n=6/group) were placed on a Western type diet for 1.5; 3; 4.5; and 9 weeks. 
Chow fed animals were used as control. Western type diet feeding resulted in a 
significant upregulation of serum cholesterol levels already after 1.5 weeks from 
260 ± 23 mg/dl to 862 ± 46 mg/dl. This increase in cholesterol level was constant 
throughout the experiment (Figure 1, upper panel). To determine the degree of 
atherosclerotic lesion formation, we stained the aortic valve leaflet area for lipid 
deposition using Oil-red-O. Representative photomicrographs are shown in 
figure 1 lower panels.  
In general, the onset of lesion formation in the aortic valve leaflet area precedes 
plaque formation in the aortic arch. To provide insight in the degree of lesion 
formation in the aortic arch, we used real time PCR to check for the presence of 
macrophages and T cells.  
 
Figure 2: Leukocyte influx and endothelial activation in the aortic arch. We determined the extent 
of leukocyte influx within the aortic arch in time by RT-PCR on CD68 (macrophage specific) and 
CD4 (T cell specific) mRNA expression. Endothelial activation was assessed by vWF expression. 
mRNA was isolated from the aortic arch of LDLr -/- mice using the GTC method and expression of 
genes is expressed relative to 36B4 and HPRT, and subsequently related to the expression in mice on 
chow diet. An unpaired Student t test was applied to test whether mRNA levels were significantly 
different from the mRNA levels in chow fed animals (week 0) (*p < 0.05, n= 6 per time point). 


















































Figure 2 shows that only after 9 weeks of Western type diet feeding, a 
significant upregulation of both CD68 mRNA (macrophage specific, 2.8 fold, 
p=0.023) and CD4 (T cell specific, 2.2 fold, p=0.02) was observed. This indicates 
that these leukocytes have entered the aortic wall and atherosclerotic plaque 
formation has been initiated. The activation of the endothelium that precedes 
the leukocyte influx is already visible after 4.5 weeks of Western type diet. This 
is shown by the significant upregulation of von Willebrand factor at 4.5 and 9 
weeks of diet (2.0 fold, p=0.01, and 2.1 fold, p=0.03 respectively). 
 
Transcriptional regulation in the aortic arch during Western type diet feeding 
Transcriptional differences between the aortic arch of control mice and diet fed 
mice were determined by micro-array analysis. mRNA, isolated from every 
aortic arch was amplified one round, labeled with Cy5 and subsequently 
hybridized against a common reference (Cy3). Genes significantly regulated in 
time were identified by using Bayesian one-way ANOVA with Benjamini-
Hochberg correction for multiple testing. Genes were considered differentially 
expressed when expression was observed in all the arrays, and the False 
Discovery Rate (FDR) < 25%. The resulting significant genes (N=354) were 
clustered using hierarchical clustering software. The time points were grouped 
in control tissue on chow diet resulting in low cholesterol levels (LC, 0 weeks), 
high serum cholesterol and no lesion formation (HC, 1.5 and 3 weeks,) and high 
cholesterol and initial lesion formation (HCIL, 4.5 and 9 weeks) and regulation 
profiles over these 3 situations were analyzed. The resulting clusters and gene 
lists are visualized in figure 3. Clustering resulted in 5 unique clusters as 
visualized in the following order; A: Induced HC and HCIL, N=76 genes; B: 
reduced HCIL only, N=19; C: induced HCIL only, N=16; D: reduced HC only, 
N=239; E: reduced HC and HCIL, N=10. 
 
Transcription factor binding sites overrepresented within the clusters 
Once we identified the above described differentially regulated gene clusters, we 
searched for coordinate regulation of these genes via possible common 
transcription factor binding sites in upstream regions of the genes present in 
each cluster by using rVISTA. We used the human-mouse alignment of May 
2004 and searched within a 500 base pair upstream region of ATG. Distinct 
transcription factor binding sites were identified for each cluster and these are 
visualized in figure 3 right panel.  In the genes that are present in the upper 
cluster, with induced expression in both high cholesterol situations, we found 
overrepresentation of transcription factor binding sites for FOXO1, GATA2, 
MEIS1, and c-myb.  FOXO1 is involved several metabolic signaling pathways; 
overexpression of FOXO1 leads to hyperglycemia and hypertriglyceridemia, and 
exercise leads to downregulation of FOXO1 regulated genes17-20. GATA2 
regulation is described for vascular endothelial and/or smooth muscle cells and 
Seo et al. have shown that GATA2 expression is one of the most predictive genes 
for human aortic sites with high lesion burden5.  
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Figure 3: Differentially regulated genes during diet induced lesion formation. Differential regulation 
due to Western type diet feeding in the aortic arch was assessed by Bayesian one-way ANOVA with 
BHB correction and 354 genes were found to be significantly differentially expressed in time. 
Hierarchical clustering of these significant genes resulted in 5 distinctly regulated clusters as shown 
in by }. Presence of overrepresented TFBS in the promoter region of the genes in each cluster was 
identified by comparison with the 2004 mouse/human conserved genome database by using rVista. 
For each cluster these transcription factors are shown. Transcription factors that have been 
previously associated with vascular biology are shown in bold. LC: aortic arch from mice on chow; 
HC: aortic arch from mice on high cholesterol diet, no plaque formation; HCIL: aortic arch from 









LC  HC    HCIL 
 
A: Induced HC and HCIL: N=76 (61 without clones) 
Aadat Cox7a1 Gpd2 Kel Prr6 Tead4 
Aatk Ctgf Gpr155 Lcn5 Ptp4a1 Tex23 
Abca8b Cyp2j9 Gria1 Lin7c Retn Tshb 
Akap12 Decr1 Gsh2 LOC545854 Rpl27a Ugt8a 
Aldh1a7 Ebf3 Hadhb Lum Sardh Vac14 
Arl4a Ecgf1 Igh-6 Mrpl15 Sh2d2a Yipf1 
Btd Eya4 Igh-VS107 Mylk Ski  
Ccndbp1 Fabp9 Inpp4a Nmral1 Smarcd1  
Cd164l2 Fbxl22 Irak1bp1 Nppc Smpdl3a  
Cdk5rap3 Fga Itga8 Ogdh Ssfa2  
Chi3l1 Fmo1 Kcne4 Ogn Supt4h2  
B: reduced HCIL only: N=19 (16 without clones) 
Ablim1 C1qtnf3 Fabp4 Kpna2 Uqcr Zfp777 
Ap1m1 D10Ertd610e Gng10 Oip5 Usp10  
Bub3 Egfr Hars Pctp Wbscr16  
 C: induced HCIL only: N=16 (14 without clones) 
Acss2 D10Jhu81e Lincr Magmas Prkar1a Tacstd2 
Agpat3 Gm1077 Lpin1 Nfat5 Sox18 Vps53 
Cyp2c38 Il6st     
 
D: reduced HC only: N=239 (210 without clones) 
Acp2 Cops3 Gmnn Metap2 Psma1 Ssb 
Acyp1 Copz1 Gnpnat1 Mettl9 Psma5 St6gal1 
AK013368 Cript Gorasp2 Mobk1b Psmd10 St7 
AK018642 Crisp2 Gpiap1 MOU384-2 Psmd3 Stam 
Ak3 Csnk1g3 Grina Mphosph6 Ptges Stat2 
Ankrd11 Cxcl1 Gstt1 Mrpl13 Rab35 Sugt1 
Apex1 D4Wsu53e Gtf2i Mrpl49 Rad21 Sulf2 
Aplp1 Dars Hdgf Mrps10 Ranbp1 Tbc1d10b 
Apobec1 Ddef1 Hp Mtdh Rbm17 Tbrg1 
Apof Ddx5 Hsd11b1 Mttp Rbx1 Tdrkh 
Apoh Derl1 Id2 Mup1 Rpl30 Timm17b 
Aqp2 Dhx15 Ifi204 Mxi1 Rpl38 Tm9sf3 
Arhgef6 Dnaja1 Igj Myh8 Rps10 Tmed4 
Arid1a Drctnnb1a Igk-V Myo5a Rps13 Tmem165 
Asns Eef1a1 Igk-V19-14 Nasp Ryk Tmpo 
Aspm Efemp2 Igkv4-91 Nbn S100a4 Top3b 
Atg5 Eif2ak3 Inpp5b Ndrl Sap30bp Trex1 
Azgp1 Eif2b4 Josd1 Nktr Serpina1b Ttc18 
BC005512 Eif3s5 Josd3 Nol5 Serpine1 Ttn 
Bgn Eif4g2 Kifc3 Npm1 Set Tubb2b 
Birc5 Elk3 Klf10 Oat Setdb1 Txnrd1 
Bxdc2 Emcn Krr1 Omt2b Sfrs1 U86712 
Calu Eno2 Larp-pending Pacsin2 Sgk2 Ubb 
Cast Eprs Lgals9 Pbk Slc35a3 Ube2c 
Cct4 Ergic2 Lilrb4 Pdpn Slc38a4 Ubl4 
Cd53 Esd LOC280487 Pef1 Slc7a6os Ubp1 
Cdt1 Fbln2 LOC280487 Phc2 Slco1b2 Ulk2 
Cebpg Fbxo7 LOC544945 Phf3 Slpi Wac 
Cenpa Fkbp1a LOC545854 Pias1 Smarcd1 Wars2 
Cetn3 Fscn1 LOC629915 Piga Smu1 Xlr3a 
Chia Ftl1 Lsm5 Pja2 Snrpe Xpo1 
Chm Gc Lsm8 Pla2g4a Snx1 Zfand1 
Chuk Gcap27 M17761 Prkcd Snx5 Zfand5 
Cited2 Glud1 Map3k5 Prpf40a Spsb3 Zfp58 
Cks2 Gm1419 Mark3 Prss23 Sptlc1 Zfpm1 
 
D: reduced HC and HCIL: N=10 (8 without clones) 
 Apex1 Id2 Rab35 Timm17b  




Next to this finding, 5 polymorphisms in the GATA2 gene were shown to be 
correlated to coronary artery disease5,21.  MEIS1 is mainly associated with 
leukemogenesis and lymphocyte cell differentiation during early life22. C-myb 
was initially described as proto-oncogene, but some evidence exists that is 
functions as a mediator of vascular smooth muscle cell proliferation and neo-
intima formation23-26. 
 
In initial lesion formation, when initial leukocyte infiltration has started, we 
observed an expected upregulation of genes regulated by the inflammatory 
regulator NFkappaB. This transcription factor has been extensively researched in 
the context of atherogenesis, and induces the expression of adhesion molecules, 
chemokines and matrix-metalloproteinases26,27. Other transcription factor 
binding sites that are enriched within this time point are MAZR and AP4, both 
with no direct described function in vascular cells until now.  
Interestingly, during initial lesion formation, genes with a MEF2 and HFH8 
(FOXF1) transcription factor binding site are downregulated. MEF2 regulation is 
associated with both endothelial and smooth muscle cell function28,29. 
Furthermore, a mutation in MEF2a is linked to coronary artery disease30. HFH8 
is less well described, but has been linked to vascular endothelial growth factor 
(VEGF) expression and LKLF mediated regulation during lung development30.  
The largest gene cluster contains genes that were reduced in both high 
cholesterol no lesions and high cholesterol with initial lesions. The 
overrepresented transcription factor binding sites are E2F1DP2 and GLI. 
E2F1DP2 has no downstream genes that are functionally described. GLI 
however, has been studied in more detail and is reported as a mediator of 
hedgehog signaling in oncogenic pathways leading to a variety of lethal tumors 
31. The last cluster contains genes that are downregulated during Western type 
diet feeding, both in initial and early atherogenesis, and shows enrichment for 
AP-4 binding sites. This transcription factor was also associated with an 
upregulation of genes in early atherogenesis. 
 
The expression of HMG-CoA reductase is upregulated during Western type diet 
feeding 
Recent reports link the expression of 3-hydroxy 3-methylglutaryl coenzyme A 
(HMGCoA) reductase directly to the level of active FOXO117. In order to 
functionally validate the observed enrichment of FOXO1 induced genes after 
Western type diet feeding, we analyzed the expression of HMGCoA reductase in 
our samples. We observed a clear and significant upregulation of this gene due to 
Western type diet administration and this regulation profile correlates with the 
cluster profile (Fig 4). This indicates that FOXO1 downstream gene expression is 
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Figure 4: Expression of HMG Co-A 
reductase in the aortic arch on Western 
type diet feeding. mRNA was isolated 
from the aortic arch of LDLr-/- mice using 
the GTC method and expression of genes 
is expressed relative to 36B4 and HPRT, 
and subsequently related to the 
expression in mice on chow diet. An 
unpaired Student t test was applied to test 
whether mRNA levels were significantly 
different from the mRNA levels in chow 





Next to the gene based pattern analysis, we performed pathway based Gene Set 
Enrichment Analysis to study transciptome differences in the aortic arch of 
initial and early lesion formation. This method enables the interpretation of 
genome-wide expression profiles based on biological function. Next to the 
functional output, this analysis tool identifies a top 100 of signature genes of one 
situation compared to another15. An enrichment score and relevant p value is 
calculated based on the ranked difference in expression of genes between two 
situations. In this way, gene sets that are overrepresented at the extremes of the 
ranked gene list will result in high enrichment scores. Tables 1 A and B  show 
the enriched pathways for both initial and early lesion formation, and the 
nominal P values calculated by weighted Kolmogorov-Smirnov-like statistics as 
described earlier15. 
Immediately after Western type diet feeding (1.5 and 3 weeks of diet) a clear 
enrichment of metabolism associated genes is observed compared to early 
atherosclerosis (upper table). However, none of these sets were significantly 
enriched. In initial atherosclerosis (4.5 and 9 weeks of diet), the number of 
significant (p<0.05) enriched gene sets is 24. Next to metabolism associated sets, 
cell adhesion and map kinase activation pathways are observed. 
Figure 5 shows the top 100 signature genes (50 top, 50 bottom) according to the 
intensity differences between initial and early atherosclerosis. 
We used real-time PCR to validate genes that were present in the gene list 
generated by GSEA. ABCB10 expression is one of the top enriched genes in the 
high cholesterol, no lesion time point, indicating a diet induced effect on its 
regulation. ABCB10 is a relatively new member of the ABC binding cassette 
transporter family and has not been linked to atherogenesis yet. A significant 
upregulation of ABCB10 expression is observed after 3 weeks of Western type 
diet. 
CCL8 (formerly known as MCP-2) is one of the top ranked genes in early 
atherosclerosis. CCL8 functions as a chemotactic factor for monocytes via CCR1 
and CCR2b32-35. Real-time PCR showed that CCL8 expression indeed increased 
markedly by 2.4 fold (p=0.02) in aortic tissue with early lesions. 

































Table 1: enriched gene sets identified using GSEA. GSEA was used on our data set to identify 
differential pathways in week 1.5-3 (high cholesterol and initial lesion formation (week 4.5-9) in the 
aortic arch. GSEA identified no significant pathways in the initial stage, but 24 pathways were 
significantly enriched in the initial lesion formation stage. Next to pathways associated with 
metabolism, 4 immunological pathways are identified (indicated in gray). 
 










































Figure 5: Ranked gene list of top 100 most differential genes between initial and early lesion 
formation. GSEA analysis uses a ranked gene list of expression differences between initial and early 
lesion formation to identify the above described pathways. A heat map of the 100 most differentially 
regulated genes, 50 from initial, and 50 from early lesion formation, is shown. Verification of some 
of these candidates was performed by RT-PCR and the resulting expression profiles are shown in the 
right panels.  









































































































































In the present study we compared gene expression profiles from vascular tissue 
of LDLr-/- mice on different times of diet. We used whole mount material of the 
aortic arch, consisting of endothelial cells, smooth muscle cells and when plaque 
formation has started, leukocytes. This leukocyte influx was clearly 
demonstrated after 4.5 weeks and was significantly present at 9 weeks of diet 
feeding, as the mRNA levels of CD68 and CD4 were elevated at week 9. 
Furthermore, we showed that endothelial activation was already present at 4.5 
weeks of Western type diet by increased expression of vWF36. Based on these 
observations we decided to group our arrays in control (chow fed animals), high 
cholesterol and no lesions (1.5 and 3 weeks of diet) and initial lesion formation 
(4.5 and 9 weeks). In this way, we enlarged the statistical power of our analysis 
and created the opportunity to compare aortic tissue from mice on diet without 
any lesion with very early lesions. We used two statistical approaches to find 
relevant transciptome differences between the time points, because no straight 
forward analysis pipeline exists for the analysis of time dependent microarray 
data. These two methods, one-way ANOVA followed by transcription factor 
binding site scan and GSEA pathway analysis are discussed separately below. 
 
Transcription regulation during initial and early lesion formation 
From the transcription factor binding site analysis, we identified FOXO-1 as a 
new possible regulator of diet induced vascular transcription. Genes regulated by 
this transcription factor are specifically overrepresented in the cluster with 
genes that are upregulated both in initial as well as in early lesion formation. 
This transcription factor expression inside the nucleus is regulated by 
phosphorylation by Akt and AMPK, as phosphorylation results in rapid 
degradation. Fissltaler et al. show that shear stress resulted in rapid phos-
phorylation FOXO1 and that its downstream target HMGCo-A reductase is 
subsequently decreased17. Next to this, FOXO1 has been shown to mediate 
responses in diabetes,  glucose metabolism and  exercise18-20. We show in our 
study, that diet induced genes are regulated by FOXO1 and that subsequently, 
its downstream target HCR is significantly upregulated in the aortic arch during 
Western type diet feeding. This is an interesting observation and indicates that 
FOXO1 is a mediator of both shear stress, as shown by Fissltaler et al, and diet 
induced alterations in vascular transcription. Pro-atherogenic conditions such as 
low shear stress, high glucose or lipid levels and little exercise all increase 
FOXO1 mediated transcription17-20. Therefore FOXO1 provides an interesting 
switch mechanism uniting the pro- atherogenic effects of several identified risk 
factors in atherogenesis. 
 
Furthermore, we identified specific transcription factors for initial lesion 
formation. At this point, a moderate influx of leukocytes was confirmed by 
increased mRNA expression of both CD68 and CD4.  Genes with a TFBS for 
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MEF2 were significantly overrepresented in the gene set that was 
downregulated at this time point. In contrast, genes with a TFBS for the 
inflammation associated transcription factor NFkappaB were overrepresented in 
the cluster with upregulated genes. MEF2 is a transcription factor that has been 
mostly associated with muscle development but is currently investigated in 
endothelial cell biology28,37. A mutation of the MEF2A gene is associated with 
increased risk for coronary artery disease30. Interestingly, MEF2 activity is 
inversely correlated with NFkappaB in our aortic material with early lesions. 
Kumar et al. have described a similar activity regulation profile in TNFα 
stimulated endothelium. The pro-inflammatory mediator TNFα downregulates 
the expression of KLF2, and this decrease is mediated by inhibition of MEF2 by 
NFkappaB38. We propose that a similar regulatory mechanism is activated in 
vascular tissue in a high fat environment leading to atherosclerotic plaque 
formation. 
 
Pathways and genes identified by GSEA  
In the current study we have found some interesting new target genes that were 
overexpressed in aortic tissue with initial or early atherosclerosis. In the top 50 
most differentially regulated genes in initial lesion formation we identified 2 
ABC transporters namely ABCB7 and ABCB10. ABCB10 is a member of the 
MDR/TAP subfamily, which members are associated with multi-drug resistance. 
Until now, the function of this mitochondrial protein is unknown, but a role in 
antigen presentation is suggested39,40. We confirmed the upregulation of ABCB10 
by RT-PCR and identified this molecule as initially elevated due to Western 
type diet feeding.  
CCL8, belonging to the small inducible cytokine family, was identified by GSEA 
as one of the top most differentially expressed within initial atherosclerosis. Real 
time PCR confirmed these findings by GSEA. Several chemokines, such as CCL5 
and CCL2 have been shown to be upregulated in atherogenesis, and specific 
blockade or downregulation of these chemokines has been shown to be 
protective in atherogenesis8, 41-44. CCL8 functions as an attractor for monocytes 
via the CCR2 receptor. Unlike the receptor CCR2, the ligand CCL8 has never 
been associated with (early) atheroma so far. Functional blockade of this 
(possibly endothelial derived) molecule in animal models for atherosclerosis is 
necessary to address its now theoretical role in lesion formation. 
 
We conclude that leukocyte influx into the vessel wall to initiate plaque 
formation is preceded by regulation of genes which are transcriptionally 
regulated by FOXO1. When the fist leukocytes enter the vessel wall, NFkappaB 
regulation is enhanced, combined with a decrease in MEF2 associated 
transcription. Our study thus identifies new transcriptional pathways and genes 
that underlie the early changes in the vessel wall, ultimately leading to 
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Atherosclerosis is an inflammatory disease of the larger arteries that is 
accompanied by an immune response in the context of oxidized lipids and 
lipoproteins within the vessel wall. We quantified the mRNA expression of 
interleukins, chemokines and T cell activation markers in the spleen of LDLr-/- 
mice fed a Western type diet for 3, 6, 9, and 12 weeks and compared this to the 
expression on chow diet. We observed that week 6 of diet feeding is the most 
differentially regulated time point, with a vast upregulation of many pro-
inflammatory mediators. 
We then focussed on the dominant regulators of atherosclerosis associated 
immune responses, the CD4 positive T cell. We used magnetic beads to isolate 
CD4+ cells from the spleen of LDLr-/- after 0-6-12 weeks of diet and determined 
the transcriptional differences in mRNA regulation at these time point by using 
micro-arrays. Interestingly, after 6 weeks of diet, the enriched gene sets iden-
tified are mostly associated with cholesterol homeostasis, and the single 
immunologically relevant gene set is the CCR5 pathway. After 12 weeks of diet, 
the cholesterol homeostasis genes are still significantly enriched, but are now 
accompanied by gene sets involved in leukocyte adhesion, Th1/Th2 activation 
and TNF receptor activation. The CCR5 gene set is also significantly enriched 
after 12 weeks of Western type diet. 
We conclude that a pro-atherogenic diet results in the regulation of cholesterol 
homeostasis associated genes in CD4 cells in the spleen, and that this precedes 
the massive upregulation of the common T cell activation associated molecules 





Atherosclerosis is a disease of the larger vessels characterized by deposition of 
lipids and fibrous tissue and it has been recently recognized as an inflammatory 
disease. Next to lipid deposition within the vessel wall, an ongoing adaptive 
immune reaction against lipids or modified lipoprotein antigens is observed1-5. 
CD4 positive T cells are the predominantly identified T cells subset within 
atherosclerotic plaques of humans6, ApoE deficient (ApoE-/-) and LDL receptor 
deficient (LDLr-/-) mice7-8 and a pathogenic role for these CD4 T cells is indicated 
by the reconstitution of immune-deficient SCID/SCID/ mice with CD4 cells 
which leads to accelerated atherogenesis9. This information is complemented by 
studies with depleting antibodies against CD4 that reduced plaque formation in 
C57/Bl6 mice on high fat diet and attenuated plaque formation in CD4 deficient 
mice10. However, these effects are not observed in ApoE-/- mice11-12. Not only the 
removal of the total CD4 population affects atherogenesis, the specific 
prevention of T cell activation by blockade of T cell co-stimulatory molecules 
such as CD40, OX40 B7 and ICOS have shown to be involved in 
atherosclerosis13-18. The spleen plays an important role in orchestrating the 
immune response during lesion formation. Removal of the spleen leads to 
increased atherogenesis in ApoE-/- mice and to reduced levels of antibodies 
against oxidized lipid antigens15.  
In this study we evaluated the expression of an array of genes associated with 
the regulation of immune responses, such as chemokines, interleukins and T cell 
activation in the spleen of LDLr-/- mice on a Western type diet. Diet dependent 
differential regulation was observed and several regulatory patterns are 
described. Based on these initial results we performed full gene expression 
analysis in isolated splenic CD4 cells during diet feeding and identified genes 
and pathways that are involved in the systemic ongoing immune response 
during atherosclerotic lesion formation. 
Transcriptional Profiling of CD4+ T Cells During Atherogenesis 
 61 
Material and methods 
 
Animal studies 
LDLr-/- mice (n=6 per time point) were fed a Western type diet for 0-3-6-9-12 
weeks. After the indicated time points, mice were anesthetized and flushed with 
PBS. The spleen was snap frozen in liquid nitrogen for RNA isolation. Cryostat 
sections of the aortic root (10 µm) were collected and stained with Oil-red-O. 
Lesion size was determined in 10 sections of the aortic valve leaflet area. For the 
microarray experiments, spleen single cell suspensions were prepared and CD4 T 
cells were isolated using CD4 specific IMag beads (Becton Dickinson) according 
to the manufacturers’ protocol. 
 
Serum lipid levels 
Blood samples were collected by tail bleeding from non-fasted animals.  
Concentrations of serum cholesterol and triglycerides were determined using 
enzymatic colorimetric procedures (Roche/Hitachi, Mannheim, Germany). 
Precipath (Roche/Hitachi) was used as a standard. 
 
Real Time PCR assays 
Total RNA was isolated from spleen using the guanidium isothiocyanate (GTC) 
method. Purified RNA was DNase treated (DNase I, 10 units/µg of total RNA) 
and reverse transcribed (RevertAid M-MuLV reverse transcriptase) according to 
manufacturers protocol. Quantitative gene expression analysis was performed on 
an ABI PRISM 7700 (Applied Biosystems, Foster City, CA) using SYBR Green 
technology. PCR primers (Appendix I) were designed using Primer Express 1.7 
software with the manufacturer's default settings (Applied Biosystems) and 
validated for identical efficiencies (slope = –3.3 for a plot of the threshold cycle 
number (Ct) versus log ng cDNA). Acidic ribosomal phosphoprotein PO (36B4) 
and hypoxanthine phosphoribosyl transferase (HPRT) were used as 
housekeeping genes.  
 
Microarray analysis 
RNA was isolated from CD4 T cells using Trizol. RNA was linearly amplified for 
1 round (starting material 1 μg total RNA) synthesizing anti-sense cRNAs with 
an average base length of 500 nucleotides using the Message-Amp kit from 
Ambion. Aminoallyl-UTP was incorporated with a molar ration of 1:1 to rUTP. 
Cy3 or Cy5 mono-reactive dyes were coupled according to the manufacturers’ 
instructions (Amersham Bioscience, Piscataway, New Jersey). Labeled cRNA was 
purified using the RNeasy purification kit (Qiagen, Germany). All RNA samples 
were hybridized against a common reference containing (in equal amounts and 
amplified one round); liver, spleen and aorta of LDLr-/- mice 6 weeks on Western 
type diet and LDLr-/- mice treated with LPS, RAW cells treated with LPS, H5V 





Figure 1: Diet induced atherosclerosis in LDL receptor deficient mice Female LDLr-/- mice (n=6 per 
group) were placed on a Western type diet for 0-3-6-9-12 weeks. Serum free and total cholesterol 
and triglycerides were determined during the experiment and a significant increase is observed at 3 
weeks of Western type diet feeding that is maintained throughout the experiment. Lesion formation 
in the aortic root was quantified at the indicated time points after Oil red o staining and average 
lesion size is indicated in upper right panel. Representative slides are shown for every time point. 
 
Hybridization was performed on glass based micro-arrays representing 22.056 
unique murine oligonucleotide sequences (Micro Array Department, University 
of Amsterdam, The Netherlands (http://www.microarray.nl/libraries.html). 
Microarray data were acquired and imported in Rosetta Resolver database and 
Loess normalized (limma package, Bioconductor). Genome wide analysis at 
group level was performed using GSEA after conversion of mouse to human 
signature16. The molecular signature database that was used was a modified 
version of the original named c2.symbols.gmt(available on-line at http:// 
www.broad. mit .edu/gsea/msigdb/msigdb_index.html) set and earlier described 
by Volger et al16. The dataset contained 594 gene sets. Analysis was performed 
with the following settings: 100 permutations on phenotype, gene sets with 
more that 10 genes were included in the analysis.   
 










































Transcriptional Profiling of CD4+ T Cells During Atherogenesis 
 63 
Statistical analysis  
Values are expressed as mean ± SEM. Two-tailed student’s T-test was used to 
compare normally distributed data between two groups of animals. Mann-
Whitney test was used to not normally distributed data. A probability value of 





Atherosclerotic lesion formation in LDLr-/- mice during Western type diet 
feeding 
We used LDLr-/- mice as a model for atherosclerosis and these animals were fed 
a Western type diet for 0-3-6-9-12 weeks. This diet does not contain cholate and 
only 0.25 % cholesterol. Diet feeding results in elevated cholesterol and 
triglyceride levels already after 3 weeks, and these elevated levels were 
maintained throughout the experiment (figure 1 upper left). Basal free 
cholesterol levels were 91 ± 44 mg/dl vs 331 ± 83 mg/dl at week 3. Total 
cholesterol level at chow feeding were 265 ± 115 mg/dl and these rose to 1249 ± 
398 mg/dl after 3 weeks of Western type diet. An induction was also observed in 
triglyceride levels, from 109 ± 57 mg/dl to 229 ± 44 in week 3. The observed 
induction in cholesterol and triglyceride levels was accompanied by the 
formation of atherosclerotic plaques. Figure 1 clearly shows the induction in 
lesion formation in the aortic valve leaflet area in time. After 12 weeks, lesion 
size averaged 583 ± 50 mm2 and a sharp increase in lesion size is observed 
between 3 and 9 weeks of diet feeding (from 31 ± 9.2 to 518 ± 86 mm2). 
Representative pictures of the aortic valves are shown for every time point. 
 
Gene expression in the spleen during Western type diet feeding in LDLr-/- mice 
To investigate the systemic immunological changes within the spleen in relation 
to the observed induction of atherosclerosis, we isolated mRNA from spleens of 
LDLr-/- mice at the indicated time points (0-3-6-9-12 weeks of diet). We 
determined the gene expression of a panel of genes associated with immune 
responses, including interleukins, chemokines and T cell activation molecules. 
The results are shown in figure 2. 
We observed 3 distinct regulatory patterns within the array of interleukins we 
scanned. Panel 2A shows the regulation of, IL-9, IL-10 and TNFα, all clearly 
being downregulated during Western type diet feeding from week 6. 
Interestingly, IL-4 was significantly upregulated after 6 weeks of diet feeding, 
only being downregulated after 12 weeks.  IL-1β, IL-2 and IL-17A expression is 
already significantly upregulated at 3 weeks of diet feeding, showing a peak 
expression at week 6 and returning to basal level at 12 weeks (Panel 2B). This 
peak at week 6 was also observed when we determined the expression of IFNγ, 
IL-6, and not for the T cell activator IL-12 and the growth factor TGFβ.  (Panel 





Figure 2: Transcriptional regulation of interleukins (A-C), chemokines (D-E) and T cell activation 
markers (F-G) in the spleen during atherogenesis 
mRNA was isolated from the spleen of LDLr-/- using the GTC method and expression of different 
genes is expressed relative to 36B4 and HPRT, and subsequently related to the expression of mice on 
chow diet. An unpaired Student t test was applied to test whether mRNA levels were significantly 
different from the mRNA levels in chow fed animals (*p < 0.05, n=6 per time point). 
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by T cells. The expression of TGFβ was extremely high in all time points (as 
compared to house hold gene expression) and not differentially regulated. 
Not only interleukins, but chemokines are involved in immune activation and 
migration during atherogenesis. We therefore checked the expression profile of 
several chemokines and chemokine ligands during Western type diet feeding. 
Interestingly, the expression profile of CCR5, MCP-1, MIP-1α and RANTES is 
similar to the regulation of IL-6 and IFNγ (panel 2C), showing a sharp increase 
in expression after 6 weeks of Western type diet feeding (Panel 2D). Diet 
feeding however resulted in a decreased expression of CCR3 and CXCR3 as 
shown in panel 2E. One of the ligands for CXCR3, CXCL10 was only 
downregulated after 9 weeks of diet feeding but was significantly upregulated 
after 3 weeks.  
 
The differential expression of interleukins and chemokines may suggest an effect 
on the T cell population present in the spleen. We therefore determined the 
expression of the T cell activation markers CD40, CD69 and CTLA-4. 
Surprisingly, for these molecules a very vast and significant increase in 
expression was observed only after 6 weeks of Western type diet feeding (Panel 
2F). A different profile is observed for CD25 (IL-2 receptor expressed on 
regulatory T cells) and CD28, a co-activation marker. The expression of these 
molecules is effectively downregulated by Western type diet feeding after week 
6 (Panel 2G). A distinct pattern is observed for CD134 (OX40), a T cell activation 
marker from the TNF receptor superfamily used for co-stimulation. Its 
expression is nicely correlated with the induction of atherosclerosis, increasing 








Figure 3: M versus A plots of re-ratio 
profiles from CD4 T cells isolated from 
the spleen after 6 and 12 weeks of diet 
compared to chow. CD4+ T cells were 
isolated from the spleen of LDLr-/- mice 
after 0-6-12 weeks of Western type diet 
feeding by using anti-CD4 magnetic bead 
separation. RNA was isolated and 
amplified one round and hybridized 
against a common reference. Rosetta 
Resolver was used to generate M vs. A 
plots and the significantly regulated genes 
compared to chow fed animals are shown 













Transcriptional regulation of CD4 T cells in the spleen during diet induced 
atherogenesis  
The regulation patterns observed above indicate a differential regulation of 
genes associated with immune activation and regulation during diet induced 
lesion formation. Especially week 6, the time point that correlates with 
extensive plaque growth, and week 12 seem to show distinct regulatory patterns. 
The spleen however, consists of many cell types, including macrophages, T and 
B lymphocytes. As CD4+ effector T cells are the predominant T cell subclass 
linked to atherosclerotic lesion formation, we decided to investigate the 
transcriptional regulation of this specific cell type during atherogenesis. We 
isolated CD4+ T cells from the spleen after 0, 6 and 12 weeks of diet using 
magnetic beads.  Homogeneity of the isolated population was tested using FACS 
and bead isolation resulted in >95% CD4+ T cells (data not shown). 
Transcriptional differences in this population during diet induced lesion 
formation (0, 6 and 12 weeks) were determined by micro-array. Isolated mRNA 
from every CD4 sample (n=4 per time point) was amplified one round and 
hybridized against a common reference. M versus A plots that show relative 
expression to week 0 versus intensity are shown in figure 3.  
 
Gene set enrichment analysis 
Pathway based Gene Set Enrichment Anaysis (GSEA) was used to study 
transciptome differences in CD4+ T cells in the spleen during Western type diet 
feeding. This method enables the interpretation of genome-wide expression 
profiles based on biological function. Next to the functional output, this analysis 
tool identifies a top 100 of signature genes of one situation compared to 
another16. In this way, gene sets that contain genes that are overrepresented at 
the extremes of the ranked gene list will result in high enrichment scores.  
Tables 1 A and B  show the enriched pathways for both  6 weeks of diet feeding 
and 12 weeks of diet feeding, and the nominal P values calculated by weighted 
Kolmogorov-Smirnov-like statistic as described earlier16. 
The gene sets enriched in CD4+ cells after 6 weeks of diet (compared to chow 
fed, early atherosclerosis) are visualized in table 1A. Interestingly, metabolic 
pathways such as PPARα, fatty acid metabolism and glucose metabolism 
associated pathways are present at this time point. This indicates that the CD4+ T 
cells in the spleen respond to the increase in cholesterol and triglyceride levels 
upon Western type diet feeding.  Next to these metabolic pathways, genes 
associated to the CCR5 pathway are enriched after 6 weeks of diet 
corresponding to extensive plaque growth. 
After 12 weeks of diet, the number of gene sets significantly enriched compared 
to chow fed animals is 23, and a list of these gene sets is shown in table 1B. 
Again, several gene sets associated with metabolism, some similar to week 6, are 
observed. These include PPARα and fatty acid metabolism. The number of gene 
sets associated with inflammation was clearly increased. Again, the gene set 
CCR5 is  significantly enriched compared  to week 0.  Additional immunological  
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Table 1 A + B: enriched gene sets identified using GSEA. GSEA was used on our data set from CD4+ T 
cells to identify differential pathways in week 6 and 12 compared to week 0. Gene set and nominal p 
value are shown for week 6 (table A) and week 12 (table B). 
 
gene sets include 41bb, which consists of T cell co-activation genes, TNF 
pathways, which include T cell activation and cell death receptors, and Th1/Th2 
genes that regulate the differentiation of T cells. The most significantly enriched 
pathway is a cell adhesion pathway, indicating increased adherence capacity of 
the CD4+ T cell population in the spleen.   
 
Lipid metabolism associated genes 
Western type diet feeding has a profound effect on cholesterol metabolism in 
CD4+ T cells. This is remarkable, as no specific lipid uptake or scavenging 
systems have been described in T cells. We looked in our array database for lipid 
associated genes with a minimum fold in- or decrease of 2 and a (Rosetta) p 
value < 0.05 in week 6 and 12 compared to the control mice and the results are 
shown in table 2. 
When we compare the gene list of weeks 6 and 12, 4 genes are significantly 
induced in both time points; CD36, fatty acid binding protein (FABP) 1, ABCA8, 
and lipocalin 5 (shown in gray).  








































Table 2 A + B: Significantly regulated genes involved in lipid metabolism. Genes with a role in lipid 
metabolism that were significantly regulated in week 6 (table A) and week 12 (B). Fold change and 
nominal p value are indicated. 
 
CD36 is a member of the scavenger receptor family and has an important role in 
the uptake of modified LDL and is used in the clearance of pathogens. FABP1 
binds long chain fatty acids and is associated with fatty acid metabolism. ABCA8 
is identified as an ATP dependent lipophilic drug transporter. Lipocalin 5 
belongs to the lipocalin family and shares functional homology with the FABP 
family. This family is involved in binding to hydrophobic molecules and has 
been suggested to play a role in cell homeostasis and regulation of the immune 





The hypothesis that atherosclerosis is a lipid driven chronic inflammatory 
disease is now widely accepted. Several important publications have indicated 
the pivotal role of CD4 cells in the initiation and maintenance of this 
immunological response within the atherosclerotic plaque5, 11.  
Next to a local inflammatory response at the site of the atherosclerotic lesion, 
systemic upregulation of interleukins and elevated levels of antibodies against 
oxidized lipoproteins and heat shock proteins have been identified in humans 
with atherosclerotic lesions17,18. This study shows that next to a local 
inflammation of the arterial wall, systemic immune-regulation takes place in the 
spleen during diet-induced atherosclerotic lesion formation. This is not 
unexpected, as the spleen is continuously exposed to the elevated circulating 
Week 6 (A) Fold change NOM p-val 
CD36 antigen 4.57 0.0192 
Fatty acid binding protein 1, liver 4.55 0.0000 
Cytochrome P450, family 3, subfamily a, polypeptide 44 3.90 0.0018 
Stearoyl-Coenzyme A desaturase 2 3.84 0.0000 
ATP-binding cassette, sub-family A (ABC1), member 8b 3.50 0.0216 
Lipocalin 5 3.07 0.0000 
Tocopherol (alpha) transfer protein 2.89 0.0346 
Cytochrome P450, family 4, subfamily a, polypeptide 14 2.87 0.0000 
3-oxoacid CoA transferase 2A 2.77 0.0454 
Apolipoprotein A-V 2.51 0.0138 
Cytochrome P450, family 8, subfamily b, polypeptide 1 2.28 0.0321 
ATP-binding cassette, sub-family C (CFTR/MRP), member 5 2.06 0.0025 
 
Week 12 (B) Fold change NOM p-val 
Fatty acid binding protein 1, liver 5.05 0.0000 
ATP-binding cassette, sub-family A (ABC1), member 8b 4.81 0.0475 
CD36 antigen 3.18 0.0700 
Lipocalin 5 2.63 0.0017 
Cytochrome P450, family 2, subfamily c, polypeptide 29 2.41 0.0001 
Acyl-Coenzyme A dehydrogenase, very long chain 2.12 0.0013 
Cytochrome P450, family 7, subfamily b, polypeptide 1 -2.44 0.0440 
Bile acid-Coenzyme A: amino acid N-acyltransferase -2.57 0.0077 
Cytochrome P450, family 3, subfamily a, polypeptide 44 -3.99 0.0005 
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 -18.27 0.0172 
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lipoproteins. Both direct activation via the diet and indirect activation of the 
spleen cells due to migrated dendritic cells that have taken up antigens in the 
vascular wall can result in systemic immune-activation.  
We used female LDLr-/- mice on a pro-atherogenic Western type diet as a model 
for atherosclerosis. This diet induces lesion formation in the large vessels of the 
animal, and we examined the expression of known immunologically active genes 
in the spleen after 0-3-6-9-12 weeks of diet. We show that between 3 and 9 
weeks of diet, lesion area is rapidly increased. One of the most interesting 
observations is the combined upregulation of known pro-inflammatory factors 
after 6 weeks of diet feeding, correlating to the point of extensive lesion growth. 
Upregulation at this time point was observed for interleukins (IFNγ, IL-6, IL-1β, 
IL-17), chemokines (CCR5, MCP-1, MIP-1α, RANTES) and T cell specific 
activation markers (CD40, CD69, CTLA-4, OX40). A pro-atherogenic role was 
established for the vast majority of these factors19. Next to this interesting peak 
profile observed at week 6, the severe downregulation of a number of genes at 
week 12 deserved attention. Downregulation is seen for identified anti-
atherogenic factors such as IL-9 and IL-10 that are associated with Th2 and 
regulatory T cells20-22. This decrease is accompanied by the reduced expression of 
CD25, expressed on regulatory T cells23. Next to the expected downregulation of 
anti-atherogenic markers, the expression of  CD28, a co-stimulatory molecule 
for T cells is also decreased at this time point24.  Furthermore, the expression of 
CXCL10 and CXCR3, both identified as being pro-atherogenic, decreased as 
well25-28. Due to the multi-cellular composition of the spleen, the observed 
regulatory profiles are hard to address. Macrophages, T cells and B cells all can 
contribute to the observed transcriptional differences especially for interleukins 
such as IL-6 and IL-10, which can be produced by many cell types.  
 
During recent years, it was shown that CD4+ T cells are an important  immuno-
regulatory cell associated with atherosclerosis6-10. We therefore focused our 
attention on this specific subclass of T cells, and determined the transcriptional 
regulation induced during atherosclerosis induction upon feeding atherosclerosis 
prone LDLr-/- mice a Western type diet.  
We isolated CD4+ T cells from mice that received 6 and 12 weeks of diet, and 
compared the transciptome of these cells with CD4+ T cells isolated from mice 
on chow. We performed Gene Set Enrichment analysis on the expression profile 
datasets to identify gene sets that were significantly enriched at these time 
points. It appears that the gene set for CCR5 was enriched after both 6 and 12 
weeks of diet feeding. This is interesting, as the expression of CCR5, RANTES 
and CCR2 in the whole spleen is only elevated after 6 weeks of diet feeding. 
After 12 weeks of atherosclerosis induction, more inflammatory pathways are 
enriched, including TNF receptor super family members, Th1/Th2 
differentiation genes and cell adhesion markers. This clearly indicates the 




One intriguing issue is the difference in regulatory profile between the entire 
spleen and the isolated CD4 population. When analyzing the profiles of most 
pro-inflammatory genes such as IL-1β, IL-6, IFN-γ, a peak is observed after 6 
weeks of Western type diet feeding. When we compare this to the gene sets in 
the specific CD4+ population at week 6, only CCR5 is clearly associated with 
immunological activation as it is predominantly expressed on activated Th1 
cells.  Most of the gene sets identified at this time point are however metabolism 
related. Only after 12 weeks we observed gene sets that indicate T cell 
differentiation and activation, including Th1/Th2 differentiation and TNF 
receptor superfamilies. The CCR5 gene set was significantly enriched at this 
time point as well. 
During inflammation, the innate immune response precedes the adaptive T cell 
mediated reaction. The innate response is mediated by macrophages and other 
antigen presenting cells and the interleukins IL-1β, IFNγ and IL-6 are known 
mediators of this process. The observed upregulation of these molecules in the 
spleen already after 3-6 weeks most likely results from this early defence system, 
and possibly results from activation by elevated levels of circulating lipids that 
are possibly minimally modified.  The adaptive, T cell mediated reaction is 
taking over between 6 and 12 weeks of atherosclerosis. This is shown by the 
upregulation of T cell activation pathways in the isolated CD4 subset. Possibly, 
at this time point, presentation of antigens derived from the atherosclerotic 
plaque is facilitated by dendritic cells that specifically induce the activation of 
these T cells. 
 
An interesting and rather unexpected finding in our study was the profound 
representation of lipid homeostasis genes that are normally associated with 
hepatic lipid metabolism. Especially after 6 weeks of diet, these gene sets clearly 
outnumber the immune response associated gene sets (except for CCR5). When 
we looked for genes associated with lipid homeostasis in the single gene list we 
found several significantly differentially regulated genes. Most of these genes are 
involved in the removal or degradation of (potentially) harmful lipids and free 
fatty acids. These include the cytochrome P450 enzymes and ATP binding 
cassette transporters that mediate transport of cholesterol in and out of cells. 
Also the fatty acids binding proteins and lipocalins are involved in the 
neutralization,  removal or degradation of molecules such as fatty acids. 
 
A possible link between the observed regulation in the areas of lipid metabolism 
and immunological activation is provided by 2 transcription factors, PPARα and 
NFAT. 
 
PPARα is a nuclear receptor that has been shown to modulate both lipid 
homeostasis and inflammation29,30. PPARα agonist such as fenofibrates and 
benzofibrates reduce triglycerides and induce HDL levels and attenuate 
atherosclerotic lesion formation in animal models31,32. Interestingly, GSEA 
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analysis after diet feeding resulted in the enrichment of the PPARα gene set in 
CD4+ T cells after both 6 and 12 weeks of Western type diet feeding, indicating a 
role for this nuclear receptor in T cell activation during atherosclerotic lesion 
formation. Possibly, in a high fat environment the expression of PPARα in T 
cells is induced to prevent large scale cholesterol uptake by these cells. PPARα is 
able to induce the removal of cholesterol from macrophages in a high fat 
environment via stimulation of efflux transporters such as ABCA133. However, 
not only the upregulation of efflux transporters is the effect of increased PPARα 
activity. This also results in suppression of NF-κB activity and decreased IFNγ 
production by T cells. This suggests a negative feedback loop on T cell 
activation, so further research will be necessary to address these effects. 
However, when looking at the general expression of inflammatory markers in 
the spleen during diet feeding for 12 weeks, downregulation of genes activated 
by NF-κB such as IL-1β and IL-12 is observed. 
 
The nuclear factor of activated T cells (NFAT), is a transcriptional factor that is 
expressed in T cells 34. It regulates the transcription of (cytokine) genes that are 
critical during an immune response such as IL-2, IFN-γ, TNF-α and CD40 ligand 
35. Immune-suppression using cyclosporine A and KF506 have been shown to be 
protective in atherosclerosis36,37 due to reduced calcineurin mediated phos-
phorylation of NFAT and its subsequent translocation to the nucleus38. One of 
the most differentially regulated genes in CD4+ T cells during induction of 
atherosclerosis after Western type diet feeding is Lipocalin-5. The expression of 
this gene is regulated by the transcription factor FOXA1 that in turn is activated 
by NFAT34,39. Mazière et al. provide evidence that oxidized LDL activates NFAT 
in a T cell line34. Upregulation of NFAT signaling can therefore be caused by the 
increased levels of circulating (oxidized) lipoproteins and subsequently induce a 
systemic immune response. 
 
The data shown in this study indicate that T cells are heavily influenced by high 
levels of circulating (oxidized) lipids. Further research is necessary to determine 







1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 
2005;352:1685-1695. 
2. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. 
Nat Rev Immunol. 2006;6:508-519. 
3. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the 
pathogenesis of atherosclerosis. Circ Res. 2002;91:281-291. 
4. Mallat Z, Ait-Oufella H, Tedgui A. Regulatory T cell responses: potential role in the 
control of atherosclerosis. Curr Opin Lipidol. 2005;16:518-524. 
5. Zhou X. CD4+ T cells in atherosclerosis. Biomed Pharmacother. 2003;57:287-291. 
6. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. 
Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-
inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33-
43. 
7. Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis. 
CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol. 
1996;149:359-366. 
8. Roselaar SE, Kakkanathu PX, Daugherty A. Lymphocyte populations in atherosclerotic 
lesions of apoE -/- and LDL receptor -/- mice. Decreasing density with disease 
progression. Arterioscler Thromb Vasc Biol. 1996;16:1013-1018. 
9. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates 
atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 
2000;102:2919-2922. 
10. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP. T helper-cell phenotype regulates 
atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation. 
2001;103:2610-2616. 
11. Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK. Lesion development and 
response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res. 
2005;96:427-434. 
12. Elhage R, Gourdy P, Brouchet L, Jawien J, Fouque MJ, Fievet C, Huc X, Barreira Y, 
Couloumiers JC, Arnal JF, Bayard F. Deleting TCR alpha beta+ or CD4+ T lymphocytes 
leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-
deficient mice. Am J Pathol. 2004;165:2013-2018. 
13. Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ. Both 
early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. 
Proc Natl Acad Sci U S A. 2000;97:7464-7469. 
14. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA. 
Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313-1316. 
15. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against 
atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest. 
2002;109:745-753. 
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich 
A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl 
Acad Sci U S A. 2005;102:15545-15550. 
17. Tsimikas S, Palinski W, Witztum JL. Circulating autoantibodies to oxidized LDL correlate 
with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. 
Arterioscler Thromb Vasc Biol. 2001;21:95-100. 
18. Szodoray P, Timar O, Veres K, Der H, Szomjak E, Lakos G, Aleksza M, Nakken B, Szegedi 
G, Soltesz P. TH1/TH2 imbalance, measured by circulating and intracytoplasmic 
inflammatory cytokines--immunological alterations in acute coronary syndrome and 
stable coronary artery disease. Scand J Immunol. 2006;64:336-344. 
Transcriptional Profiling of CD4+ T Cells During Atherogenesis 
 73 
19. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. 
Physiol Rev. 2006;86:515-581. 
20. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, Nicoletti A. 
Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density 
lipoproteins in apolipoprotein E knockout mice. Mol Med. 2003;9:10-17. 
21. Von Der Thusen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ, Biessen EA. 
Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of 
interleukin-10 in LDLr-/- mice. Faseb J. 2001;15:2730-2732. 
22. von Der Thusen JH, Stitzinger M, van Wanrooij E, De Vos P, van Berkel TJ, Biessen EA, 
van Snick J, Kuiper J. Interleukin-9 inatherosclerosis: therapeutic application and 
endogenous function. 
23. Scheffold A, Huhn J, Hofer T. Regulation of CD4+CD25+ regulatory T cell activity: it 
takes (IL-)two to tango. Eur J Immunol. 2005;35:1336-1341. 
24. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 
2005;23:515-548. 
25. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, Luster AD. Differential 
expression of three T lymphocyte-activating CXC chemokines by human atheroma-
associated cells. J Clin Invest. 1999;104:1041-1050. 
26. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, Jones K, Koehn SL, Lok VM, 
Aikawa E, Moore KJ, Luster AD, Gerszten RE. Chemokine CXCL10 promotes 
atherogenesis by modulating the local balance of effector and regulatory T cells. 
Circulation. 2006;113:2301-2312. 
27. Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, Charo IF, Mach F. Differential 
influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in 
vivo. Circulation. 2005;112:870-878. 
28. van Wanrooij EJ, Happe H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, van Berkel TJ, 
Kuiper J. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density 
lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:2642-2647. 
29. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and 
inflammation. Pharmacol Ther. 2006;110:371-385. 
30. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target 
genes. Cell Mol Life Sci. 2004;61:393-416. 
31. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, 
Burton CA, Tedgui A, Fruchart JC, Fievet C, Wright SD, Staels B. Reduction of 
atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate 
in mice. J Biol Chem. 2002;277:48051-48057. 
32. Kooistra T, Verschuren L, de Vries-van der Weij J, Koenig W, Toet K, Princen HM, 
Kleemann R. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for 
multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb 
Vasc Biol. 2006;26:2322-2330. 
33. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, 
Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-alpha and PPAR-
gamma activators induce cholesterol removal from human macrophage foam cells through 
stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58. 
34. Yu X, Suzuki K, Wang Y, Gupta A, Jin R, Orgebin-Crist MC, Matusik R. The role of 
forkhead box A2 to restrict androgen-regulated gene expression of lipocalin 5 in the 
mouse epididymis. Mol Endocrinol. 2006;20:2418-2431. 
35. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and 
function. Annu Rev Immunol. 1997;15:707-747. 
36. Donners MM, Bot I, De Windt LJ, van Berkel TJ, Daemen MJ, Biessen EA, Heeneman S. 
Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes 
plaques in ApoE-/- mice. Am J Transplant. 2005;5:1204-1215. 
37. Drew AF, Tipping PG. Cyclosporine treatment reduces early atherosclerosis in the 
cholesterol-fed rabbit. Atherosclerosis. 1995;116:181-189. 
Chapter 3 
 74 
38. Loh C, Shaw KT, Carew J, Viola JP, Luo C, Perrino BA, Rao A. Calcineurin binds the 
transcription factor NFAT1 and reversibly regulates its activity. J Biol Chem. 
1996;271:10884-10891. 
39. Dave V, Childs T, Xu Y, Ikegami M, Besnard V, Maeda Y, Wert SE, Neilson JR, Crabtree 
GR, Whitsett JA. Calcineurin/Nfat signaling is required for perinatal lung maturation and 















The HIV Entry Inhibitor TAK-779 Attenuates 
Atherogenesis in LDL Receptor Deficient mice 
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HIV combination therapy using protease-inhibitors is associated with elevated 
plasma levels of atherogenic lipoproteins and increased risk for atherosclerosis. 
We investigated whether the HIV entry inhibitor TAK-779, affects lipoprotein 
levels and atherogenesis in LDL receptor deficient mice. 
TAK-779 is an antagonist for the chemokine receptors CCR5 and CXCR3, that 
are expressed on leukocytes, especially Th1 cells, and these receptors may be 
involved in recruitment of these cells to atherosclerotic plaques.  
TAK-779 treatment of LDLr-/- mice did not elevate the levels of atherogenic 
lipoproteins, whereas it dramatically reduced atherosclerosis in the aortic root 
and in the carotid arteries. The number of T cells in the plaque was reduced by 
95%, concurrently with a 98% reduction in relative IFN-γ area. TAK-779 treated 
animals showed a decreased percentage of CD4+ and CD8+ T cells in peripheral 
blood and in mediastinal lymph nodes compared to control treated animals.  
TAK-779 not only suppresses HIV entry via blockade of CCR5 but also 
attenuates atherosclerotic lesion formation by blocking the influx of Th1 cells 
into the plaque. TAK-779 treatment may be especially beneficial for young HIV 






Leukocyte recruitment into the vessel wall is a key step in atherosclerotic lesion 
formation and chemokines are known to regulate this process. Chemokines can 
be divided into four families including the CC receptors that bind CC 
chemokines, and the CXC receptors which bind CXC chemokines1. CCR5 and 
CXCR3 are two chemokine receptors that are implicated in the migration of 
activated Th1 cells to the site of inflammation, and both receptors have been 
suggested as potential targets for the treatment of auto-immune like diseases2,3. 
A 32 base pair deletion in the CCR5 gene (CCR5∆32) results in a non-functional 
receptor and individuals that are homozygous for this deletion are resistant to 
infection with HIV4,5.  Interestingly, it is also shown that this natural deficiency 
in CCR5 protects individuals from early myocardial infarction and severe 
coronary artery disease. The ligands for CCR5, RANTES and MIP-1α, have been 
detected in atherosclerotic plaques of both humans and mice6-9. Furthermore, 
inhibition of CCR5/CCR1 using the receptor antagonist met-RANTES attenuates 
atherosclerosis in LDLr deficient mice10. Antibody mediated blockade of CXCR3 
results in a decreased recruitment of Th1 cells to the site of inflammation3. 
TAK-779 (N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzo-
cyclorepten-8-yl]carbonyl]amino]benzyl]-tetrahydro-2H-pyran4-aminiumchlo-
ride) is a non-peptide CCR5/CXCR3 antagonist, that was developed for the 
treatment of HIV infection by inhibiting HIV cell entry via CCR511-13. TAK-779 
however has also some anti-immunogenic effects. It has been shown to block 
the influx of CCR5 and CXCR3 positive T cells into inflamed joints in an 
experimental model for arthritis14.  
Both CCR5 and CXCR3 are predominantly expressed on Th1 cells15. As 
atherosclerosis is considered to be a Th1 mediated disease16,17, treatment with 
TAK-779 could possibly attenuate atherogenesis by blocking the influx of Th1 
cells into the atherosclerotic lesion. Both studies in humans and mice 
demonstrate an increase in atherosclerotic lesion formation and myocardial 
infarction in relation to the protease inhibitor treatment in HIV positive 
patients18-22. TAK-779 could therefore have a dual function in these patients, as it 
not only blocks virus entry, but at the same time inhibits the severe side effects 
of their therapy. 
In the present study we show that treatment of LDLr-/- mice with TAK-779 
attenuates atherosclerotic lesion formation.  TAK-779 treatment may therefore 
serve as a new convenient treatment of HIV infection and at the same time 
attenuate atherosclerotic lesion formation, in contrast to the now available 
combination therapy with protease inhibitors.  
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Materials and methods 
 
Animal experiments 
Female LDLr deficient (LDLr-/-) mice, 15 weeks old (n=10/group), were put on a 
Western-type diet containing 0.25 % cholesterol and 15% cocoa butter two 
weeks before collar placement. Silastic collars (0.3 mm inside diameter, Dow 
Corning, Midland, USA) were placed around the carotid artery to induce 
atherosclerosis as described previously23.  
Mice were treated immediately after collar placement with an injection of 150 
µg TAK-779 in 100 µl of 5% mannitol(w/v) subcutaneously every other day 
during 6 weeks after which mice were anesthetized and subsequently sacrificed 
during tissue harvesting (5% mannitol was used as a control). 
In a second experiment female LDLr-/- (mice n=10/group) were fed a Western 
type diet and TAK-779 treatment was started simultaneously. Treatment was 
performed for 6 weeks and hearts were excised and stored in Zinc Formal-Fixx 
and the aortic root was taken out for analysis.  
 
Histological analysis 
Cryosections were stained with hematoxilin (Sigma Diagnostics) and eosin 
(Merck diagnostics). Corresponding sections were stained with antibodies 
directed against a macrophage specific antigen (MOMA-2, polyclonal rat IgG2b,; 
Research diagnostics); α-smooth muscle cell actin (monoclonal mouse IgG2a, 
clone 1A4, Sigma Diagnostics); IFN-γ (rat IgG1, clone XMG1.2, BD Pharmingen) 
or CD3 (molecular complex 17A2, BD Pharmingen) for 2 hours. As secondary 
antibodies (1 hour incubation) goat anti-rat IgG alkaline phosphatase conjugate 
(Nordic) with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate 
as enzyme substrates, or biotinylated goat anti-rat polyclonal Ig (BD 
Pharmingen) was used in combination with streptABC complex (DAKO), with 
Nova Red as enzyme substrate (Vector Laboratories). Collagen was visualized by 
picosirius red (Direct red 80) and lipids by Oil red O staining.    
 
Serum lipid levels 
Concentrations of serum cholesterol and triglycerides were determined using 
enzymatic colorimetric procedures (Roche/Hitachi, Mannheim, Germany). 
Precipath was used as a standard. Cholesterol distribution over the different 
lipoproteins was determined by fractionation of the serum using a FPLC system 
and subsequent cholesterol assay.  
 
Real time PCR assays 
Total RNA was isolated from spleens of the mice using GTC method. Purified 
RNA was DNase treated (DNase I, 5 units/µg of total RNA) and reverse 
transcribed (RevertAid M-MuLV reverse transcriptase) according to 
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appendix I) was performed on an ABI PRISM 7700 machine (Applied 
Biosystems, Foster City, CA) using SYBR Green technology.  
 
Flow cytometry 
Lympholite (Cedarlane Laboratories, Hornby, Ontario, Canada) was used to 
separate lymphocytes from whole blood and spleen. Cell suspensions from 
mediastinal lymph nodes, spleen and blood were incubated with 1% normal 
mouse serum in PBS and stained for surface markers (0.5 µg Ab/200.000 cells, 
BD Bioscience). All data were acquired on a FACSCalibur and 10000 lymphocyte 
events were analyzed with CELLQuest software (BD Biosciences). 
 
Figure 1. mRNA expression of inflammatory markers in the spleen in response to a Western type 
diet.  mRNA was isolated from spleen using the GTC method and expression of different genes is 
expressed relative to 36B4 and HPRT, and subsequently related to the expression of mice on chow 
diet. An unpaired Student t test was applied to test whether mRNA levels were significantly 




Figure 2. Effect of TAK-779 treatment on 
serum lipid levels. LDLr-/- mice (n=6 per 
group) were put on a Western type diet 
and treated with 150 µg of TAK-779 s.c. 
per mouse every other day or control. At 
the indicated time points blood samples 
were taken and serum cholesterol (2A) and 
triglyceride (2B) levels were determined. 
Distribution of cholesterol over 
lipoproteins was determined using FPLC.  
30 µl aliquots of serum of individual mice 
were loaded on a Pharmacia SMART 
column and 24 fractions were collected. 
Cholesterol concentrations were deter-
mined at chow (2C) and Western type diet 

















































mRNA expression in spleen of CCR5, CXCR3 and their ligands 
Atherosclerosis is considered to be an inflammatory disease, primarily 
characterized by a Th1 mediated inflammatory reaction16,17. CCR5 and CXCR3 
are chemokine receptors that are mainly expressed on Th1 cells25,26. The spleen 
plays a central role in the immune system and is exposed to circulating antigens 
associated with atherosclerosis such as oxidized LDL. We examined the mRNA 
expression of CCR5 and CXCR3 and their ligands in the spleen during the 
process of atherosclerosis in LDLr-/- mice on Western type diet (Figure 1). 
After 6 weeks of diet, CCR5 relative mRNA expression in the spleen is 
significantly upregulated 2.4 fold (1.0±0.06 vs. 2.4±0.21, p=0.01). The expression 
of CXCR3 is not differentially regulated during the first 6 weeks of feeding a 
Western type diet and atherosclerotic lesion formation. Both CCR5 and CXCR3 
are downregulated in the spleen in later stages of atherosclerotic lesion 
formation in the used model (> 9 weeks of Western Type diet).  The expression 
of established ligands for CCR5 was also monitored. RANTES and MIP-1α are 
both significantly upregulated after 6 weeks of Western type diet. This coincides 
with the regulation pattern of CCR5 and MCP-1. CXCL10, a ligand specific for 
CXCR3 is downregulated after 9 weeks of Western type diet and showed no 
regulatory similarity with the other ligands. 
TAK-779 reduces atherogenesis in LDLr-/- mice without altering cholesterol 
levels 
Two different experiments were performed to study the effect of TAK-779 on 
atherogenesis.  
After two weeks of Western type diet LDLr-/- mice were equipped with collars 
around both carotid arteries. Subsequently, the mice were treated with TAK-779 
or control treated for 6 weeks. Yang et al. showed that administration of 150 µg 
per mouse every other day was sufficient to induce the maximum blocking effect 
14.  No difference in cholesterol levels and lipoprotein concentration could be 
observed between the control and TAK-779 treated group (Figure 2). Figure 3 
shows representative sections of TAK-779 treated (figure 3D) and control treated 
(figure 3E) mice. Lesion size significantly decreased by 68% upon treatment 
with TAK-779 (18384±3370 µm2 vs. 5926±1842 µm2, p=0.004) (figure 3A), 
intima media ratio decreased by 49% (0.46±0.07 vs. 0.26±0.06) (figure 3B), and 
also the relevant clinical parameter, intima lumen ratio, decreased significantly 
by 56% (0.26±0.04 vs. 0.11±0.03, p=0.01) (figure 3C).  
The general composition of the carotid lesions of TAK-779 treated mice was not 
altered compared to control treated mice (figure 4). The relative MOMA-2 
stained area was comparable in control (4B) and TAK-779 treated animals (4C), 
(0.265 ± 0.05 vs. 0.252 ± 0.06, p=0.88). We visualized the collagen content of the 
plaque by picosirius red staining. No difference was observed between control 




actin, specific for smooth muscle cells (ASMA) is shown in on line figure 4H 
(control) and 4I (treated). TAK-779 treatment did not affect relative ASMA area 
(0.084 ± 0.016 vs. 0.078 ± 0.011). 
In a second experimental setup, Western type diet and TAK-779 treatment were 
started simultaneously and 8 weeks later LDLr-/- mice were sacrificed. 
Atherosclerosis in the aortic valves was decreased by 40% in TAK-779 treated 




Figure 3. Effect of TAK-779 treatment on plaque formation in a collar induced carotid artery 
atherosclerosis model. Cross-sectional carotid plaque area (3A), intima/ lumen ratio (3B), and intima 
/ media ratio (3C) following a treatment with 150 µg of TAK-779 in 100 µl of 5% mannitol injection 
fluid s.c. every other day during 6 weeks. A marked and significant decrease was seen for all three 
parameters. Lower panel gives representative pictures of the carotid artery of control (3D) and TAK-
779 treated (3E) LDLr-/- mice. Error bars represent SEM, n = 10 per group, (**= p<0.005, *=p<0.05, 
Mann Whitney test).  
TAK-779 treatment impairs the influx of Th1 T cells to the atherosclerotic 
plaque 
Both CCR5 and CXCR3 are expressed predominantly on Th1 cells and both 
receptors are implicated in the migration of these cells to their site of action and 
treatment with TAK-779 may block the migration of Th1 cells into the 
atherosclerotic plaque. We performed a staining for CD3 (figure 6A), a general T 
cell marker and scored for positive cells in both the plaque and the adventitia. A 
vast and significant decrease is observed in the number of T cells in the plaque 
and adventitia of TAK-779 treated mice compared to control (plaque 0.53 ± 0.31 
vs. 0.03 ± 0.03, p=0.04, adventitia 4.98 ± 0.63 vs. 2.01 ± 0.38, p=0.0007).  In order 
to investigate whether the reduction of T cells resulted in a decreased expression 
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mice (6E) for IFN-γ. A significant reduction of 98% was observed in the IFN-γ 
positive area in TAK-779 treated animals compared to control (0.55% ± 0.21% 
vs. 0.01% ± 0.0004%, p=0.013). 
 
Figure 4. General plaque composition is not altered by TAK-779 treatment. Plaque composition of 
TAK-779 treated and control treated mice was determined using a macrophage specific antibody 
(MOMA-2) (figure 4A-C), picosirius red staining to visualize collagen (figure 4D-F) and smooth 
muscle cell specific staining (α-SM acin) (figure 4G-I). Representative sections are shown for each 




TAK-779 reduces T cell counts in LDLr-/- mice  
Both CCR5 and CXCR3 are reported to be involved in T cell migration to 
inflamed tissue3,14.  To investigate whether T cell numbers were affected during 
atherogenesis in TAK-779 treated mice versus control treated mice, lymphocytes 
were harvested from blood, from mediastinal lymph nodes, which drain from 
the aortic arch, and from spleen 6 weeks after the start of Western type diet. 
Cells were stained for CD4 and CD8, gated for lymphocytes in the FSC/SSC plot, 
and the percentages of CD4+ and CD8+ T cells were determined by flow 
cytometric analysis. Figure 7A shows representative dot plots for control treated 
mice (upper three panels) and TAK-779 treated mice (lower three panels) on a 
Western type diet. A vast decrease in the percentage of CD4+ T cells in 
peripheral blood (21.6±3.11 % vs. 10.46±1.57 %, p=0.02) and a modest decrease 

















































































Figure 5. TAK-779 treatment reduces plaque formation in the aortic leaflet area.  
Representative photomicrographs of oil red O stained cross sections of the aortic root of control (5A) 
and TAK-779 treated mice (5B) are shown. A significant reduction in plaque size was found as 
compared to control (p=0.001, n=8 per group) (5C). Relative macrophage staining of control (5D) and 
treated mice (5E) is visualized using a monoclonal antibody specific for macrophages (MOMA-2). No 




Figure 6. Migration of Th1 cells in TAK-779 treated animals is reduced compared to control treated 
animals. 
Sections of collar induced lesions were stained for T cells using an anti-CD3 antibody (6A). The 
number of positive cells in both plaque and adventitia was quantified. A significant reduction of the 
number of CD3 positive cells was observed both in the plaque (6B) as in the adventitia (6C) of TAK-
779 treated animals compared to control (n=10 per group). Representative sections with IFN-γ 
staining are shown for control (6D) and treated mice (6E). A significant reduction in the relative 
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In contrast, the CD4+ population was significantly increased in the spleen of the 
TAK-779 treated mice (9.6± 1.22 % vs. 13.5± 0.9 %, p=0.03) (figure 7B). An even 
more pronounced decrease was observed in the CD8+ T cell population. In the 
circulation the percentage CD8+ T cells decreased from 10.2±1.8 % in the control 
group to 3.8±0.7 % in the treated group (p=0.01). In the mediastinal lymph 
nodes draining from the aortic arch, a reduction of 34% in the number of CD8+ 
cells was observed (21.4±0.52 % vs. 14.6±2.0 %, p=0.02) (figure 7C).  
No significant differences in total white blood cell counts were observed 
between control and treated mice.  
 
Inflammatory status in the spleen after TAK-779 treatment 
After 6 weeks of simultaneous Western type diet feeding and TAK-779 
treatment, the mRNA expression of CCR5 and CXCR3 was determined to 
evaluate the expression of the two chemokine receptors that were specifically 
blocked by TAK-779 (figure 8). CCR5 expression was 1.9-fold increased in TAK-
779 treated mice in comparison with control mice (p=0.02), whereas the 
expression of CXCR3 remained unchanged.  The expression of CCR2, a 
chemokine receptor involved in the migration of macrophages and T cells and 
also implicated in atherosclerosis, is highly elevated in the spleen upon TAK-779 
treatment. The expression of endogenous ligands for these receptors was also 
evaluated.  The splenic mRNA levels for MIP-1α, RANTES and CXCL10, which 
bind to CCR5 and CXCR3 respectively, were not affected by TAK-779 
treatment, while the expression of monocyte chemotactic protein-1 (MCP-1), a 
ligand for CCR2, was significantly upregulated 8.1-fold. We also determined the 
expression of some cytokines that are important in the Th1/Th2 balance.  IL-12, 
a general Th1 stimulatory interleukin is 2.8-fold upregulated in the spleen of 
TAK-779 treated mice as compared to control treated mice, while the Th2 
interleukin IL-4 is 3.2-fold upregulated. This results in an unaffected Th1/Th2 
balance upon TAK-779 treatment, and the observed increase in splenic cytokine 
expression might be explained by the increased number of CD4+ T cells in spleen 




Infiltration of mononuclear cells into the vessel wall is an important hallmark of 
atherosclerosis. It has become clear that next to macrophages, T lymphocytes are 
present in the atherosclerotic plaque and exert a significant role in plaque 
progression. The majority of these T cells is CD4 positive. Activation of CD4+ T 
cells via MHC class II on antigen presenting cells results in the release of 
cytokines and the expression of several surface markers. Activated CD4+ T cells 
can be divided in 2 distinct categories based on their phenotype. Th1 cells 
secrete IFN-γ, IL-2 and TNF-α. Th2 cells produce IL-4, IL-5 and IL-13 leading to 




The HIV entry inhibitor TAK-779 is a CCR5 and CXCR3 antagonist in mice and 
several studies have shown that TAK-779 reduces autoimmune responses by 
interfering with the migration of Th1 cells to the inflamed tissue14. We argue 
that TAK-779 may therefore also affect atherogenesis in a similar way. As the 
current treatment for HIV patients is associated with increased atherogenic 
lipoprotein concentration and accelerated atherosclerosis, an anti-HIV drug that 
reduces atherosclerosis would be of great importance.  
As atherosclerosis is considered to be a Th1 mediated disease16,17, modulation of 





Figure 7.  Percentages of CD4 and CD8 positive T cells in mediastinal lymph nodes (MLN), blood 
and spleen. Mononuclear cell suspensions of draining lymph nodes, spleen and blood were isolated 
from control mice and mice following a treatment with 150 µg of TAK-779 in 100 µl of 5% mannitol 
injection fluid s.c. every other day during 6 weeks. Representative dot plots are shown in figure 7A. 
Cells were stained for CD4 (7B), and CD8 (7C). Results represent the mean percentage of positive 
cells ± SEM from 5 individual mice (**=P<0.005, *=P<0.05, Students T test). A decrease is seen in the 
percentage CD4 and CD8 positive T cells in DLN and blood in the TAK-779 treated group (White 
bars) compared to control (Black bars). In the spleen, the percentage of CD4 positive cells is 











































Figure 8. Spleen mRNA expression of inflammatory markers after TAK-779 treatment. mRNA 
expression of different genes in the spleen of TAK-779 treated mice (8 weeks) is expressed relative to 
36B4 and HPRT, and subsequently related to the expression in control mice. White bars represent 
control mice, black bars represent TAK-779 treated mice. An unpaired Student t test was applied to 
test if mRNA levels were significantly different from the mRNA levels in chow fed animals (n=10 
per group) (*P<0.05). 
 
CCR5 and CXCR3 are chemokine receptors that are both primarily expressed on 
Th1 T cells15. A putative role for CCR5 and CXCR3 in atherogenesis is 
implicated by studies in which a mutation in the CCR5 sequence (∆32 mutation) 
was found to be associated with a reduced incidence in myocardial infarction 
and severe coronary artery disease6,7. Furthermore, antagonizing CCR5 using 
met-RANTES also resulted in reduced atherosclerotic lesion formation10. 
In the present study we firstly examined the expression of CCR5 and CXCR3 in 
the spleen of LDLr-/- mice during Western type diet feeding. It appeared that 
CXCR3 was not differentially regulated in the spleen during the first 6 weeks of 
atherogenic diet, whereas CCR5 showed a significant upregulation in this 
period. The known ligands of CCR5, RANTES and MIP-1α have been detected 
in atherosclerotic plaques, and these molecules were also upregulated at 6 weeks 
of Western type diet feeding in the spleen8. No distinct regulatory pattern could 
be observed for the ligands of CXCR3, interferon gamma inducible protein-10 












































































































prominent role in the response of the immune system towards elevated 
cholesterol levels and atherogenesis.  
In our studies the synthetic low molecular weight CCR5/CXCR3 antagonist 
TAK-779 was used to assess the role of these receptors in the process of 
atherosclerotic lesion formation.  Treatment with this potential HIV entry 
inhibitor appeared to reduce plaque formation in the carotid artery with 68% 
and lesion formation in the aortic root with 40%. These findings are in line with 
a study by Veillard et al., who used met-RANTES to antagonize CCR5 and CCR-
1, and observed a decrease in lesion formation as a result of reduced infiltration 
of mononuclear cells into the lesion10. In contrast with these observations, 
Kuziel et al. have published that disruption of the mouse CCR5 gene has no 
effect on early lesion formation in apoE deficient mice28. As these mice lack 
CCR5 throughout their development, it may be that impaired T cell migration 
due to CCR5 disruption is counterbalanced by a compensatory chemokine 
receptor mediated mechanism such as CCR-2/MCP-1.  
The expression of CCR5 and CXCR3 has been well characterized on CD4+ T cells 
and both chemokine receptors are preferentially expressed on the Th1 cell 
subset25,26. Limited expression of CCR5 is also reported on CD8+ cells, human 
vascular smooth muscle cells and macrophages30,31.  Our data show that the 
relative macrophage content of the atherosclerotic plaques did not differ 
between TAK-779 treated and control treated mice. This implies that migration 
of macrophages into the intima is not impaired by CCR5/CXCR3 blockade by 
TAK-779. Therefore the decreased lesion formation is more likely to be 
explained by the diminished migration of T cells from the spleen towards the 
sites of atherogenesis. This is further supported by the finding that the number 
of CD3 positive T cells in the plaque as well as in the adventitia is significantly 
decreased in TAK-779 treated animals. We also observed that the relative T cell 
counts in the blood and draining lymph nodes for both CD4+ and CD8+ T cells 
are significantly decreased in TAK-779 treated animals. Simultaneously, the 
percentage of CD4+ T cells in the spleen is increased, suggesting that these T cells 
are retained in the spleen upon TAK-779 treatment.  
Veillard et. al. described that antagonizing CCR1 and CCR5 with met-RANTES 
results in decreased macrophage and T cell influx into the atherosclerotic lesion, 
in contrast to antagonizing CCR5/CXCR3 with TAK-779 which only affects  T 
cell influx. This difference may be explained by the fact that met-RANTES 
antagonizes CCR1 which is expressed at high levels on macrophages, in contrast 
to CCR5 and CXCR3. TAK-779 is therefore more selective in antagonizing Th1 
T cells, leaving macrophage recruitment mostly intact. We furthermore used an 
in vitro setup to test whether TAK-779 had any effect on macrophage adhesion 
to LPS stimulated endothelial cells. No dose-effect relationship for TAK-779 
incubation of macrophages on endothelial adhesion was observed (data not 
shown). This further strengthens our findings that there is no major effect on 
macrophage adhesion and infiltration in TAK-779 treated animals. 
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It has been shown that local T cells secrete cytokines, which in turn activate and 
attract other inflammatory cells and therefore stimulate the inflammatory 
process. As CCR5 and CXCR3 are most strongly expressed on Th1 cells it is 
expected that mice treated with TAK-779 show smaller amounts of Th1 
cytokines in the atherosclerotic plaque. We stained atherosclerotic plaque 
sections of control and treated mice for IFN-γ, a Th1 marker. In plaques of 
treated animals, the relative IFN-γ area was decreased by 98%, indicating that 
IFN-γ production by Th1 cells was almost completely absent upon TAK-779 
treatment. 
 
Our data show that TAK-779 blockade resulted in a marked upregulation of 
CCR2/MCP-1in the spleen, which coincides with an upregulation of CCR5 in 
the spleen in comparison to control mice. This may be explained by the fact that 
CCR2 and CCR5 coexist in the same lipid raft domain and both receptors share a 
migratory function29. Inhibition of CCR5 is then compensated by an 
upregulation of CCR2 to sustain migratory capacity. 
Baba et al. have shown that TAK-779 has some affinity for CCR2b in humans, 
but this is 100 fold lower in comparison with CCR511. In addition, TAK-779 is 
not able to bind human CXCR3. Therefore it is likely that TAK-779 exerts its 
action by inhibiting CCR5 function in humans. We observed similar effects in 
our study in mice, as the expression of CXCR3 in spleen of mice treated with 
TAK-779 is not increased, in contrast to the expression of CCR5, thus implying a  
dominant role for CCR5 as target of TAK-779.  
The increase in individual expression of the different chemokine receptors, 
combined with the unaltered Th1/Th2 ratio supports the theory that TAK-779 
targets CCR5 and impairs T cell migration to the site of action, the 
atherosclerotic plaque, and does not alter the general inflammatory status of the 
animals.  
Combination therapy which is commonly used to treat HIV patients has been 
shown to lead to elevated serum levels of the atherogenic lipoproteins LDL and 
VLDL, which result in a higher incidence in cardiovascular disease. We now 
show that TAK-779, a novel HIV entry inhibitor, does not elevate serum total 
cholesterol levels or triglyceride levels. More important, no increase in 
atherogenic lipoprotein levels was observed in the blood of TAK-779 treated 
animals, and a decrease was observed in atherosclerotic lesion formation. This is 
in contrast with patients and animal models treated with protease inhibitors. 
 
In summary, the use of HIV entry inhibitors in the long-term treatment of HIV 
would be preferential over the now used combination therapy. It achieves long-
term suppression of the virus and as shown in this study, retained 
atherosclerotic lesion formation by blocking the influx of Th1 cells in the 
atherosclerotic plaque.  This finding is primarily beneficial for young HIV 
patients, as they face a livelong treatment and are currently confronted with the 
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The chemokine receptor CXCR3 is implicated in migration of leukocytes to sites 
of inflammation. Antagonizing CXCR3 could therefore be a potential strategy to 
inhibit inflammation induced leukocyte migration, and subsequently reduce 
atherosclerotic lesion formation. In this study we used the CXCR3 specific 
antagonist NBI-74330 to block CXCR3 mediated signaling in thioglycolate 
induced peritonitis and diet induced atherosclerosis. Antagonizing CXCR3 with 
NBI-74330 resulted in a significant reduction in CD4+ T cell and macrophage 
migration to the peritoneal cavity. Ex-vivo migration studies with cells isolated 
from the peritoneal cavity after NBI-74330 treatment showed that this reduction 
in migration was totally CXCR3 dependent. Atherosclerotic lesion formation in 
both the aortic valve leaflet area as well as the total aorta was significantly 
inhibited in NBI-74330 treated mice. Lymph nodes draining from the aortic arch 
were significantly smaller in treated mice and showed enrichment in regulatory- 
and less activated T cells. This study shows for the first time that treatment with 
a CXCR3 antagonist results in attenuating atherosclerotic lesion formation, not 
only by blocking direct migration of effector cells from the circulation to the 
atherosclerotic plaque, but also by beneficially modulating the inflammatory 





Atherosclerosis is a progressive multi-factorial disease of the larger arteries 
characterized by cholesterol deposition, leukocyte influx, cell death and fibrosis. 
In recent years, it has become increasingly clear that next to a lipid storage 
disorder, atherosclerosis can be considered as an ongoing inflammatory process 
within the vasculature1,2. Migration of leukocytes into the vessel wall is an 
essential step in atherosclerotic lesion formation and progression and chemo-
kines are defined as key regulators of this process3, 4.  
Chemokine receptors are trans-membrane spanning, G-protein-coupled 
receptors which are classified by the position of the N-terminal cysteins (CC, 
CXC, C, CXXXC). They play an important role in the recruitment, migration and 
trafficking of immune cells to sites of inflammation. An increasing amount of 
evidence underscores the relevance of chemokines in the pathogenesis of 
atherosclerosis5-10.  
The chemokine receptor CXCR3 is expressed on different types of leukocytes, 
including T cells, B cells, natural killer (T) cells and monocytes 11, 12, 13, 14. Its 
expression is highly induced upon CD4 T cell activation and is preferentially 
expressed on activated auto-reactive T cells15. Antibody-mediated blockade of 
CXCR3 results in a decreased recruitment of Th1 cells to sites of inflammation16. 
CXCR3 has 3 known ligands; MIG (monokine induced by IFN-γ (CXCL9)), IP-
10 (IFN- γ-inducible protein, (CXCL10)) and ITAC (IFN-γ-inducible T-cell α-
chemoattractant (CXCL11)). The expression of these ligands is highly inducible 
by interferon-γ (IFN-γ) and associated with several inflammatory disorders. 
Recent publications point towards a prominent role for CXCR3 mediated 
migration of inflammatory cells in atherosclerosis. Human atherosclerotic 
lesions express high amounts of all three CXCR3 ligands 17. Targeted deletion of 
CXCR3 in ApoE deficient (ApoE-/-) mice resulted in decreased lesion formation 
in the abdominal aorta5. Furthermore, deletion of the CXCR3 ligand CXCL10 in 
ApoE-/- mice resulted in decreased lesion formation by reducing the migration of 
CD4 effector T cells to the atherosclerotic plaque18.  
Blockade of CXCR3 mediated migration could therefore provide a potential 
strategy to reduce leukocyte migration to sites of inflammation and in this way 
attenuate atherosclerotic lesion formation. In this study, we describe the highly 
specific CXCR3 antagonist NBI-74330 and its inhibitory effects on cell migration 
and diet induced atherosclerosis in LDL receptor deficient (LDLr-/-) mice. 
 
 
Antagonizing CXCR3 Decreases Atherosclerosis 
 
 93 
Material and methods 
 
Determination of appropriate in vivo dosage of NBI-74330 
The quinazolinone-derived CXCR3 antagonist NBI-74330 was synthesized as 
described by Medina et al (WO02083143, 2002 oct 24).  Mice were treated with 
NBI-74330 in 0.1% Na Docusate in 0.5% 400Cp Methylcellulose and serum 
concentration at indicated time points were determined using LC-MS-MS.  
Serum was subjected to protein precipitation prior to analysis. HPLC mobile 
phase consisted of H2O with 0.1% (v/v) formic acid and Acetonitrile with 0.1% 
(v/v) formic acid using a gradient profile. 
 
Peritonitis induced migration and mobility assay 
LDLr-/- mice were treated with a subcutaneous injection of 100mg/kg CXCR3 
antagonist NBI-74330 in 100 µl 0.1% Na Doc in 0.5% 400Cp Methylcellulose 
(n=6) or vehicle (n=5) for 6 days. At day 2, all mice were injected intra-
peritoneally with sterile 3% (w/v) Brewers thioglycolate solution. Peritoneal 
cells were isolated by peritoneal cavity lavage with PBS and counted and 
phenotyped by flow cytometry at day 6. Migration capacity of the isolated 
peritoneal cells in response to CXCL10 (100ng/ml), and the chemotactic peptide 
FMLP (1µM) was quantified using a chemokinesis assay19. 
 
Atherosclerosis experiments 
Female LDLr-/- mice, 10 weeks old (n=8-12 per group), were fed a Western-type 
diet containing 0.25 % cholesterol and 15% cocoa butter two weeks before collar 
placement20. Mice were treated with a subcutaneous injection of 100mg/kg 
CXCR3 antagonist NBI-74330 in 100 µl 0.1% Na Doc in 0.5% 400Cp 
Methylcellulose every day during the entire experiment. After 8 weeks of 
Western-type diet and treatment, the mice were sacrificed and organs were 
harvested for histology, FACS and RNA isolation. Blood samples were collected 
by tail bleeding from non-fasted animals and concentrations of serum 




Cryostat sections of the aortic root (10 µm) were collected and stained with Oil-
red-O. Lesion size was determined in 5 sections of the aortic valve leaflet area. 
Corresponding sections on separate slides were stained immunohistochemically 
with an antibody directed against a macrophage specific antigen (MOMA-2, 
monoclonal rat IgG2b, diluted 1:50). Goat anti-rat IgG-AP (dilution 1:100) was 
used as secondary antibody and NBT-BCIP as enzyme substrates. Masson 
trichrome staining (Sigma Diagnostics) was used to visualize collagen (blue 
staining). TGFβ was stained with a polyclonal rabbit antibody (Santa Cruz, USA) 
and biotinylated goat anti rabbit (Dako cytomatics, The Netherlands) was used 
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as a secondary antibody with Nova Red as enzyme substrate (Vector 
Laboratories). 
 
Real time PCR assays 
Total RNA was isolated from aortic arch and collar induced atherosclerotic 
plaques and was DNase treated. Quantitative gene expression analysis was 
performed on an ABI PRISM 7500 (Applied Biosystems, Foster City, CA) using 
SYBR Green technology. PCR primers (Online table I) were designed using 
Primer Express 1.7 software with the manufacturer's default settings (Applied 
Biosystems). Acidic ribosomal phosphoprotein PO (36B4) and hypoxanthine 
phosphoribosyl transferase (HPRT) were used as housekeeping genes.  
 
Flow cytometry 
Leukocytes from whole blood and spleen were isolated by density gradient 
centrifugation with Lympholyte (Cedarlane Laboratories, Hornby, Ontario, 
Canada). Cell suspensions from spleen, blood, lymph nodes draining from the 
aortic arch and peritoneal cavity were stained for surface markers (0.2 µg 
Ab/300.000 cells) and subsequently subjected to flow cytometric analysis 
(FACS). Antibodies were purchased from Immunoscource (Belgium). All data 




Values are expressed as mean ± SEM unless indicated otherwise. Two-tailed 
student’s T-test was used to compare normally distributed data between two 
groups of animals. Mann-Whitney test was used to compare not normally 
distributed data. A probability value of P<0.05 was considered to be significant 
for both tests. 
 
Figure 1: Daily s.c. inject-
tions of 100 mg/kg NBI-
74330 result in serum levels 
sufficient to fully anta-
gonize CXCR3 in vivo. A 
formulation of NBI-74330 
was constructed using 1% 
Na Doc in 0.5% 400Cp 
Methylcellulose and the 
mice (n=3) were treated 
with 100 mg/kg compound 
every day for 5 days. Serum 
levels were determined at 
indicated time points using 
LC-MS-MS. Dotted line 
indicates  ∼Ki. 
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Figure 2:  Macrophage and T cell migration to thioglycollate induced peritonitis is inhibited by NBI-
74330 treatment. A: Female LDLr-/- mice were treated with a subcutaneous injection of 100mg/kg 
CXCR3 antagonist NBI-74330 in 100 µl 1% Na Doc in 0.5% 400Cp Methylcellulose (n=6) or vehicle 
(n=5) for 6 days. At day 2, all mice were injected intra-peritoneally with sterile 3% (w/v) Brewers 
thioglycollate solution. Peritoneal cells were isolated by peritoneal cavity lavage with PBS and 
counted and phenotyped by FACS at day 6. A: recruitment of cells to the peritoneal cavity was 
reduced by 56% after NBI-74330 treatment. The percentage of CD4+ T cells and macrophages 
(F4/80+, Gr-1low) present in the peritoneal cavity was significantly decreased in mice treated with 
NBI-74330 compared to control treated mice. (Error bars represent SEM, *: p< 0.05, **: p<0.01) 
B: 5000 isolated peritoneal cells (triplicate per mouse/ situation) were seeded on fibrinogen coated 
96-wells and left to adhere at a nearly upright position. Migration in response to CXCL10 and FMLP 
(positive control) was then assessed at a 15º tilted position by counting the number of cells that 
migrated across a defined threshold. (Error bars represent SD, ***: p<0.001 compared to cells from 
control mice cultured with X100ng/ml CXCL10, ###:p<0.001 compared to cells from control mice 




In vivo use of NBI-74330 
NBI-74330 is a small molecular high affinity CXCR3 antagonist that is a potent 
inhibitor of CXCR3 ligand binding with a Ki in the low nanomolar range 
(∼8nM). In vitro data have shown that it inhibits CXCL10 and ITAC induced 
calcium mobilization at concentrations below 10 nM21. A formulation of NBI-










































































We tested the optimal dosing of this formulation in vivo and found that daily 
dosage of 100mg/kg via subcutaneous injections resulted in serum 
concentrations of approximately 1µM (figure 1). This concentration is sufficient 
to fully block the CXCR3 receptor in vivo. 
 
 
Figure 3: mRNA expression of CXCR3 is 
significantly upregulated in the aortic arch of 
LDLr-/- mice on Western typed diet feeding. 
mRNA was isolated from the aortic arch of 
LDLr -/- mice using the GTC method and 
expression of CXCR3 is expressed relative to 
36B4 and HPRT, and subsequently related to 
the expression in mice on chow diet. (*p < 0.05, 




The CXCR3 antagonist NBI-74330 inhibits CD4 T cell and macrophage 
migration during thioglycolate induced peritonitis 
To show the in vivo capacity of NBI-74330 to antagonize CXCR3 mediated cell 
migration, we used a peritonitis model. In this model, leukocytes migrate to the 
peritoneal cavity in response to a single intraperitoneal thioglycolate challenge. 
Female LDLr-/- mice were treated with NBI-74330 or control for 6 days.  At day 
2, all mice were injected intra-peritoneally with sterile 3% (w/v) Brewers 
thioglycolate solution and 5 days later the number of cells present in the 
peritoneum was quantified. A significant 56%  reduction in leukocyte 
recruitment could be observed after 5 days in NBI-74330 treated mice compared 
to control treated mice (Fig. 2A, p=0.01). FACS analysis of the isolated peritoneal 
cells showed that this reduction was mainly due to reduced migration of CD4 T 
cells and macrophages (Fig 2A). To investigate the capacity of the isolated 
peritoneal cells from control and NBI-74330 treated mice to migrate in response 
to the CXCR3 ligand CXCL10 we performed an ex vivo mobility study. Isolated 
peritoneal cells from control and treated mice were allowed to accumulate at the 
lower end of a 96-well culture plate and migration in response to 100ng/ml 
CXCL10 and FMLP (positive control) was then assessed. Results are shown in 
figure 2B. 
Peritoneal cells isolated from mice treated with vehicle for 6 days had a clear 
migratory response when exposed to 100 ng/ml CXCL10, and this effect could be 
completely reversed by the in vitro addition of the CXCR3 antagonist NBI-
74330 to the culture medium. Cells isolated from mice treated with CXCR3 
antagonist in vivo during the thioglycolate challenge were not able to respond to 
CXCL10. Their capability to migrate while exposed to the general chemotactic 
peptide FMLP was not different compared to control treated mice.  
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These findings clearly show that the reduced migration towards thioglycollate 
induced peritonitis by NBI-74330 treatment is the result of an effective in vivo 
blockade of CXCR3. 
  
Figure 4: Atherosclerotic lesion formation is significantly inhibited in mice treated with NBI-74330 
Representative photomicrographs of oil red O stained cross sections of the aortic root of control 
treated mice (A) and NBI-74330 treated mice (B) are shown. A significant reduction in plaque size 
was found as compared to control (p=0.03, n≥8 per group) (C).  
Relative plaque area was quantified in en face pinned aortas. Representative pictures are shown for 
control (D) and NBI-74330 treated mice (E). Lesion formation is significantly inhibited by NBI-
74330 treatment by 53% (p=0.01). 
 
Atherosclerotic lesion formation in LDLr-/- mice is attenuated by antagonizing 
CXCR3 
We use LDL receptor deficient mice on a Western type diet as a model for 
atherosclerosis and the mRNA expression of CXCR3 during lesion formation was 
monitored in the aortic arch at different stages of western type diet feeding. A 
significant increase was observed in CXCR3 mRNA expression after 9 weeks of 
diet, indicating initial influx of CXCR3 expressing leukocytes (Figure 3). This 
showed that CXCR3 could be involved in the atherosclerotic process in our 
model. We then assessed the effect of NBI-74330 treatment on atherosclerotic 
lesion formation. 
Female LDLr-/- mice were fed a Western-type diet and received daily 
subcutaneous injections of 100mg/kg NBI-74330 or vehicle. No difference was 
observed in serum cholesterol and triglyceride levels between control and 
treated animals (data not shown). Figure 4 shows representative sections of 











































Atherosclerotic lesion formation in the aortic valve leaflet area was significantly 
inhibited in mice treated with NBI-74330 (536*103µm2 vs. 391*103µm2, p<0.05). 
Relative macrophage staining (MOMA-2) was comparable in plaques from 
control and treated animals, as well as the relative collagen content as 
determined by Masson trichrome staining (Figure 5). 
Next to lesion formation in the aortic valve leaflets, we quantified the 
percentage of lesion area in the aorta of control and NBI-74330 treated mice by 
en face pinned out aortas stained with oil red O. Representative pictures of 
control (4D) and NBI-74330 treated aortas (4E) are shown. NBI-74330 treatment 
resulted in a 53 % reduction in lesion formation compared to control treated 
mice (18 ± 2 % vs. 8 ± 2 %, p=0.01).  
Figure 5: NBI-74330 treatment has no effect on relative macrophage and collagen content of 
atherosclerotic plaques. Plaque composition of NBI-74330 treated and control treated mice was 
determined using a macrophage specific antibody (MOMA-2) (figure 4A-C), and Masson Trichrome 
staining to visualize collagen (figure 4D-F). Representative sections are shown for each group. No 
significant effects could be observed between control and treated animals (n≥8 per group). 
 
 
CXCR3 antagonist NBI-74330 treated mice have smaller lymph nodes draining 
from the aortic arch and a beneficial regulatory/effector T cell balance during 
atherogenesis 
Recent publications suggest a role for CXCR3 in the migration of effector cells 
towards  the site of inflammation18,22,23. We isolated the lymph nodes draining 
from the aortic arch of LDLr-/- mice after 8 weeks of Western type diet and 
subsequent treatment with either control or the CXCR3 antagonist NBI-74330. 
The size of the isolated lymph nodes was assessed by quantifying the number of 
cells. Treatment with NBI-74330 resulted in a 64% reduction of cell numbers in 
lymph nodes draining from the aortic arch (Fig. 6). Characterization of the 
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A significant increase was observed in the percentage CD4+CD25+ regulatory T 
cells in NBI-74330 treated mice (p<0.05).  This increase in regulatory T cells was 
accompanied by an increase in the expression of CD62L on CD4 cells (p<0.001), 
suggesting a reduction in the activation state of effector T cells. These effects 
were restricted to the lymph nodes draining from the aortic arch, as no such 
effects were observed in spleen or the circulating white blood cell population.  
 
Plaques from mice treated with NBI-74330 express more genes associated with 
regulatory T cells 
To determine whether the local reduction in effector cells and the increase in 
regulatory T cell phenotype resulted in a resembling cytokine profile inside the 
atherosclerotic plaque we stained for the regulatory T cell cytokine TGFβ. 
Representative slides are shown for control (7A) and NBI-74330 treated (7B) 
mice. A significant increase was observed in the relative expression of TGFβ in 
the plaque of mice treated with NBI-74330 compared to control.  
We performed QPCR on atherosclerotic plaques isolated from the carotid artery 
after collar induced atherosclerosis from both control and treated mice and 
determined the expression of the regulatory T cell associated genes FOXP3, 
CD25 and CTLA-4. The expression of FOXP3 was 2.5 fold upregulated (p<0.05), 
and the expression of CTLA-4 was 6 fold upregulated (p<0.05) compared to 
expression in control treated mice. The expression of CD25 showed a trend 





Figure 6: Draining lymph nodes from the aortic arch of NBI-74330 treated mice are smaller in size 
and contain less activated and more regulatory T cells 
Draining lymph nodes were isolated from control and NBI-74330 treated mice after 8 weeks of 
western type diet feeding. Single cell suspensions were prepared and total cell number was 
quantified.  NBI-74330 treatment resulted in a 64% decrease in cell number compared to control. 
(Error bars represent SEM, *: p< 0.05). FACS was used to asses the relative amount of CD4+CD25+ 











































Figure 7: Atherosclerotic plaques from NBI-74330 treated mice express increased levels of regulatory 
T cell associated molecules  
A: Sections of the aortic leaflet area were stained for TGFβ using anti TGFβ antibodies. We then 
quantified the TGFβ positive area relative to total plaque area. Treatment with NBI-74330 resulted in 
a significant increase in relative TGFβ positive area (red staining).  
B: mRNA expression of different genes isolated from collar induced atherosclerotic plaques (8 weeks) 
is expressed relative to 36B4 and HPRT, and subsequently related to the expression in control mice. 
White bars represent control mice; black bars represent NBI-74330 treated mice. An unpaired 
Student t test was applied to test if mRNA levels were significantly different from the mRNA levels 





Evidence is building that CXCR3 mediated cell migration plays an important 
role in several (auto-) immune diseases24-27. CXCR3 positive cells enter the site of 
inflammation followed by a local upregulation of CXCR3 expression. These 
CXCR3 positive cells are attracted by the 3 known ligands, CXCL9, 10 and 11, 
and it was shown that these ligands are highly expressed in atherosclerotic 
lesions17.  
In this study we used the highly specific CXCR3 antagonist NBI-74330 to block 
CXCR3 mediated signalling and migration. Firstly, we showed the in vivo 
capacity of this compound to reduce cell migration to a site of inflammation 
using a thioglycolate induced peritonitis model. Total leukocyte migration to the 
peritoneal cavity was reduced by 56% upon daily treatment with NBI-74330. 
The reduction in total cell migration was the consequence of a reduction in the 
number of CD4+ T cells and macrophages to the peritoneal cavity. The observed 
decrease in migration was the result of selective blockage of CXCR3, as shown 
by a subsequent ex vivo mobility assay. Peritoneal cells isolated from control 
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from mice that received NBI-74330 during the induction of peritonitis were not 
responsive to CXCL10, but were still capable of migrating in response to an 
FMLP stimulus.  
 
After we established the in vivo efficacy of the compound, we used LDL 
receptor deficient mice to test the effect of antagonizing CXCR3 on 
atherosclerotic lesion formation.  
We show that the expression of CXCR3 is upregulated in the aortic arch of 
LDLr-/- mice fed a western type diet for 9 weeks. This indicates that CXCR3 
positive leukocytes migrate to the developing atherosclerotic plaque.  It was 
shown that CXCR3 deficient mice on an ApoE background show reduced lesion 
burden compared to control ApoE mice. In addition, mice lacking CXCL10, the 
main ligand for CXCR3, show decreased atherogenesis compared to control 
ApoE mice. These are interesting observations, clearly suggesting that CXCR3 is 
involved in the disease initiation and progression of atherosclerosis in ApoE 
deficient mice. However, these mice lack the expression of these proteins 
throughout their development and compensating mechanisms to overcome this 
deficiency may have taken place.  
 
In this study, we use the compound NBI-74330, a highly specific low molecular 
weight CXCR3 antagonist, to investigate the effect of antagonizing CXCR3 in a 
diet induced model for atherosclerosis. Treatment with NBI-74330 resulted in a 
significant decrease in atherosclerotic lesion formation at the aortic valve leaflet 
area as well as the total aorta. We observed a more pronounced decrease in 
lesion size in the aorta compared to the valve leaflet area. In their study with 
CXCR3/apoE double deficient animals, Veillard et al. also showed a difference in 
lesion formation between these two sites, since they observed a significant 
decrease in the degree of lesion formation in the descending aorta was observed, 
but no effect in the aortic sinus. They suggest a more prominent role for CXCR3 
in the initial stages of lesion formation. Our findings strengthen this idea as we 
had quite large and advanced lesions in the valves, while the lesion burden in 
the aorta was more moderate. 
  
As shown in literature, CXCR3 mediates the migration of effector cells to the 
site of inflammation. Absence of CXCR3 or its main ligand CXCL10 in mice on 
an ApoE background resulted in an induction of regulatory T cells markers 
within the atherosclerotic plaque but not in lymph nodes or in the circulation.  
Our experiments however clearly show that administration of a 
pharmacologically active CXCR3 antagonist results in smaller lymph nodes 
draining from the aortic arch compared to control treated mice. Next to this, the 
activation state of T cells is decreased and regulatory phenotype is enhanced in 




When LDLr-/- mice are fed a Western type diet, the lymph nodes draining from 
the aortic arch increase in size due to locally induced inflammatory signals. 
Administering a CXCR3 antagonist clearly reduces the migration of leukocytes 
to the lymphatic sites draining to the site of inflammation. This indicates that 
not only direct migration of effector cells from the circulation to the 
atherosclerotic plaque is inhibited, but that also migration to the draining lymph 
system is beneficially modulated. Possibly CXCL9 and 11 are involved in this 
process, because no increase in regulatory T cells was observed in lymph cells 
isolated from CXCL10 deficient mice.  The amount of TGFβ in plaques from 
mice treated with NBI-74330 is significantly increased. Several mechanisms 
could lead to this finding. We observed that NBI-74330 treated mice have an 
increased number of CD4+CD25+ positive regulatory T cells in the lymph nodes 
draining directly from the aortic arch28. Next to this treated mice have an 
increased expression of the regulatory T cell markers FOXP3, CTLA-4 and CD25 
within the atherosclerotic plaque. This indicates that regulatory T cells are the 
likely source of the observed increase in (surface bound) TGFβ expression within 
the atherosclerotic plaque29-34.  
 
In general, we hypothesize that the observed reduction in lesion formation and 
the accompanying induction in regulatory T cell phenotype is a result of a 
reduction in migration of effector cells both from the circulation to the 
atherosclerotic plaque and to the locally draining lymph nodes. This will in turn 
lead to a relative induction of anti-inflammatory and regulatory cells. 
Eventually, due to the continuing exposure to antigens such as oxLDL or heat 
shock proteins, the ongoing attraction of leukocytes via other pathways than 
CXCR3 will facilitate the process of lesion formation. The blockade of CXCR3 
thus provides a “lag-time” in this response. 
It is clear that selective blockade of CXCR3 migration in vivo using NBI-74330 
provides an attractive way to beneficially balance the immune response in an 
auto-inflammatory situation such as atherosclerosis. A possible drawback of 
interfering with CXCR3 mediated migration could be a potentially hampered 
immune response against invading pathogens. For example, lung infection with 
B. Bronchiseptica results in strong upregulation of CXCR3 ligands and influx of 
CXCR3+ cells. However, CXCR3 deficient mice do not show increased mortality 
to this pathogen. Furthermore, Chackavarty et al. have shown that CXCR3 
deficient mice are more resistant to Mycobacterium tuberculosis infection35. 
CXCR3 is also associated with cellular influx into CMV infected liver. Infection 
of the liver with CMV attracts CXCR3+ CD8+ cells that contribute to the 
protective response to the virus but these cells are not exclusive required for its 
clearance36. Based on these observations treatment with a selective CXCR3 
antagonist is unlikely to result in severe infections with pathogens.  
 
Small molecular antagonists are the preferential and most widely used drugs and 
have clear advantages over protein or antibody formulations. We conclude that 
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this study shows for the first time that a small molecular CXCR3 antagonist 
inhibits lesion formation in an animal model for atherosclerosis. This study 
therefore provides evidence that CXCR3 antagonists can be a possible new 
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Vaccination Against CD99 Inhibits Atherogenesis 
in LDL Receptor Deficient Mice  
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Murine CD99 was recently found to be expressed on leukocytes and endothelial 
cells where it is concentrated at inter-endothelial contacts. Blockade of CD99 by 
specific antibodies inhibits leukocyte extravasation to inflamed sites in vivo. 
We constructed a DNA vaccine against CD99 by cloning the extracellular 
domain of murine CD99 into pcDNA3. Vaccination was performed by oral 
administration of attenuated Salmonella typhimurium transformed with 
pcDNA3-CD99. This vaccination results in a CD8 mediated cytotoxic response 
targeting cells transfected with CD99 and the subsequent reduction of CD99 
expressing cells. We showed that CD99 is expressed on vascular endothelium 
overlying atherosclerotic plaques and found that CD99 expression is up-
regulated during Western type diet feeding. CD99 vaccination induced the 
formation of CD8 positive T cells that were cytotoxic against cells transfected 
with pcDNA3-CD99. Activation of CD8+ T cells was demonstrated by a 30% 
increase in CD8+CD69+ double positive T cells in spleen and mediastynal lymph 
nodes. Furthermore, lymphocytes isolated from CD99 vaccinated mice 
specifically lysed CD99 expressing cells. More importantly, vaccination against 
CD99 attenuated atherosclerotic lesion formation in the aortic valve leaflets by 
38% and in the carotid artery by 69% as compared to mice that were vaccinated 
with a control vector. Furthermore, a lower number of cells were found in 
atherosclerotic lesions implying that fewer leukocytes were recruited to these 
sites. These observations were accompanied by a decrease in CD99 expression on 
leukocytes. We conclude that vaccination against CD99 decreases atherogenesis 
by the selective removal of CD99 expressing cells, which could reduce leukocyte 






Atherosclerosis is a chronic inflammatory disorder of the large arteries and the 
prominent cause of death in the western world1. Recruitment of leukocytes into 
the vessel wall is driving the initiation and progression of atherosclerotic plaque 
formation2,3. The atherosclerotic process is orchestrated by several groups of 
molecules on both the activated endothelium as well as on the infiltrating 
leukocytes4. Activation of the endothelium due to low shear stress and/or local 
damage results in the upregulation of leukocyte adhesion molecules and 
secretion of chemoattractants5.  
Recruitment of blood leukocytes to sites of inflammation is initiated by 
interaction of P- and E-selectins that are upregulated on activated endothelium 
with their sialylated ligands on leukocytes6-10. This transient interaction slows 
down leukocytes from the flowing blood resulting in rolling behavior on the 
endothelial surface. After activation, leukocytes come to a firm arrest by binding 
to endothelial cell adhesion molecules. In experimental animals, endothelial 
cells in the arteries express in particular vascular cell-adhesion molecule-1 
(VCAM-1) resulting in the predominant recruitment of monocytes and 
lymphocytes to atherosclerotic regions11. Blocking this interaction results in 
attenuation atherosclerosis and other inflammatory disorders12-14. The last step in 
leukocyte transendothelial migration that is also known as diapedesis occurs 
largely through junctions between adjacent endothelial cells. Indeed a number 
of cell adhesion molecules locates at endothelial cell junction have been 
implicated in this process. These molecules include platelet-endothelial cell 
adhesion molecule (PECAM-1)15, members of the junctional adhesion molecule 
(JAM) family16, CD9917-19 , ESAM20 and ICAM-221. 
CD99, a long known leukocyte membrane protein that was initially described to 
function in T cell activation and lymphocyte aggregation22-24, was only recently 
reported to participate in the transmigration of human monocytes through 
cultured endothelial cells19. Schenkel et al.  showed that CD99 is expressed at 
endothelial cell contacts and that a monoclonal antibody against CD99 inhibits 
diapedesis of human monocytes across a monolayer of cultured endothelial cells 
by 90%19. The mouse counterpart was identified and cloned few years later by 
Bixel et al.17-18. Antibodies against mouse CD99 efficiently block migration of 
lymphocytes and neutrophils through a monolayer of cultured endothelioma 
cells17-18. More importantly, these antibodies block recruitment of in vivo-
activated T cells into inflamed skin17 and inhibit neutrophil extravasation to 
inflamed sites in two inflammatory mouse models18. As the recruitment of both 
monocytes and T cells contribute to the initiation and progression of the 
atherosclerotic plaque, blockade of their transmigration may provide protection 
against atherosclerosis3. 
In the present study we assessed the role of CD99 in the process of 
atherosclerosis by vaccinating atherosclerosis prone mice against CD99. Oral 
administration of a DNA vaccine encoding the extracellular domain of murine 
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CD99 by attenuated Salmonella typhimurium evoked a T-cell mediated immune 
response against cells expressing CD99 in mice. We demonstrate that 
vaccination of mice against CD99 generates antigen-specific CD8+ T cells that 
target 3T3 fibroblasts transfected with CD99. Vaccination of LDL receptor 
deficient mice against CD99 significantly reduced the formation of 
atherosclerotic lesions in the aortic valve leaflet and the carotid artery as 
compared to mice vaccinated with the vector alone. 
 
 
Material and methods 
 
Construction of the vaccine 
The cDNA encoding the extracellular part of murine CD99 (BC019482), 
obtained by HindIII/EcoRI digestion of the Fc fusion plasmid earlier described 
by Bixel et al17 was cloned into pcDNA3 plasmid (Invitrogen California). This 
plasmid was electroporated into S. typhimurium Aro/A (strain SL7207) bacteria 
as previously described25. Female LDL receptor deficient mice, aged 10-12 weeks 
were immunized by oral administration of 1*108 cfu S.typhimurium transformed 
with either pcDNA3-CD99 or pcDNA3 empty (control) 3 times with 2 week 
intervals. 
 
Induction of CD8+ specific cytotoxic T cells 
Spleens were isolated from control and CD99 vaccinated mice and their capacity 
to lyse CD99 expressing cells was determined in the following assay. Murine 
fibroblasts (3T3) were cultured in a 24 wells plate and incubated with DMEM 
containing 10% Fetal bovine serum, 2mmol/L L-glutamine, 100U/ml penicillin 
and 100 µg/ml streptomycin in a humified atmosphere (5% CO2) at 37 °C. Cells 
were co-transfected with pcDNA3-CD99 (encoding for the extracellular part of 
murine CD99) and pEGFP-N1 vector using ExGen500 (Fermentas, Germany) as 
transfection reagent according to the manufacturers protocol. After 24 hours the 
transfected cells were incubated with splenocytes derived from control or CD99 
vaccinated mice (2 weeks after last vaccination) for 24 hours. Non-adherent cells 
were washed away with PBS and specific lysis of the cells expressing CD99 was 
analyzed on a FACScalibur (BD Biosciences, The Netherlands) by quantifying 
the percentage of eGFP positive cells. The percentage of specifically lysed of 
cells transfected with CD99 was plotted as percentage of eGFP positive cells in 
absence of splenocytes. 
 
Atherosclerosis experiments and histology 
Female LDLr deficient (LDLr-/-) mice (n=12 per group), 8 weeks old, were 
vaccinated with pcDNA3 empty of pcDNA3-CD99 3 times in two week 
intervals. After vaccination, mice were placed on a Western type diet containing 
0.25 % cholesterol and 15% cocoa butter two weeks before collar placement. 
Silastic collars (0.3 mm inside diameter, Dow Corning, Midland, USA) were 
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placed around the carotid artery to induce atherosclerosis. After 8 weeks of 
western type diet, mice were sacrificed and organs were harvested. 
Cryosections from carotid artery (5 µm) were stained with hematoxilin and 
eosin. Site of maximal stenosis was used for morphometric assessment using a 
Leica DM-RE microscope and LeicaQwin software (Leica imaging systems, 
Cambridge, UK). Cryostat sections of the aortic root (10 µm) were collected and 
stained with Oil-red-O. Lesion size was determined in 5 sections of the aortic 
valve leaflet area. Expression of CD99 was visualized using an affinity-purified 
anti-mouse CD99 polyclonal antibody17. As secondary antibody, biotinylated 
goat anti-rabbit (DAKO, the Netherlands) was used in combination with 
streptABC complex (DAKO), with Nova Red as enzyme substrate (Vector 
Laboratories). 
 
Real time PCR assays 
Total RNA was isolated from aortic arch and collar induced atherosclerotic 
plaques using the guanidium isothiocyanate (GTC) method. Purified RNA was 
DNase treated (DNase I, 10 units/µg of total RNA) and reverse transcribed 
(RevertAid M-MuLV reverse transcriptase) according to manufacturers protocol.  
Quantitative gene expression analysis was performed on an ABI PRISM 7700 
(Applied Biosystems, Foster City, CA) using SYBR Green technology. (PCR 
primers see apeendix 1) 
 
Flow cytometry 
Leukocytes from whole blood and spleen were isolated by density gradient 
centrifugation with Lympholyte (Cedarlane Laboratories, Hornby, Ontario, 
Canada) according to manufacturer’s protocol. Cell suspensions from spleen, 
blood, lymph nodes draining from the aortic arch and peritoneal cavity were 
stained for surface markers (0.20 µg Ab/300.000 cells) and subsequently 
subjected to flow cytometric analysis. Antibodies were purchased from 
eBiosciences (Immunoscource, Belgium). All data were acquired on a FACS-




Values are expressed as mean ± SEM unless indicated otherwise. Two-tailed 
student’s T-test was used to compare normally distributed data between two 
groups of animals. Mann-Whitney test was applied to analyze not-normally 
distributed data. A probability value of P<0.05 was considered to be significant 
for both tests. 




Figure 1: CD99 is expressed by vascular endothelial cells in an atherosclerotic vessel and is 
upregulated after Western type diet feeding. Expression of CD99 was visualized using an affinity 
purified polyclonal antibody against CD99.  Representative pictures are shown in figure 1A and at 
higher magnification in 1B. mRNA was isolated from the aortic arch of LDLr -/- mice using the GTC 
method. mRNA levels for CD99 were determined for mice receiving Chow or Western type diet and 
levels were related to mRNA levels of 36B4 and HPRT. Statistical analysis was done by an unpaired 




CD99 expression is upregulated on vascular endothelium overlying 
atherosclerotic plaques  
Several molecules expressed at endothelial cell junctions such as JAM-A have 
been associated with atherosclerosis, and are upregulated in atherosclerosis 
prone sites of the vasculature26. We stained cryosections of collar induced 
atherosclerotic plaques in LDLr-/- mice and observed a profound expression of 
CD99 by vascular endothelial cells covering the plaque. A representative picture 
is shown in figure 1A-B. To further investigate the regulation of this expression, 
we isolated the aortic arch of LDLr-/- mice after 2 weeks of western type diet and 
compared CD99 mRNA levels of mice that received a chow diet. We observed a 
1.5-fold increase in CD99 expression upon western type diet feeding (Fig. 1C). 
This increase was not accompanied by elevated expression of T cell or 
macrophage markers, indicating that the cellular composition of the aorta was 
not changed due to an influx of leukocytes. 
 
 
Vaccination against CD99 induces T cell-mediated lysis of cells expressing CD99 
We developed a vaccination strategy based on the induction of CD99 specific 
cytotoxic T cells that specifically lyse cells that express high levels of CD99 as 
recently shown for FLK-127. To test the functionality and specificity of this 
vaccination protocol we determined the antigen-specific cytotoxicity of splenic 
CD8+ T cells derived from mice vaccinated against CD99. Therefore 3T3 
fibroblasts were co-transfected with pcDNA-CD99 and EGFP-N1, which allows 
the identification of CD99 expressing cells by their simultaneous expression of 
GFP using flow cytometry. Splenocytes were isolated from control and CD99 




















Figure 2: Vaccination against CD99 generates cytotoxic cells that specifically lyse cells expressing 
CD99. Murine fibroblast CD99 transfected with pcDNA-CD99 and eGFP were exposed to spleen 
cells isolated from control and CD99 vaccinated mice. After 24 hours, the percentage of eGFP 
positive cells was quantified using flow cytometry. Representative histograms are shown for spleen 
cells isolated from mice vaccinated with control vector (black line) or with pcDNA-CD99 (gray line). 
Specific lysis of 3T3 fibroblasts that present CD99 peptides on MHC class I was determined by 
quantifying the percentage of GFP positive cells compared to controls were no splenocytes were 
added. The percentage of GFP positive cells was significantly decreased when splenocytes were used 
derived from animals that were vaccinated against CD99 (right panel, p=0.01, n=7 per group).  
 
were transfected with CD99. Specific lysis of CD99 expressing cells was 
determined by quantifying the percentage of eGFP positive cells compared to 
controls were no splenocytes were added. The percentage of CD99 expressing 
cells was significantly decreased after incubation with splenocytes from CD99 
vaccinated mice (Fig. 2, 86.6  ± 10.2 % vs. 46.3 ± 11.8), whereas no decrease was 
observed splenocytes from control vaccinated mice were added (Fig. 2). This 
observation indicates that CD99 vaccination induces the formation of T cells 
that specifically lyse CD99 expressing cells. 
 
 
Vaccination against CD99 inhibits atherosclerotic lesion formation in LDLr-/- 
mice 
After showing the effectiveness of our vaccination strategy, we investigated the 
effect of CD99 vaccination on atherosclerotic lesion formation. Female LDLr-/- 
mice were vaccinated with pcDNA3-empty (control) or pcDNA-CD99 3 times at 
a 2 week time interval. Mice were subsequently placed on a Western type diet 
(0.25% cholesterol) and  two weeks later mice were equipped with peri-carotid 
collars. Six weeks later, mice were sacrificed and the atherosclerotic lesion 
burden was determined in the carotid artery and aortic root. Representative 
photomicrographs of cross sections of the aortic root of control and treated mice 
are shown in figure 3A and B respectively. The mean lesion area in mice 
vaccinated against CD99 was decreased by 38% compared to control animals 
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Middle panels show representative sections of the carotid artery of control (Fig. 
3D) and CD99 vaccinated (Fig. 3E) mice. Lesion size was significantly decreased 
by 69% after CD99 vaccination (Fig. 3F. 24.15 ± 7.7x103 µm2 vs. 7.71 ± 4.0x103 
µm2, in Fig. 3F 2.4. ± 0.7 x104 µm2 is shown, which is accompanied by an 83% 
decrease in intima/media ratio (Fig. 3G) and a 78% diminished degree of lumen 
stenosis (Fig. 3H). 
In addition, the number of cells that had infiltrated the carotid plaques of 
control and CD99 vaccinated mice was determined by quantifying the number 
of nuclei per square micrometer (Fig. 3I). Vaccination against CD99 resulted in a 
35% decrease in number of nuclei per area in atherosclerotic plaques from CD99 
vaccinated mice compared to controls, indicating that a lower number of cells 
have infiltrated the vessel wall. 
Figure 3: Atherosclerotic lesion formation is significantly inhibited in mice vaccinated against CD99. 
Representative photomicrographs of oil red O stained cross sections of the aortic root of control 
treated mice (A) and vaccinated mice (B) are shown. A significant reduction in plaque size was found 
in CD99 vaccinated mice compared to control mice (C). Lower panels demonstrate representative 
pictures of the carotid artery of control (D) and CD99 vaccinated animals (E). A significant decrease 
(p=0.02) was observed in carotid plaque area after vaccination against CD99 (F). This decrease in 
lesion formation is accompanied by a significant decrease in lumen stenosis (G) and intima/lumen 
ratio (H). Number of cells that infiltrated into the plaque area was decreased in mice vaccinated 
against CD99 compared to controls (I). Error bars represent SEM, n = 12 per group. Statistical 








































































Vaccination activates CD8+ T cell in LDLr-/- mice 
The vaccination strategy is based on the induction of specific CD8+ T cells that 
induce apoptosis of cells that express high levels of CD99 via MHC class I. To 
test whether our vaccine had an effect on the activation state of the CD8+ T cell 
population during atherogenesis, we isolated lymphocytes from spleen and 
lymph nodes of control and CD99 vaccinated mice at the end of the 
atherosclerosis experiment. The activation state of the T cell population was 
determined by flow cytometry using CD69 as an early marker for T cell 
activation. CD8+ cells were gated and the percentage of CD8+ T cells expressing 
CD69 was determined (Fig. 4, upper panels). A significant increase of 
CD8+CD69+ double positive cells within the CD8+ T cell population was observed 
in spleen (43.4 ± 3.9% vs. 59.3 ± 4.5%) and in lymph nodes draining the aortic 
arch (4.8 ± 0.2% vs.  5.9 ± 0.1%, Fig. 4, lower panels). This observation was 
restricted to the CD8+ T cell population, since the activation state of CD4+ T cells 
was not changed as shown by measuring the percentage of CD4+/CD69+ double 
positive cells among the CD4+ T cell population (data not shown). These findings 
indicate that vaccination against CD99 specifically activates CD8+ T cell subsets, 
but not CD4+ T cells. 
 
 
Vaccination against CD99 decreases expression of CD99 on CD4+ T cells and 
F4/80+ macrophages 
CD99 is expressed on most leukocytes, including lymphocytes and monocytes 
derived from peripheral blood17-18. To determine whether vaccination against 
CD99 would affect CD99 expression levels on leukocytes, we stained CD4+ T 
cells and F4/80+ macrophages with anti-CD99 antibodies and determined CD99 
expression on these cells by flow cytometry. The percentage CD99 positive cells 
within the CD4+ and F4/80+ cell population is shown in Figure 5. 
The expression of CD99 on CD4+ T cells was significantly decreased upon 
vaccination against CD99 (Fig. 5, left panel; 37.6 ± 2.7 % vs. 28.5 ± 1.6 %). In 
addition, the percentage of CD99 expressing cells within the macrophage 
population was also decreased by 31% after vaccination (Fig. 5, right panel; 24.5 
± 1.7 vs. 16.9 ± 2.7). The percentage of macrophages and CD4+ T cells was not 
changed compared to control vaccinated mice as determined by FACS (data not 
shown). 




Figure 4: Vaccination against CD99 activates CD8+ T cells. Activation of CD8+ cells was analyzed by 
flow cytometry. CD8+ cells were gated and expression of the early T cell activation antigen CD69 
was determined (upper panels). The percentage of CD8+CD69+ double positive cells was quantified 
within the CD8+ cell population. In CD8+ T cells derived from spleen and lymph nodes, vaccination 
against CD99 resulted in a significant up-regulation of CD69. White bars represent controls, black 




Human CD99 was recently reported to be involved in migration of human 
monocytes through a monolayer of cultured endothelial cells19. Cloning of 
mouse CD99 by Bixel et al. opened the possibility to examine the physiological 
relevance and role of CD99 in mouse models of inflammatory diseases17. 
Recruitment of leukocytes into the vessel wall is a hallmark of atherosclerosis 
and several facilitators of this process have been identified. A prominent role for 
cell adhesion molecules that are expressed at cell contacts of endothelial cells 
was reported, i.e. increased expression of PECAM-1 was found to be associated 
with atherosclerosis-prone regions of the vessel wall and blocking anti-PECAM-
1 antibodies reduced leukocyte migration into atherosclerotic plaques15,28,29. Mice 
deficient in JAM-A, another junctional cell adhesion molecule that participates 
in leukocyte extravasation, were shown to have reduce neointima formation on 
apoE background30. We hypothesized that CD99 may also be involved in the 
recruitment of leukocytes into atherosclerotic plaques. A lower amount of CD99 














































Figure 5: Expression of CD99 on CD4+ T cells and F4/80+ macrophages is decreased after vaccination 
against CD99. Single cell suspensions of spleens from control and CD99 vaccinated mice were 
prepared and analyzed by flow cytometry to determine CD99 expression on CD4+ T cells and F4/80+ 
macrophages. Expression of CD99 was quantified by assessing the relative amount of CD99 positive 
cells among the CD4+ and the F4/80+ positive cell population. Expression of CD99 in CD4+ T cells and 
F4/80+ macrophages was significantly decreased after CD99 vaccination compared to controls. White 




leukocyte recruitment to inflamed areas of the artery and could attenuate the 
formation of atherosclerotic plaques.  
First we demonstrate that CD99 is expressed on vascular endothelium overlying 
vessels with atherosclerotic lesions. Second, Western type diet feeding of 
atherosclerosis prone LDLr-/- mice induced a 1,5-fold upregulation of CD99 
mRNA levels in the aortic arch after 2 weeks of diet. This upregulation was not 
due to CD99 expressing leukocytes infiltrating the vessel wall, as CD99 
expression was already increased before an increase in CD68+ or CD4+ cells was 
observed. This indicates that no additional CD99 expressing leukocytes were 
recruited and that the cellular composition of the examined vessels after 
Western type diet or chow diet feeding was not changed (data not shown).   
To test the hypothesis that CD99 is involved in leukocyte recruitment to sites in 
the vessel wall where atherosclerotic lesions are formed we developed a DNA 
vaccination strategy to immunize LDL receptor deficient mice against CD99. An 
attenuated S. typhimurium strain was transformed with a pcDNA3 vector 
encoding the extracellular domain of murine CD99. The S. typhimurium carrier 
is taken up by M cells and processed in the Peyers patches of the gastrointestinal 
tract. The bacteria are taken up by antigen presenting cells; the vector is 
transcribed and translated into protein. Processing the protein by the antigen 
presenting cells leads to presentation of peptide fragments in a complex with 
MHC class I. These MHC class I presented peptides activate specific cytotoxic 
natural killer cells and CD8+ T cells that clonally expand and break peripheral 
tolerance against CD99. This vaccination protocol therefore generates T cells 
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DNA vaccination strategy has been successfully validated for other proteins in 
animal models for tumor growth and cancer therapy and arthrosclerosis25,27, 31.  
Here we show that vaccination against murine CD99 of LDLr-/- mice specifically 
activates CD8+ T cells during atherogenesis that are able to target CD99 
expressing cells. Based on these observations we conclude that our vaccination 
strategy generates cytotoxic CD8+ T cells that break through immune tolerance 
against a self antigen and kill cells that express high levels of CD99. 
Once we had validated our vaccination protocol, we induced atherogenesis in 
LDLr-/- mice that were vaccinated with control (pcDNA3-empty) or CD99 
(pcDNA3-CD99). This approach has been shown to reduce plaque formation in 
mice that were vaccinated against vascular endothelial growth factor (VEGF) 
receptor 2 (flk-1), which is expressed by activated endothelial cells that cover 
the atherosclerotic plaque25. 
The importance of CD99 for leukocytes diapedesis was first shown by Schenkel 
et al.19 for human CD99 and later by Bixel for mouse CD9918. For human 
monocytes and neutrophils and for mouse lymphocytes is has been shown that 
the separate blockade of both endothelial or leukocyte CD99 by specific 
antibodies is sufficient to inhibit leukocyte transmigration17. Lower CD99 
expression levels or a reduced functionality of CD99 on leukocytes could 
possibly interfere with leukocyte extravasation and reduce their migration 
through the vascular endothelium. We have shown that vaccination against 
CD99 significantly decreases CD99 expression on CD4+ T cells and macrophages.  
It was suggested for human CD99 that homotypic interaction of CD99 on 
leukocytes with CD99 on endothelial cells is important for leukocyte diapedesis 
through endothelial contacts. A lower expression level of CD99 on leukocytes 
and/or endothelial cells could possibly attenuate plaque formation due to a 
reduced transmigration rate. We clearly show that vaccination against CD99 
indeed strongly reduced the formation of atherosclerotic lesions and attenuated 
atherogenesis at two different sites within the vasculature. In addition to smaller 
size of atherosclerotic plaques they contained fewer cells when mice were 
vaccinated against CD99. This indicates that fewer cells that could contribute to 
plaque initiation and growth have migrated into the activated vessel wall. The 
observed reduction in lesion formation is not the result of differences in 
cholesterol and triglyceride levels between control and CD99 vaccinated mice 
(data not shown).  
 
In summary, we generated an attenuated Salmonella vaccine against mouse 
CD99 that induced the generation of a CD8+ T cell population that specifically 
targets CD99 expressing cells. Vaccination against CD99 of LDL receptor 
deficient mice significantly reduced the formation of atherosclerotic plaques and 
attenuated clinical symptoms of atherogenesis. This flexible, easy to prepare, and 
non invasive method provides a rationale for the future development of DNA 
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atherogenesis in LDL Receptor Deficient Mice  
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Atherosclerosis is an auto-immune disease characterized by the influx of 
leukocytes into the vessel wall and the deposition of lipids.  Interruption of the 
migration of specific subsets of leukocytes into the lesion can exert protective 
effects on lesion formation. IL-16 is a chemotactic factor that specifically induces 
the migration of CD4+ cells to sites of inflammation. It has been shown to have 
pro-inflammatory effects in several auto-immune diseases and we therefore 
proposed that blockade of IL-16 would be protective in atherogenesis. We 
constructed an orally administrated DNA IL-16 vaccine and confirmed the 
induction of anti-IL16 specific antibodies. LDL receptor deficient mice were 
vaccinated against IL-16 and we determined the effect on lesion formation in 
the aortic leaflet area and in collar induced atherogenesis after 8 weeks of diet 
feeding. No effects were observed in the aortic leaflets, but lesion formation was 
significantly induced in the carotid artery. At this time point, the number of 
circulating T cells, both CD4+ and CD8+, was significantly increased in IL-16 
vaccinated mice compared to control. Vaccinated mice on a diet for 20 weeks 
showed an even more profound 2-fold induction of lesion formation in the total 
aorta. Vaccination did not affect serum cholesterol and triglyceride levels. We 
propose that IL-16 has a protective role, especially in late stage atherogenesis. 
More research will be necessary to address the mechanism behind the observed 





Accumulation of leukocytes in the vessel wall is a hallmark of atherosclerosis. 
Both macrophages and CD4+ T cells are attracted to the activated endothelium 
and contribute to the growing atherosclerotic plaque. IL-16 is one of the first 
described proteins that displays chemoattractant properties for lymphocytes and 
IL-16 was therefore originally designated as Lymphocyte Chemoattractant 
Factor (LCF)1,2. It selectively mediates the migration of CD4+ T cells to sites of 
inflammation and has been extensively studied since it was cloned in 19943. IL-
16 is produced by a variety of cells, including leukocytes, fibroblasts and 
epithelial cells and is synthesized as a precursor that has to be cleaved by 
caspase-3 to become biologically active4,5. Secreted IL-16 forms homo-tetramers 
that are able to induce cross linking of its receptor CD4. CD4 is expressed by a 
subset of T cells and to a lesser extend on most monocytes/macrophages. IL-16 
induces cell activation and migration, and therefore a prominent role for this 
molecule can be suggested in (auto-)immune diseases. IL-16 seems to exert a 
pro-inflammatory stimulus in animal models for experimental autoimmune 
encephalomyelitis (EAE)6,7, rheumatoid arthritis (RA)8,9 and asthma 10-12. 
Leukocyte accumulation in the arterial wall initiates the formation of 
atherosclerotic plaques and inhibition of this migration, for example by selective 
blockade of chemokines or pro-inflammatory mediators, has resulted in the 
successful attenuation of lesion formation. It can be speculated that blockade of 
IL-16 will result in decreased migration of CD4 positive cells, and thus will 
result in attenuated plaque formation. This hypothesis was further underlined 
by the finding that CD4 deficient mice show reduced lesion formation when 
backcrossed to several atherosclerosis prone animal models and adoptive transfer 
of CD4+ cells led to accelerated atherosclerosis13-15. 
Lynch et al have identified CCR5 as a co-receptor for IL-1616. As blockade of 
CCR5 results in significant attenuation of atherosclerotic lesion formation17, 18, 
this could point to a pro-atherogenic effect of IL-16 as well. 
In this study, we used oral DNA vaccination to induce IL-16 specific antibodies 
that selectively block IL-16.  To break IL-16 tolerance, we used a PAN-DR 
epitope that enables a MHC-II mediated antibody response against the self-
peptide IL-16. We show that vaccination against IL-16 results in increased lesion 
formation in the carotid artery in LDL receptor deficient (LDLr-/-) mice. This 
effect was more prominent in later stages of plaque formation in the total aorta. 
We therefore propose an anti-inflammatory role for IL-16 in atherosclerotic 
lesion formation. 
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Material and methods 
 
Vaccination strategy 
The sequence of murine IL-16 was fused with the PADRE sequence and cloned 
into pcDNA3.1 plasmid (Invitrogen, CA) and electroporated into attenuated 
Salmonella typhimurium (Aro/A (strain SL7207). HEK 293-T cells were 
transfected with the plasmids and IL-16 protein expression was determined by 
Western blotting. Vaccination was performed by 3 times oral administration of 
1x108 cfu of S. typhimurium transformed with pcDNA3.1-PADRE-IL-16 or 
pcDNA3.1-PADRE (control) in 100 µl of PBS at 2 week intervals19. All animal 
experiments were in accordance with guidelines issued by the Dutch law and 
approved by the ethics committee for animal Experiments of Leiden University 
(DEC).  
 
Antibody titer determination 
96-wells plates were coated with 250 ng/mL IL-16 in PBS and incubated 
overnight at 4°C. After washing, the plates were blocked with FCS for 1 hour at 
room temperature. Plasma of IL-15 or control vaccinated mice was added in 
serial dilutions with PBS 5% Triton-X100 and incubated for 1 hour at room 
temperature. Plates were washed with PBS + 0.1% Tween-20, and horseradish 
peroxidase conjugated Goat-anti Mouse antibody (Dako) was used as detection 
antibody. After washing, the anti-IL-16 antibody titer was determined using a 
TMB kit (Pierce).  
 
Atherosclerosis experiments 
Female LDLr-/- mice were vaccinated with control (pcDNA3.1-PADRE) or 
pcDNA3.1-PADRE-IL-16 as described (n=12/13 per group). After the last 
vaccination, mice were fed an atherogenic diet containing 0.25% cholesterol and 
15% cocoa butter (Special Diet Service, UK). After 2 weeks of diet, 
atherosclerosis was induced by placing silastic collars around both common 
carotid arteries as previously described20. After 8 and 20 weeks of Western type 
diet, mice were sacrificed and lesion size (8 weeks aortic root, 20 weeks en face 
aorta) was analyzed using a Leica-DM-RE microscope and Leica Qwin software. 
Concentrations of serum cholesterol and triglycerides were determined using 
enzymatic colorimetric procedures (Roche/Hitachi, Mannheim, Germany). 
Precipath (Roche/Hitachi) was used as a standard. 
 
Histological analysis 
Cryostat sections of the aortic root (10 µm) and carotid artery (5 µm) were 
collected and stained with Oil-red-O and H/E respectively. Lesion size was 
determined in 5 sections of the aortic valve leaflet area and at the site of 
maximal stenosis in the carotid artery. Corresponding sections on separate slides 
were stained immunohistochemically with an antibody directed against a 
macrophage specific antigen (MOMA-2, monoclonal rat IgG2b, diluted 1:50). 
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Goat anti-rat IgG-AP (dilution 1:100) was used as secondary antibody and NBT-
BCIP as enzyme substrates.  
 
Real time PCR assays 
Total RNA was isolated from aortic arch and was DNase treated. Quantitative 
gene expression analysis was performed on an ABI PRISM 7500 (Applied 
Biosystems, Foster City, CA) using SYBR Green technology. PCR primers 
(Appendix I) were designed using Primer Express 1.7 software with the 
manufacturer's default settings (Applied Biosystems). Acidic ribosomal 
phosphoprotein PO (36B4) and hypoxanthine phosphoribosyl transferase 
(HPRT) were used as housekeeping genes.  
 
Flow cytometry 
Leukocytes from whole blood and spleen were isolated by density gradient 
centrifugation with Lympholyte (Cedarlane Laboratories, Hornby, Ontario, 
Canada). Cell suspensions from spleen, blood, lymph nodes draining from the 
aortic arch and peritoneal cavity were stained for surface markers (0.2 µg 
Ab/300.000 cells) and subsequently subjected to flow cytometric analysis 
(FACS). Antibodies were purchased from Immunoscource (Belgium). All data 




Values are expressed as mean ± SEM unless indicated otherwise. Two-tailed 
student’s T-test was used to compare normally distributed data between two 
groups of animals. Mann-Whitney test was used to compare not normally 
distributed data. A probability value of P<0.05 was considered to be significant 




IL-16 mRNA is increased during initial lesion formation 
IL-16 functions as a chemotactic factor for CD4+ cells and we speculated that IL-
16 could be involved in the attraction of leukocytes during atherosclerotic 
plaque formation.  
We used LDL receptor deficient mice on a Western type diet as a model for 
atherosclerosis and the mRNA expression of IL-16 during lesion formation was 
monitored in the aortic arch at different stages of western type diet feeding. A 
vast and significant increase was observed in IL-16 mRNA expression after 9 
weeks of diet (20-fold, p=0.001), indicating a role for IL-16 in diet-induced 
atherosclerotic lesion formation (Figure 1). At this time point a moderate influx 
of CD4+ and CD68+ cells was observed in the vessel wall (data not shown), 
indicating that lesion formation has started. 
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Figure 1: mRNA expression of IL-16 is 
significantly upregulated in the aortic 
arch of LDLr-/- mice on Western typed 
diet feeding. mRNA was isolated from 
the aortic arch of LDLr-/- mice and 
expression of IL-16 is expressed relative 
to 36B4 and HPRT, and subsequently 
related to the expression in mice on chow 
diet. An unpaired Student t test was 
applied to test whether IL-16 mRNA 
levels were significantly different from 
the mRNA levels in chow fed animals 
(week 0) (*p < 0.05, n= 6 per time point). 
 
 
PADRE- IL-16 vaccination 
Once we found a diet induced regulation of IL-16, we constructed a DNA 
vaccine against IL-16 to address the functional role of this interleukin during 
lesion formation. The vaccination strategy is based on the generation of IL-16 
specific antibodies that will functionally block IL-16 signaling. We used a PAN-
DR epitope (PADRE) to overcome tolerance against the self peptide IL-16 by 
facilitating MHC-II mediated T cell activation. We cloned a fusion construct of 
PADRE-IL-16 into pcDNA 3.1 and in vitro experiments were used to determine 
the expression of the used construct in eukaryotic cells. HEK-293T cells were 
transfected with the PADRE-IL-16 plasmid and the presence of pro-IL-16 
protein was confirmed by Western blot (Figure 2A). Lane 4 and 5 clearly show a 
band of approximately 70 kD that indicated pro-IL-16 protein (68 kD). Non-
transfected control cells and transfection with pcDNA 3.1 empty did not show 
the expression of pro-IL-16 (Lane 2 and 3). 
To test the induction of anti-Il-16 antibodies after vaccination, we titrated serum 
from control and IL-16 vaccinated mice to determine the concentration of anti-
IL-16 antibodies by ELISA. Serial dilutions of serum from IL-16 vaccinated mice 
resulted in a sigmoidal decrease in the binding of antibodies to the IL-16 coated 
wells as shown in figure 2B. Binding of antibodies in serum of control vaccinated 
mice to IL-16 was not observed in control vaccinated mice (open dots).  
 
Vaccination against IL-16 aggravates atherogenesis in LDLr-/- mice 
Subsequently, we used the plasmid in a vaccination protocol to determine the 
effect of the induction of anti-IL-16 antibodies on lesion formation. Mice were 
vaccinated 3 times by oral administration of attenuated S. typhimurium 
transformed with pcDNA 3.1PADRE-IL16 or control (pcDNA 3.1PADRE). After 
vaccination, mice were fed a Western type diet for 2 weeks after which collars 
were placed around the carotid artery to induce atherosclerosis in the carotid 
arteries. Six weeks after collar placement, animals were sacrificed and initial 
atherosclerotic lesion formation was assessed. Vaccination did not affect 
cholesterol (2753 ± 432 vs. 2733 ± 544 mg/dl) and triglyceride levels (475 ± 134 
vs. 533 ± 205 mg/dl) during the experiment.  




















Representative sections of the aortic valve leaflet area of control (A) and IL-16 
vaccinated mice (B) are shown in figure 3. Lesion formation at this site was not 
affected by IL-16 vaccination (2.85 ± 0. 26 *105 µm2 vs. 2.56 ± 0.56 *105 µm2, 
p=0.55).  
 
Figure 2: IL-16 vaccination results in protein expression in eukaryotic cells and specific antibody 
titers. A: HEK 293T cells were transfected with pcDNA3.1 (lane 3) and pcDNA containing PADRE-
IL-16 (lane 4+5) and incubated for 24 hours. Cells were lysed and subjected to Western blotting. Pro-
IL16 protein (68kD) was detected with a IL-16 specific antibody. Control cells (lane 1) and cells 
transfected with pcDNA3.1 showed no expression of IL-16, in contrast to PADRE-IL16 transfected 
cells (lanes 4+5). 
B: Serum from control and vaccinated mice was obtained at the termination of the atherosclerosis 
experiments (8 weeks) and anti-IL-16 titer was determined by ELISA. Serial dilutions are plotted 
against the relative signal with average control serum stated as 0%. A clear sigmoidal decrease in 
ELISA signal is appreciated in mice vaccinated against IL-16 (closed dots). This was not visible in 
mice that were vaccinated with pcDNA3.1 PADRE only (open dots). N=12 per dilution, at all points 
the amount of antibody as determined against a calibration curve was significantly increased in IL-16 
vaccinated mice compared to control vaccinated mice.  
 
 
We also assessed the degree of atherosclerosis in a model for flow-induced lesion 
formation.  Representative slides of collar induced atherosclerosis in the carotid 
artery are shown for control (A) and PADRE-IL-16 (B) vaccinated mice in figure 
4. Lesion formation at this site was significantly increased by 60% upon IL-16 
vaccination. (44,850 ± 7,036 µm2 vs. 71,739 ± 10,383 µm2, p=0.04) (figure 4C). 
This was reflected in a 73% increase in intima media ratio (0.86±0.12 vs. 1.50 ± 
0.20, p=0.01, 4E) and also the relevant clinical parameter, intima lumen ratio, 
increased by 41% (0.46 ± 0.06 vs. 0.65 ± 0.06, p=0.05, 4D).  
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Figure 3: Initial atherosclerotic lesion formation after Il-16 vaccination. Representative 
photomicrographs of oil red O stained cross sections of the aortic root of control vaccinated mice (A) 
and IL-16 vaccinated mice (B) are shown. No difference in lesion area was observed after IL-16 
vaccination.  
 
In addition to the effect of IL-16 vaccination on initial lesion formation after 8 
weeks of Western type diet, we assessed the result of IL-16 vaccination on 
advanced lesion formation. Again, animals were vaccinated with control or 
PADRE- IL-16 3 times at a two-week interval and were fed a Western type diet 
for 20 weeks. The degree of plaque formation was determined along the aorta by 
en face staining of the lipid rich areas using Oil red O. Representative examples 
of control (A) and IL-16 vaccinated (B) aortas are shown in figure 5. The lesion 
burden in IL-16 vaccinated mice is 1.9-fold higher in comparison to control 
vaccinated mice (13.8 ± 1.3 % vs. 26.2 ± 2.3 %, p=0.0004).  
 
Circulating T cell numbers are increased after IL-16 vaccination 
IL-16 functions as a chemotactic factor for CD4 positive cells and we were 
interested in the effect of IL-16 vaccination on the leukocyte population during 
atherogenesis.  To investigate this we harvested leukocytes from blood, spleen 
and lymph nodes, which drain from the aortic arch from control and IL-16 
vaccinated mice after 6 weeks of Western type diet. We stained the cell 
suspensions for CD4, CD8 and F4/80 and the percentage of positive cells was 
determined by FACS. 
Figure 6A shows the relative percentage of CD4+ T cells in blood, spleen and 
lymph nodes. A significant 50 % increase is observed in the percentage of these 
cells in the circulation of IL-16 vaccinated mice compared to PADRE vaccinated 
mice (17.2 ± 1.5 vs. 24. 9 ± 2.1, p=0.01). No differential effects of IL-16 
vaccination were observed on the CD4 population in spleen and lymph nodes. A 
similar pattern, however more modest, can be observed in the CD8+ population 
(6B). The percentage CD8+ cells is significantly increased in blood after IL-16 
vaccination (10.8 ± 1.6 vs. 12.8 ± 0.8, p=0.03), and no such effects were observed 
in spleen or lymph nodes. As macrophages and monocytes can express (low 
amounts of) CD4, we also analyzed the F4/80 positive population. No differential 
effects were observed on this cell type after vaccination against IL-16 (figure 
6C). No significant differences in total white blood cell counts were observed 























Figure 4: Initial atherosclerotic lesion formation after Il-16 vaccination. Collar induced plaques from 
control (A) and IL-16 vaccinated (B) mice were stained with H/E and lesion area was assessed. Lesion 
size significantly increased by 60% upon treatment vaccination against IL-16 (n=12 per group, 
p=0.04). This translated into a 73 % increase in intima media ratio (E) and also the relevant clinical 





In this study we showed anti-atherogenic effects of IL-16 in atherosclerosis. We 
used a DNA vaccination strategy to block IL-16 function in vivo. IL-16 is an 
endogenous  protein and antibody formation against a endogenous proteins is 
inhibited due to the lack of T cell help resulting in tolerance21. A vaccination 
strategy that will result in antibodies against a self protein is therefore 
depending on overcoming this T cell unresponsiveness22. Vaccination against IL-
12 by using the fusion protein of IL-12 and the T helper cell restricted epitope 
PADRE has been shown to be successful in preventing both experimental 
autoimmune encephalomyelitis (EAE) and atherosclerosis by induction of IL-12 
autoantibodies23, 24. In this study, we use a DNA vaccination strategy where we 
overcome tolerance by linking the PADRE sequence to murine pro-IL-16 and 
cloned the fusion construct into pcDNA 3.1.  
As protein expression of the construct is essential for further immunological 
processing, we show that transformation of eukaryotic cells with this plasmid 
resulted in protein production of the fusion construct. We then transformed 
Salmonella typhimurium with the plasmid and vaccinated mice by multiple oral 
administrations of the transformed bacteria. Niethammer et al. have nicely 
shown that oral vaccination results in the uptake of the transformed Salmonella 
by M cells and subsequent processing in the Peyers patch leads to translation of 
the proteins encoded by the plasmid19. In our case, by using the PADRE epitope, 



















































Figure 5: Lesion formation after 20 weeks of diet is significantly induced after IL-16 vaccination. 
Relative plaque area was quantified in en face pinned aortas after vaccination and 20 weeks of diet 
feeding. Representative pictures are shown for control (A) and IL-16 vaccinated mice (B) and lesion 
formation is significantly induced by 100% (n=8 per group, p=0.0004). 
 
T cell help will be facilitated via the specific MHC class II presentation of 
PADRE by the antigen presenting cells (ie the B cell), which results in T cell 
help for the IL-16 specific B cell. We confirmed the resulting IL-16 specific 
antibody titers by ELISA.  
Once we successfully validated the vaccination protocol, we vaccinated LDLr-/- 
mice against IL-16 to determine the role of this molecule in atherogenesis. No 
effect of IL-16 was observed on serum cholesterol and triglyceride levels and IL-
16 vaccination did not affect initial lesion formation in the aortic valves. 
However, an increase in lesion formation was determined in the carotid artery 
and after 20 weeks of diet feeding, lesion formation in the total aorta was almost 
100 % increased compared to control vaccinated mice. This indicated that there 
is a discrepancy in the effects of IL-16 vaccination between different sites and 
time points, and this phenomenon is observed by more authors25,26. For example 
Frederickson et al. observed a significant reduction in lesion size in the 
descending aorta and not in the aortic valve leaflets in apoE deficient mice after 
immunization with apoB-10025. Furthermore, Hauer et al. showed that DNA 
vaccination against vascular endothelial growth factor receptor 2 very 
significantly reduced lesion formation in the carotid artery and in contrast, no 
effect was observed in the valve leaflet26. 
 
The observed profound effects of IL-16 vaccination on advanced lesion 
formation and to a lesser extend on initial lesion formation may be due to the 
processing route of IL-16. It is sythesized as a pro-form and only actively 
secreted after cleavage by caspase-35, 27. This enzyme is highly expressed in lipid 
rich plaques and associated with macrophage apoptosis due to oxLDL loading28. 
It was also shown that IL-16 is spontaneously released from monocytes cells that 
undergo apoptosis29. In general, during plaque growth and differentiation the 
lipid rich core associated with necrosis and apoptosis will increase. This indicates 
that the amount of caspase-3 will increase with plaque progression, and 
therefore the active form of IL-16 will probably be more present in advanced 




















profound effect in advanced plaque progression than in the development of 
(initial) fatty streaks. This mechanism is not in contrast with the observed 
elevation of IL-16 mRNA in the vessel wall already after 9 weeks of diet feeding. 
Pro-IL-16 mRNA is constitutively expressed in leukocytes, and cellular acti-
vation or apoptosis induction is required to release the active form of IL-16.  
 
Figure 6: Relative number of circulating T cells is increased upon IL-16 vaccination. Mononuclear 
cell suspensions of draining lymph nodes, spleen and blood were isolated from control mice and 
mice following control or IL-16 vaccination. Cells were stained for CD4 (A), and CD8 (B) and F4/80 
(C). Results represent the mean percentage of positive cells ± SEM from 6 individual mice (*=P<0.05, 
Students T test). An increase is seen in the percentage CD4 and CD8 positive T cells in blood in the 
IL-16 vaccinated group (White bars) compared to control (Black bars).  
 
 
Although IL-16 is mainly presented in literature as a pro-inflammatory 
mediator, we propose that IL-16 has a protective effect during diet induced 
lesion formation. This rather unexpected finding can have several reasons. IL-16 
is able to induce migration of CD4+ cells and vaccination against IL-16 will thus 
result in the reduction of IL-16 mediated migration. Not all attracted cells 
during the formation of an atherosclerotic plaque contribute to its growth. 
Specific attraction of cell subsets such as naturally occurring regulatory T cells or 
other suppressive subsets have profound protective effects on lesion formation. 
It was shown that IL-16 can induce expression of CD25, and is a possible 
stimulator of regulatory T cells in this way30. Blocking this signalling route can 
locally modify the balance between regulatory and effector T cells and lead to 
accelerated atherosclerosis31,32. The effects of IL-16 are not restricted to the T cell 
population. Macrophages and dendritic cells are known to express low to 
moderate amounts of CD4. When these cells are exposed to IL-16, the 
production of several pro-inflammatory and pro-atherogenic mediators is 
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cells, indicating a possible protective role via the induction of this potent anti-
atherogenic molecule. 
 
In conclusion we propose that IL-16 has protective effects in advanced lesion 
formation, possibly by the attenuation of anti-atherogenic T cell subsets or by 
reducing the amount of protective cytokine production. Further research will be 
necessary to determine the specific mechanism by which IL-16 exerts these 
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Atherosclerosis is a chronic (auto-) inflammatory disease and T cell activation is 
an important factor in this process. Tnfrsf4 (OX40) and Tnfsf4 (OX40 ligand) are 
members of the TNF and TNF receptor family and OX40/OX40L mediated 
signaling is important in co-activation of T cells and facilitates B-T cell 
interaction.  In this study we assessed the role of the OX40/OX40L pathway in 
atherosclerosis and the effect of interruption of the OX40/OX40L pathway on 
lesion development.  
We treated LDLr-/- mice with an anti-OX40L antibody which lead to a 53% 
decrease in atherosclerotic lesion formation. Treatment resulted in inhibition of 
Th2 mediated isotype switching by decreasing IL-4 secretion and subsequent 
low IgG1 serum levels against oxLDL, while protective anti-oxLDL specific IgM 
titers were increased in treated mice compared to control. 
We conclude that blocking the OX-40/OX40L interaction reduced atherogenesis 
by inhibition of IL-4 mediated Th2 induced isotype switching and subsequent 





Atherosclerosis is considered to be a chronic (auto-) inflammatory disease in the 
context of high plasma cholesterol levels, in which both innate and adaptive 
immune responses play a role1, 2. It is characterized by the infiltration of the 
arterial vasculature by leukocytes in response to both endothelial injury and 
elevated levels of oxidized lipoproteins3 4. These elevated levels of oxidized lipids 
induce a strong humoral response, resulting in the production of specific 
antibodies against oxidized LDL (oxLDL) and malondialdehyde LDL (MDA-
LDL).T cell activation is an important step in this process and is initiated by 
antigen (possibly oxidized lipoproteins or heat shock proteins) recognition in 
combination with co-stimulatory signals provided by antigen presenting cells 
(APCs). The TNF receptor pathway can provide co-stimulatory signals and has 
been implicated in the onset and progression of atherosclerosis5-7.  
Tnfrsf4 (OX40, CD134) is a less well-explored member of the TNF receptor 
family and is primarily expressed on activated CD4-positive and CD8-positive T 
cells in mice and humans8-10. OX40L (Tnfsf4, CD134L) is expressed on a wide 
variety of cells including dendritic cells, B-lymphocytes, microglia, and vascular 
endothelial cells11,12 .  
OX40 and OX40L have been implicated in T cell activation and migration into 
inflamed tissue, as well as in the activation of B cells and macrophages 13. 
Activated OX40 positive T cells can provide help to B cells via OX40L expressed 
on the B cell surface, and can subsequently induce isotype switching dependent 
on their cytokine production14. 
Interruption of OX40-OX40L interaction has been shown to ameliorate several 
autoimmune like diseases15,16, 17. The expression of OX40 by T cells during EAE 18 
and graft versus host disease (GVHD)19 is correlated with the severity of disease, 
increasing during disease onset, and decreasing when the clinical parameters 
decline.  Interestingly, the OX40L gene is located within the Ath-1 QTL on 
chromosome 1, a region associated with aggravated atherosclerosis, indicating a 
role for this molecule in atherogenesis20, 21.   
In the present study we examined the expression of OX40 during the formation 
of atherosclerotic lesions in LDLr-/- on a Western type diet and determined the 
effect of an OX40L blocking monoclonal antibody (RM134) on atherogenesis.  
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Material and methods 
Animal experiments 
Female LDLr deficient (LDLr-/-) mice, 8 weeks old, were put on a Western type 
diet containing 0.25 % cholesterol and 15% cocoa butter two weeks before collar 
placement. Silastic collars (0.3 mm inside diameter, Dow Corning, Midland, 
USA) were placed around the carotid artery to induce atherosclerosis as 
described previously 22. After collar placement mice were treated with 300 µg of 
anti-OX40L antibody (RM134) in 100 µl of sterile PBS i.p. twice a week during 6 
weeks. As a control rat IgG (Sigma) in sterile PBS was used. Cryosections  from 
the carotid artery (5µm) were stained with hematoxilin and eosin. Site of 
maximal stenosis was used for morphometric assessment using a Leica DM-RE 
microscope and LeicaQwin software (Leica imaging systems, Cambridge, UK). 
Cryostat sections of the aortic root (10 µm) were collected and stained with Oil-
red-O. Lesion size was determined in 5 sections of the aortic valve leaflet area. 
Corresponding sections on separate slides were stained immunohistochemically 
with an antibody directed against a macrophage specific antigen (MOMA-2, 
monoclonal rat IgG2b, diluted 1:50). Goat anti-rat IgG alkaline phosphatase 
conjugate (dilution 1:100) was used as secondary antibody (1h, room 
temperature) and nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl 
phosphate as enzyme substrates. Lesion collagen content was visualized by a 90-
minute incubation of slides in 0.1% Sirius Red (Direct Red 80, Sigma) in 
saturated picric acid and subsequent rinsing in 0.01M HCl.  
 
Serum lipid levels 
Blood samples were collected by tail bleeding from non-fasted animals.  
Concentrations of serum cholesterol and triglycerides were determined using 
enzymatic colorimetric procedures (Roche/Hitachi, Mannheim, Germany). 
Precipath (Roche/Hitachi) was used as a standard. 
 
Real Time PCR assays 
Total RNA was isolated from spleen using the guanidium isothiocyanate (GTC) 
method. Purified RNA was DNase treated (DNase I, 10 units/µg of total RNA) 
and reverse transcribed (RevertAid M-MuLV reverse transcriptase) according to 
manufacturers protocol. Quantitative gene expression analysis was performed on 
an ABI PRISM 7700 (Applied Biosystems, Foster City, CA) using SYBR Green 
technology. PCR primers (Table I) were designed using Primer Express 1.7 
software with the manufacturer's default settings (Applied Biosystems) and 
validated for identical efficiencies (slope = –3.3 for a plot of the threshold cycle 
number (Ct) versus log ng cDNA). Acidic ribosomal phosphoprotein PO (36B4) 
and hypoxanthine phosphoribosyl transferase (HPRT) were used as 





Leukocytes from whole blood and spleen were isolated by density gradient 
centrifugation with Lympholyte (Cedarlane Laboratories, Hornby, Ontario, 
Canada) according to manufacturers protocol. Cell suspensions from spleen and 
blood were incubated with 1% normal mouse serum in PBS and stained for 
surface markers (0.25 µg Ab/200.000 cells) and subsequently subjected to flow 
cytometric analysis (FACS). Antibodies were purchased from eBiosciences. All 
data were acquired on a FACSCalibur and were analyzed with CELLQuest 
software (BD Biosciences). 
 
Serum antibody and cytokine level determination 
IgG1, IgG2A and IgM levels against oxLDL were detected in serum using the 
Mouse MonoAb ID kit (Zymed Laboratories Inc., South San Fransisco, USA). 
OxLDL (5 µg/ml) dissolved in a NaHCO3/Na2CO3 buffer (pH 9.0) was coated o/n 
onto a flat-bottom 96-wells high binding plate (Corning, NY). Serum samples 
were 1:1 diluted in PBS and absorbance was detected at 405 nm. IL-5 
concentration was determined using an IL-5 specific ELSIA (Immunosource). 
Spleen and peritoneal cells from mice which received 2 weeks of Western type 
diet and were treated with control IgG or RM134 were cultured at 2*106 cells/ml 
and stimulated with anti-CD3 and CD28 coated antibodies. Supernatants were 
collected after 24 hours and IFN-γ , IL-5 and IL-4 concentrations were 
determined by ELISA (eBioscience, Belgium). 
 
Statistical analysis  
Values are expressed as mean ± SEM. Two-tailed student’s T-test was used to 
compare normally distributed data between two groups of animals. Mann-
Whitney test was used to not normally distributed data. A probability value of 





Figure 1A. mRNA expression of OX40 in response 
to a Western type diet.  mRNA was isolated from 
spleen using the GTC method and expression of 
the indicated genes is expressed relative to 36B4 
and HPRT, and subsequently related to the 
expression in mice on chow diet. An unpaired 
Student t test was applied to test whether OX40 
mRNA levels were significantly different from the 
mRNA levels in chow fed animals (week 0) (*P < 
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Expression of OX40 during Western type diet feeding 
Atherosclerosis is characterized by both locally presented (within the vessel 
wall) and circulating antigens such as modified LDL. The spleen is therefore 
continuously exposed to atherogenic factors such as oxLDL, and the reaction of 
the spleen in response to a high cholesterol diet used in our model can provide 
insight into the systemic immunological response. We examined the mRNA 
expression of OX40 in the spleen of LDLr-/- mice fed a Western type diet for 0, 3, 
6, 9 and 12 weeks. A significant increase in the relative expression of OX40 was 
determined in the spleen of LDLr-/- mice, showing a strong positive correlation 
with time of diet administration (figure 1A).  
To correlate the elevated mRNA expression of OX40 in spleen to protein 
expression, we determined cell surface expression of OX40 during Western type 
diet feeding. The expression of CD4, CD8 and OX40 in spleen and blood was 
determined in female LDLr-/- mice using FACS analysis at 0, 2 and 4 weeks of 





Figure 1B.  Protein expression of OX40 in response to a Western type diet. Mononuclear cell 
suspensions from spleen and blood were isolated from control mice and mice following 0, 2 or 4 
weeks of Western type diet feeding. Results in panel 1B represent the mean percentage of positive 
cells ± SEM from 6 individual mice (*=P<0.05, student’s T-test). A significant increase is seen in the 
percentage CD4 (upper panels) and CD8 (lower panels) OX40 double positive T cells in blood (white 

















































































The expression is plotted as the percentage OX40+ cells in the CD4+ or CD8+ 
positive population. In the spleen, a 2-fold increase was found in both 
CD4/OX40 double positive and CD8/OX40 double positive T cells after 2 and 4 
weeks of Western type diet as compared to control. The induction of OX40 
expression in the spleen is associated with an increase in the expression of OX40 
in the circulation. Within the CD4+ population, a significant increase in the 
OX40 positive population is observed in blood after 2 and 4 weeks of Western 
type diet feeding as compared to chow fed mice. The percentage OX40 positive 
cells in the CD8+ population shows a 5-fold increase as compared to chow fed 
mice on both 2 and 4 weeks of Western type diet (figure 1B).  
 
 
Figure  2. Anti OX40L antibody treatment reduces collar induced atherosclerotic plaque formation.   
A significant decrease was observed in carotid plaque area after treatment with anti- OX40L 
antibody. Representative pictures of the carotid artery of control IgG (A) and anti- OX40L (B) 
treated mice are shown. A marked and significant decrease was seen for intima/ lumen ratio (D), and 
intima / media ratio (E). Nuclei density of the plaque significantly decreased after treatment (F).Error 
bars represent SEM, n =10 per group (*=P<0.05, Mann Whitney test).  
 
Attenuation of atherogenesis by anti-OX40L antibody administration 
OX40 positive T cells require OX40L on the vascular endothelium to enter 
inflamed tissue from the circulation, and this interaction can be inhibited by the 
anti-OX40L antibody RM134. Furthermore, the anti-OX40L antibody can 
inhibit T cell activation, and subsequently reduce their help to B cells.  
In order to investigate the effect of specific blockade of OX40L on atherogenesis, 
we used the anti-OX40L antibody in LDLr-/- mice. After two weeks of Western 
type diet, female LDLr-/- mice were equipped with pericarotid collars and 
subsequently treated twice a week with 300 µg of anti-OX40L for a period of 6 
weeks. Figure 2 shows representative sections of the carotid artery of control 
IgG treated (2A) and anti-OX40L treated mice (2B) stained with hematoxylin 
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OX40L (1.27 ± 0.16 *104 µm2 vs. 5.98 ± 0.21 *104 µm2, P=0.02), which translated 
into a diminished degree of lumen stenosis (2D) and a marked decrease in 
intima/media ratio (2E). Anti-OX40L antibody treatment reduced the cellularity 
of the plaques by 60% (P=0.01) compared to control treated mice (2F). No 
significant effects of antibody treatment were seen on body weight, serum 
cholesterol and triglyceride levels (data not shown). 
In addition, we quantified the lesion size in the aortic valve leaflet of the same 
mice. Representative photomicrographs of cross sections of the aortic root of 




Figure 3. Anti OX40L antibody treatment reduces atherosclerotic plaque formation in the aortic 
valve leaflet.  Representative photomicrographs of oil red O stained cross sections of the aortic root 
of control IgG treated mice (A) and anti-OX40L treated mice (B) are shown. A significant reduction 
in plaque size was found as compared to control (p=0.01, n=10 per group) (C). Plaque collagen 
content is stained with Pico Sirius Red in control (D) and treated (E) mice. Relative collagen area 
does not differ between groups (F). Relative macrophage staining of control (G) and treated mice (H) 
is visualized using a monoclonal antibody specific for macrophages (MOMA-2). No difference in the 
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Mean lesion area was decreased by 35% upon anti-OX40L antibody treatment 
compared to control mice (P=0.004, figure 3C). No significant difference in 
relative collagen (figures 3D-F) or macrophage content (figures 3G-I) was 
observed. 
 
Expression of OX40 after anti-OX40L treatment 
After sacrificing the animals we determined the mRNA expression of OX40. A 
significant 45% decrease in the spleen after OX40L antibody treatment 
compared to control treated mice (P<0.05) was observed (figure 4A). In addition, 
we also quantified the expression of OX40 on T cells in spleen, mediastinal 
lymph nodes and blood by FACS analysis (Figure 4B). A clear and significant 
reduction can be seen in the percentage CD4 and CD8/OX40 double positive 
cells in blood after anti-OX40L treatment. Strikingly, no decrease in OX40 
double positive cells was observed in spleen and lymph nodes. In addition no 
difference in the expression of IL-12 and IFN-γ in spleen was observed after 
anti-OX40L treatment (data not shown). 
 
 
Figure 4. OX40 expression after anti OX40L 
antibody treatment.  A: mRNA expression of 
OX40 in the spleen of α-OX40L  treated mice 
(6 weeks) is expressed relative to 36B4 and 
HPRT, and subsequently related to the 
expression in control IgG treated mice. White 
bars represent control mice (n=10), black bars 
represent antiOX40L treated mice (n=10). A 
significant decrease could be observed in OX40 
expression after anti-OX40L treatment.   
B: Results in lower panels represent the 
percentage of CD4O+OX40+ or CD8+OX40+ 
positive cells ± SEM from 8-10 individual 
mice. A significant decrease is seen in the 
percentage CD4 (upper panels) and CD8 
(lower panels) OX40 double positive T cells in 
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Antibody response against oxLDL 
OX40-OX40L interaction plays an important role in T cell dependent humoral 
responses. B cells differentiate into IgG producing cells after help from OX40 
positive, activated T cells14. In this way, OX40 positive T cells induce B cell 
isotype switching. We determined the isotype specific antibody response to 
oxLDL in control and anti-OX40L treated mice after 6 weeks of treatment and 8 
weeks of Western type diet. Figure 5 shows a significant decrease in IgG1 
antibodies against oxLDL, while IgG2a levels remained constant in treated mice 
compared to control. This resulted in a very significantly increase in the 
IgG2a/IgG1 ratio (P<0.001). 
Antigen-specific IgG production is preceded by a more general IgM antibody 
response. Anti-OxLDL specific IgM titers increased significantly in anti-OX40L 
treated mice compared to control. Even after 2 weeks of treatment (and 4 weeks 
of Western type diet) significantly higher IgM levels were observed in treated 
mice. In addition to an enhanced IgM levels due to an inhibition of isotype 
switching after OX40L blockade, the increase in IgM may result from the 
production of IgM by B1 cells, which is under control of IL-5 (Binder et al. 23). 
The concentration of IL-5 in serum of control and treated mice was determined 
after 6 weeks of treatment and a significant increase in IL-5 levels was 




Figure 5. OxLDL specific antibody production  
Specific isotypes of antibodies against oxLDL were determined by ELISA in mice after 8 weeks of 
Western type diet. Relative concentrations of control and antiOX40L treated mice are shown. A 
significant reduction in IgG1 serum level was observed. Circulating IgM levels increased during 
treatment, as well as IL-5 serum levels. White bars represent control mice (n=8), black bars represent 

















































































Figure 6. IFN-γ, IL-5 and IL-4 production by spleen and peritoneal cells  Spleen and peritoneal cells 
isolated from mice that received two weeks of western type diet feeding and treatment with control 
or anti-OX40L antibody. A significant reduction in IL-4 production is observed in both spleen and 
peritoneal cells after anti CD3-CD28 stimulation for 24 hours. IL-5 production is significantly 
decreased by peritoneal cells treated with anti-OX40L antibody, but is significantly decreased in 
spleen cell cultures from these mice.  IFN-γ production is not affected by anti-OX40L treatment. 
White bars represent control mice (n=5), black bars represent anti-OX40L treated mice (n=5). Error 
bars represent SEM, *: p< 0.05, **: p<0.01. 
 
Th2 activation is inhibited by anti-OX40L treatment 
Isotype switching of B cells to IgG1 or IgG2a producing cells is dependent on 
interleukin secretion by T cells. IL-4 secretion can induce an IgG1 isotype 
switch, while IFN-γ can induce an IgG2a switch. As shown above, anti-OX40L 
antibody treatment resulted in reduced IgG1 levels against OxLDL. We 
determined the capacity of spleen and peritoneal cells to secrete IFN-γ, IL-4 and 
IL-5 after CD3/CD28 stimulation for 24 hours (Figure 6). Cells were isolated 
from mice which received 2 weeks of Western type diet feeding and anti-OX40L 
treatment. Two weeks should be sufficient to induce isotype switching, as a 
normal IgM responses are switched to specific IgG production within 14 days. 
IL-4 production was significantly decreased after anti-OX40L treatment, while 
IFN-γ production remained unchanged in both spleen and peritoneal leukocytes. 
IL-5 production by peritoneal cells was reduced, which correlated with the 
decreased IL-4 production by these cells. In contrast, spleen cells isolated from 



























































A recent publication of Wang et al. describes the identification of Tnfsf4 
(OX40L) as the underlying gene in the Ath-1 QTL20 21 24, which renders C57Bl/6J 
mice susceptible to atherosclerosis in contrast to C3H/Hej and BALB/cJ mice. 
Mice overexpressing Tnfsf4 showed significantly larger atherosclerotic lesions 
compared to control, and mice with targeted deletion of this gene had 
significantly smaller lesions compared to control. Furthermore, the same study 
showed that humans with a SNP in the OX40L gene have a higher incidence of 
myocardial infarction. 
As Calderhead et al. have shown, OX40 expression is very low on naïve T cells, 
and upregulated after activation25, we monitored OX40 protein expression on T 
cells in spleen and blood of LDLr-/-  mice fed a Western type diet. In spleen a 
significant increase is shown in the number of CD4+OX40+ and CD8+OX40+ cells 
during 2 and 4 weeks of Western type diet feeding. This increase coincides with 
an increase of these populations in the circulation. OX40 mRNA levels 
significantly increased at a later time point than the increase in the percentage 
of OX40 double positive cells. The percentage of positive cells however, does not 
reflect the expression level of OX40 per cell since it only discriminates between 
OX40 positive and negative cells. The difference between mRNA and protein 
expression of OX40 may reflect the dynamic structure of the spleen and cells 
expressing high levels of OX40 may be more prone to migration.  
The correlation between OX40 positive CD4 and CD8 cells and autoimmune 
diseases has also been shown for EAE and GVHD18. We show that Western type 
diet feeding leads to T cell activation based on OX40 expression and OX40 may 
be an ideal candidate for modulating T cell responses in atherogenesis.   
 
The effect of anti-OX40L antibody treatment on atherosclerosis was investigated 
in LDLr-/- mice. Treatment led to a significant reduction (53%) in de novo lesion 
formation. The underlying mechanism of the observed plaque reduction by anti-
OX40L treatment may be complex. Not only systemic or local T cell activation, 
but also B cell function may be involved. Furthermore, very recently Ito et al. 
showed that OX40L strongly inhibited the generation of IL-10 producing type 1 
regulatory T cells.  These T cells are important in the maintenance of peripheral 
tolerance and were shown to be protective in the development of atherosclerosis 
26 27. Future experiments must indicate whether the blockade of OX40L by the 
anti-OX40L antibodies also results in increased numbers of type 1 regulatory T 
cells.   
As atherosclerosis is classically considered to be a Th1 mediated disease we 
quantified the mRNA levels of IFN-γ and IL-12 in spleens of anti-OX40L treated 
mice. No significant difference could be observed between the two groups, 
despite the significant reduction in plaque size and general T cell activation 
determined by expression of CD62L and CD69 was not altered between groups 
(data not shown). We did however observe a significant reduction in OX40 
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mRNA expression in spleen and a decrease in circulating OX40 positive T cells, 
indicating reduced secondary T cell activation.  
OX40 activation has been linked to both Th1 and Th2 activation in several 
disease models28-34. We determined the capability of spleen and peritoneal cells 
to produce Th1 (IFN-γ) and Th2 (IL-4, IL-5) cytokines and found a vast and 
significant decrease in IL-4 secretion after anti-OX40L treatment in these cells, 
while the production of IFN-γ was unaffected. We determined the percentages 
of T cells in these cell suspensions and no significant differences were observed 
between the two groups.  
Since knocking out IL-4 has previously been shown to be protective in 
atherosclerosis35, 36, our data further undermine the hypothesis that Th2 cytokine 
IL-4 provides protection in atherosclerosis and supports the pro-atherogenic 
effects of IL-4.  
IL-4 is an inducer of IgG1 isotype switching in B cells. In accordance with the 
reduced IL-4 production by lymphocytes, OxLDL specific IgG1 levels in mice 
treated with anti-OX40L were significantly decreased. IFN-γ production was not 
different in anti-OX40 treated mice compared to control, and correspondingly, 
IgG2a antibodies against OxLDL were not altered. 
An isotype switch towards IgG production is preceded by the production of IgM. 
The reduced isotype switching to IgG1 as observed in anti-OX40L treated mice 
may explain the observed enhanced anti-OxLDL IgM levels. Anti-OXLDL IgM 
has been shown to provide protection against atherosclerosis by contributing to 
the elimination of oxidized lipoproteins and cellular debris37-39. In addition to 
reduced isotype switching, B-1 cells may form another source for anti-OxLDL 
IgM production. These B-1 cells depend on IL-5 for differentiation and 
maturation40-42. We observed an induction of serum IL-5 in mice treated with 
anti-OX40L antibodies. IL-5 production by peritoneal cells from anti-OX40L 
treated mice was significantly decreased, and this is in correlation with the 
decreased production of IL-4 by these cells after anti-CD3/CD28 activation. In 
spleen, anti-OX40L treatment leads to increased secretion of IL-5. IL-5 is 
produced by Th2 cells but since the anti-OX40L treated mice showed a decrease 
in Th2 response (lower IL-4 and IgG1), we conclude that other cell types such as 
mast cells and NK2 cells may be responsible for the increased IL-5 production, 
and that these cells are (partially) located in the spleen. Since the anti-OX40L 
treatment resulted not only in a significant increase in IL-5, but also in a trend 
towards an increased number of CD5 IgM expressing B-1 cells in the peritoneal 
cavity (Figure 7), we conclude that the increased level of atheroprotective anti-
OxLDL IgM upon OX40L blockade may also result from B-1 cells in addition to 
a reduction in isotype switching. Based on the data it is unlikely that the 
increased OxLDL specific IgM is derived from the peritoneum, however, 
migration of activated B-1 cells from peritoneum to germinal centers in the 
spleen has been reported43. 
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Based on this study we conclude blockade of the OX40/OX40L pathway by an 
anti-OX40L antibody results in protection against atherosclerosis due to elevated 
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CD127 is Required for Macrophage and   
Regulatory T Cell Function and Has a Protective 
Role in Atherosclerosis  
 
EJA van Wanrooij, GMH van Puijvelde, 






CD127 is the receptor for interleukin 7 (IL-7) and is expressed on immature B 
cells, activated T cells and macrophages. IL-7 induces T cell activation via 
CD127, and is implicated in the survival of regulatory T cells. Furthermore, 
premature B cells need IL-7 to proliferate into mature B cells. In LDLr-/- mice 
CD127 mRNA was upregulated 5-fold (p< 0.001) in the aortic arch after 9 weeks 
of Western type diet, indicating a correlation between expression of CD127 and 
atherosclerotic lesion formation. Macrophages showed elevated the expression 
of CD127 when exposed to oxidized LDL in vitro. In order to elucidate the 
function of CD127 in the process of atherosclerosis we constructed an anti-
CD127 DNA vaccine by cloning murine CD127 into pcDNA3.1. Vaccination was 
performed by repeated oral administration of attenuated Salmonella typhi-
murium transformed with pcDNA3.1-CD127. Vaccination of LDLr-/- mice 
against CD127 aggravated collar induced lesion formation by 3-fold without an 
effect on serum cholesterol levels. Lesions from vaccinated mice showed reduced 
cellularity and increased apoptotic area compared to control vaccinated animals. 
Macrophage numbers in the spleen from vaccinated mice were reduced by 37%, 
CD4 and CD8 T cell percentages in spleen, lymph nodes and blood were not 
altered. Strikingly, the regulatory T cell population (CD4+CD25+) in draining 
lymph nodes from the aortic arch was significantly decreased by 30% (p=0.02). 
We conclude from these results that CD127 is an essential factor in the function 
and/or survival of regulatory T cells and macrophages, which may contribute to 





IL-7 plays an essential role in the development of the immune system and 
deficiencies in the IL-7 pathway lead to severe lymphopenia1, 2. It is secreted by 
fetal liver cells, stromal cells in bone marrow and thymus, and other epithelial 
cells3-5. Alongside its prominent role in thymic development, IL-7 is recently 
been identified as essential for the induction of CD4+ and CD8+ T cells with a 
memory phenotype during adult life 6, 7. Next to these predominant effects on T 
cells, evidence exists that IL-7 may induce activation and expansion of 
monocytes and natural killer cells8, 9. IL-7 signals through the IL-7 receptor that 
includes two polypeptides, a common gamma chain (CD132) and an alpha chain 
(CD127). The alpha chain is specific for the IL-7 receptor (and together with 
TSLPR for TSLP10, 11), while the gamma chain is part of several other interleukin 
receptors (IL-2,4,9,15 and 21). CD127 is expressed by B cell precursors, most T 
cells and monocytes12.  
Expression of CD127 is down-regulated when the cell is exposed to stimulatory 
factors such as OX40L, CD40L or activating cytokines such as IL-2 or IL-413. In 
contrast, it was shown that memory T cells are derived from a population of 
activated T cells that do not reduce the expression of this receptor14.  IL-7 is 
identified as a survival factor for CD4+CD25+ regulatory T cells, but recent 
publications put forward CD127 as a negative marker for regulatory T cells. It 
was shown that the expression of the transcription factor FOXP-3 is inversely 
correlated with the expression of CD127 on CD4+ T cells 15-17. IL-7 mediated 
activation and expansion of T cells is associated with several (auto-) immune 
diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD) 
and graft versus host disease (GVHD)18-20.  Next to these clear pro-inflammatory 
effects of IL-7 in auto-immune disease, Ponchel et al. describe that serum levels 
of IL-7 are decreased in patients with RA, suggesting a negative association of 
this molecule with disease21.  Atherosclerotic plaques are characterized by the 
infiltration of both monocytes and T cells. IL-7 may have a potential role in the 
initiation or progression of lesion formation by modulating the activation state 
of local or systemic T cells and the involvement in regulatory T cell homeostasis.  
No direct evidence exists on the function of IL-7/CD127 signaling in 
atherosclerosis. Raised serum levels of IL-7 were reported for patients with 
angina pectoris and correlated with the severity of disease22,23. Randi et al. 
however found that unstable coronary artery plaques show decreased levels of 
IL-7.  
 
In this study we show that macrophages exposed to different concentrations of 
OxLDL induce their expression of CD127, which correlates with the finding that 
expression of CD127 in the aorta is upregulated during lesion formation. We 
designed a vaccination strategy that induced CD8+ T cells that specifically 
removed cells that express high levels of CD127. Vaccination of atherosclerosis 
prone LDL receptor deficient (LDLr-/-) mice against CD127, resulted in a vast and 
Vaccination Against CD127 Severely Aggravates Atherosclerosis 
 153 
significant induction of lesion formation as compared to control vaccinated 
mice. This is accompanied by a reduction in the local number of regulatory T 
cells. These findings may indicate a protective effect of IL-7/CD127 signaling in 
atherosclerosis. 
 
Material and methods 
 
Cell culture 
Bone marrow derived macrophages were grown from bone marrow from 
C57/Bl6 mice using complete DMEM medium supplemented with 1% non 
essential amino acids, 1% pyruvate, 20% fetal bovine serum, 100 IU/ml 
penicillin, 100 µg/ml streptomycin, 4 mM L-glutamin (all from BioWhitthaker) 
and 25% L-929 medium (containing MCSF) for one week in a humidified 
atmosphere with 5% CO2 in non tissue culture plates. Subsequently, cells were 
incubated with oxLDL and/or LPS at various concentrations for 16 hours and 
CD127 expression was determined by FACS. 
 
Vaccination strategy 
Murine CD127 was cloned into pcDNA3.1 plasmid (Invitrogen, CA) and 
electroporated into attenuated Salmonella typhimurium (Aro/A (strain SL7207). 
Vaccination was performed by 3 times oral administration of 1x108 cfu of S. 
typhimurium transformed with pcDNA3.1-CD127 or pcDNA3.1 empty (control) 
in 100 µl of PBS at 2 week intervals24. All animal experiments were in 
accordance with guidelines issued by the Dutch law and approved by the ethics 
committee for animal Experiments of Leiden University (DEC). 
 
Atherosclerosis experiments 
Female LDLr-/- mice were vaccinated with control or pcDNA3.1-CD127 as 
described (n=12 per group). After the last vaccination, mice were fed an 
atherogenic diet containing 0.25% cholesterol and 15% cocoa butter (Special 
Diet Service, UK). After 2 weeks of diet, atherosclerosis was induced by placing 
silastic collars around both common carotid arteries as previously described25. 
After 8 weeks of Western type diet all mice were sacrificed and lesion size was 
analyzed using a Leica-DM-RE microscope and Leica Qwin software. To assess 
intimal apoptosis, corresponding sections were subjected to TUNEL staining 
using the IN Situ Cell Death detection kit (Roche Diagnostics). Concentrations 
of serum cholesterol and triglycerides were determined using enzymatic 
colorimetric procedures (Roche/Hitachi, Mannheim, Germany). Precipath 
(Roche/Hitachi) was used as a standard. 
 
FACS analysis 
Lympholyte (Cedarlane Laboratories, Hornby, Ontario, Canada) was used to 
separate lymphocytes from whole blood and spleen by density gradient 
centrifugation according to manufacturer’s protocol. Cell suspensions from 
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spleen and blood were incubated with 1% normal mouse serum in PBS and 
stained for surface markers (0.25 µg Ab/200.000 cells) and subsequently 
subjected to flow cytometric analysis (FACS). Antibodies were purchased from 
eBiosciences. All data were acquired on a FACSCalibur and 10000 lymphocyte 
events were analyzed with CELLQuest software (BD Biosciences). 
 
Gene expression 
Total RNA was isolated from the aortic arch of the mice using the guanidium 
isothiocyanate (GTC) method. Purified RNA was DNase treated (DNase I, 10 
units/µg of total RNA) and reverse transcribed (RevertAid M-MuLV reverse 
transcriptase) according to manufacturers protocol. Quantitative gene expression 
analysis was performed on an ABI PRISM 7700 machine (Applied Biosystems, 
Foster City, CA) using SYBR Green technology. PCR primers (appendix I) were 
designed using Primer Express software with the manufacturer's default settings 
(Applied Biosystems). Acidic ribosomal phosphoprotein PO (36B4) and 
hypoxanthine phosphoribosyl transferase (HPRT) were used as housekeeping 
genes.  
 
Statistical analysis  
Values are expressed as mean ± SEM. Two-tailed student’s T-test was used to 
compare normally distributed data. Mann-Whitney test was used to compare 
lesion area data and other not normally distributed data. A probability value of 






Figure 1: CD127 mRNA expression is 
upregulated in the aortic arch during 
atherosclerotic lesion formation. 
mRNA was isolated from the aortic 
arch of LDLr -/- mice using the GTC 
method and expression of genes is 
expressed relative to 36B4 and 
HPRT, and subsequently related to 
the expression in mice on chow diet. 
An unpaired Student t test was 
applied to test whether mRNA levels 
were significantly different from the 
mRNA levels in chow fed animals 
(week 0) (*P < 0.05, n= 6 per time 
point). 












































Expression of CD127 is upregulated in the aortic arch of LDLr-/- mice after 
western type diet feeding 
CD127 is expressed on several types of (activated) T cells, bone marrow derived 
macrophages and immature B cells. As the influx of leukocytes into the vessel 
wall is considered to be essential in the formation of atherosclerotic lesions, 
CD127 may also be expressed in the atherosclerotic plaque. In order to 
investigate CD127 expression during atherosclerosis, we isolated the aortic arch 
of female LDLr-/- mice at several time points of western type diet feeding. Figure 
1 shows a vast and significant 2.2 (p<0.03) and 5.1-fold (p<0.0002) increase in 
CD127 mRNA expression after 4.5 and 9 weeks of western type diet feeding, 
respectively. The increase in CD127 expression coincides with the increased 
expression of the macrophage marker CD68 in the vessel wall (lower panel). 
This suggests a possible role for CD127 expression on macrophages that are 
present in the atherosclerotic plaque. 
 
Figure 2: Bone marrow derived macrophages upregulate the expression of CD127 when exposed to 
oxidized LDL. Bone marrow derived macrophages were cultured using L929 conditioned medium 
and subsequently exposed to different concentrations of OxLDL and/or LPS. After 16 hours of 
incubation, the expression of CD127 on the cells was monitored using FACS. Upper panels give 
representative examples of control cells and cells exposed to 20 µg/ml OxLDL stained with Oil red O 
and in the right panel representative histograms are shown for CD127 expression of these cells. 


































































Macrophage expression of CD127 is upregulated after exposure to oxLDL 
To investigate the expression and regulation of CD127 on macrophages during 
atherosclerotic plaque formation we cultured bone marrow derived 
macrophages from C57/Bl6 mice by using M-CSF. We exposed these bone-
marrow derived macrophages to increasing concentrations of oxLDL and/or LPS 
to induce foam cell formation or cellular activation. Figure 2 shows 
representative pictures of control and oxLDL treated (20µg/ml) cells (upper 
panels). After 16 hours we assessed the expression of CD127 by FACS as shown 
in upper right panel. OxLDL exposure very significantly induced the expression 
of CD127 during foam cell formation already at low concentrations (5µg/ml), 
and the effect is more pronounced at an oxLDL concentration of 20 µg/ml. TLR4 
stimulation of the macrophages with LPS did only result in modest upregulation 
of CD127 and LPS had no additional effect on the expression of CD127 when 
administered simultaneously with 5µg/ml oxLDL.  
 
Lesion formation is severely aggravated after vaccination against CD127 in LDL 
receptor deficient mice 
To investigate the role of IL-7/CD127 signaling during atherogenesis we 
constructed a DNA vaccine against CD127 using S. typhimurium as a carrier. 
Vaccination will result in the generation of CD8+ cytotoxic cells (as shown 
previously by our group26), and these cells selectively remove cells that express 
high levels of CD127 and present epitopes thereof via MHC-I. 
We vaccinated female LDLr-/- mice by oral administration of S. typhimurium 
transformed with pcDNA3.1-CD127 or pcDNA3.1 empty (control) in 100 µl of 
PBS at two-week time intervals (n=12-13/group). Following the last vaccination, 
mice were placed on a Western type diet and two weeks later collars were 
placed around the common carotid arteries to generate flow-induced 
atherosclerosis. Six weeks later the mice were sacrificed and atherosclerotic 
plaque formation was analyzed. Representative pictures of control (A) and 
CD127 vaccinated mice (B) are shown in figure 3. Vaccination against CD127 
resulted in a significant 2.7-fold induction of atherosclerotic lesion formation 
(2.13 ± 0.73 *104 µm2 (control) vs. 5.67 ± 1.06 *104 µm2 p=0.004). This translated 
into a significant increase in both intima/media (D) as well as intima/lumen (E) 
ratio, showing a significant narrowing of the lumen.   
Vaccination against CD127 affected the composition of the plaque and reduced 
the cellularity of plaques compared to control vaccinated mice (Figure 3F). 
Nuclei density per mm2 was decreased by 32% (4.10 ± 0.67 (control) vs. 2.76 ± 
0.22 nuclei/mm2, p=0.03). This decrease in cellular density was accompanied by 
a significant increase in apoptosis identified by relative TUNEL positive area (5.2 
± 1.8*10-3 (control) vs. 11.2 ± 2.3*10-3, p=0.04, Figure 4). Representative pictures 
of control (A) and CD127 vaccinated (B) mice are shown in figure 4. No 
significant effects on cholesterol and triglyceride levels were observed. 
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Figure 3: Vaccination against CD127 significantly induced atherosclerotic plaque formation in LDL 
receptor deficient mice. Upper panels demonstrate representative pictures of the carotid artery of 
control (A) and CD127 vaccinated animals (B). A significant increase (p=0.004) was observed in 
carotid plaque area after vaccination against CD127. This decrease in lesion formation is 
accompanied by a significant increase in lumen stenosis (D) and intima/lumen ratio (E). Plaque 
cellularity is decreased in mice vaccinated against CD127 (F). Error bars represent SEM, n = 12/13 
per group.(*=p<0.05, Mann Whitney test). 
 
Figure 4: Apoptosis is increased in atherosclerotic plaques of mice vaccinated against CD127. 
Corresponding sections of carotid artery atherosclerotic plaques were stained for apoptosis using a 
TUNEL stain. Apoptosis is indicated by brown staining. Representative slides are shown for control 
(A) and CD127 vaccinated (B) animals. We then quantified the TUNEL positive area relative to total 
plaque area. Vaccination against CD127 led to a significant increase in TUNEL positive area 
compared to control vaccinated mice (n=12/13, p=0.04). 
 
Vaccination against CD127 leads to a relative reduction in macrophages and an 
increase in B cells in the spleen  
Vaccination against CD127 will result in the removal of activated cells that 
express high levels of CD127 and present epitopes thereof via their MHC-I 
molecules. As T cells, B cells and macrophages express CD127, we analyzed the 
effect of CD127 vaccination on the cellular phenotypes in the spleen by FACS 











































































positive. A significant reduction was seen in the relative number of macrophages 
after vaccination against CD127 (22.16 ± 1.20% (control) vs. 16.15 ± 1.03%, 
p=0.003). A relative increase was shown for B cells, identified by their 
expression of CD19 (32.90 ± 1.78% vs. 40.04 ± 0.41%, p=0.004). In order to 
determine whether the capacity of the mature B cells to produce antibodies 
against antigens was changed, we determined isotope specific antibodies against 
oxLDL in control and CD127 vaccinated mice. No significant effects were seen 
on the circulating IgG1, IgG2a or IgM antibodies against oxLDL after 
vaccination (Figure 6). This indicated that CD127 vaccination had no apparent 
effects on B cell function. No effect was observed on the relative numbers of 
CD4 and CD8 positive T cells in the spleen after vaccination against CD127 
(Figure 5, lower panels).  
 
Figure 5: The effect of CD127 
vaccination on different cell 
types of the spleen. Single cell 
suspensions of spleens of control 
and CD127 vaccinated mice were 
prepared and FACS was used to 
determine the percentage of CD4 
and CD8 positive T cells, 
macrophages (F4/80) and B cells 
(CD19). Vaccination against 
CD127 led to a significant 
decrease in macrophages and to a 
significant increase in the 
percentage of B cells. (White bars 
represent control, black bars 
represent CD127 vaccinated 
mice, error bars display SEM, n=6 
per group, *:p<0.05) 
 
 
Figure 6: Antibody production against OXLDL is not changed after vaccination against CD127. 
Specific isotypes of antibodies against oxLDL were determined by ELISA in mice after 8 weeks of 
Western type diet. Relative concentrations of control and CD127 vaccinated mice are shown. No 
significant effects could be observed. (White bars represent control mice (n=12), black bars represent 
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Vaccination against CD127 reduced the number of CD4+CD25+ regulatory T cells 
Recent publications suggest a role for CD127 regulation in the survival and 
activation of CD4+CD25+ regulatory T cells15. We isolated lymph nodes draining 
from the aortic arch of control and CD127 vaccinated mice after 8 weeks of 
Western type diet. A significant reduction was observed in the percentage of 
CD4+CD25+ regulatory T cells in the draining lymph nodes from the aortic arch 
after vaccination against CD127 (6.00 ± 0.53 vs. 4.17 ± 0.46 %, p=0.02, Figure 7). 
The relative number of CD4 and CD8 single positive T cells was not altered in 
the lymph nodes.  
 
 
Figure 7: Vaccination against CD127 decreases the number of regulatory T cells in lymph nodes 
draining from the aortic arch without altering general T cell numbers. Draining lymph nodes were 
isolated from control and CD127 vaccinated mice after 8 weeks of western type diet feeding. Single 
cell suspensions were prepared and FACS was used to asses the relative amount of CD4+CD25+ 
regulatory cells present. Vaccination resulted in a significant decrease in the number of regulatory T 
cells defined as CD4+CD25+ double positive. No effects were seen on the general T cell percentages. 
(White bars represent control, black bars represent CD127 vaccinated mice, error bars display SEM, 





The regulation and activation of the immune system during atherogenesis has 
received considerable attention over the last few years27-29. The function of T 
cells and their interaction with other leukocytes has received special interest. 
IL-7 has primarily been described as a factor in the development of the immune 
system, but recent evidence suggests that is also has a prominent role after the 
embryonic phase, in the regulation and activation of regulatory and memory T 
cells. Next to these described effects on T cells, a limited number of publications  
indicate a role for the IL-7/IL-7 receptor pathway in myelopoiesis and 
erythopoiesis9.  
The receptor for IL-7 is composed of two subunits, the γ subunit, constitutively 
expressed at low levels on lymphocytes, and CD127 (the alpha subunit) that is 
restricted to specific stages of differentiation to mediate cellular responses12, 30. 
To investigate the role of IL-7/CD127 signaling in atherosclerosis, we analyzed 







































Expression of CD127 increased over time, which largely paralleled the increase 
in macrophage influx in the aorta as determined by expression of CD68. This led 
us to determine the regulation of CD127 expression on macrophages in an 
athero-prone environment with high concentrations of oxidized LDL. 
Interestingly, a significant upregulation of the IL-7 receptor was observed in a 
concentration dependent mechanism after 24 hours of oxLDL treatment of 
isolated bone-marrow derived macrophages. This is not the effect of general 
macrophage activation, as the exposure to LPS did only result in modest 
upregulation of the IL-7 receptor. Furthermore, no additional effects of LPS 
were observed when it was added in combination with oxLDL. This indicated 
the CD127 expression on the surface of macrophages is induced in a pro-
atherogenic environment where high concentrations of oxidized lipid are 
present. This is a very interesting finding that indicated a functional role for IL-
7/CD127 signaling in macrophages during atherogenesis, next to the suggested 
function in T cell homeostasis. 
 
We then used a vaccination strategy to study the functional role of CD127 in a 
diet induced model for atherosclerosis. In this vaccination strategy, S. 
typhimurium is transformed with a vector encoding murine CD127. The S. 
typhimurium carrier is taken up by M cells and processed in the Peyer’s patches 
in the gastrointestinal tract were antigen presenting cells become activated by 
the live attenuated bacteria. The bacteria are processed by the antigen 
presenting cell and in this way the vector is transcribed and presented. These 
MHC class I presented peptides activate specific cytotoxic T cells that will 
clonally expand and break peripheral tolerance against CD127. This vaccination 
protocol results in the induction of CD8+ cytotoxic T cells that specifically target 
cells that express high levels of CD127 and has been successfully validated for 
other proteins in animal models for tumor growth and atherosclerosis24, 26,31. 
Vaccination against CD127 will lead to the removal of cells that express high 
levels of CD127 and the observed upregulation of CD127 on macrophages is 
therefore likely to lead to removal of these cells via CD8 mediated cytotoxicity. 
We clearly show that vaccination against CD127 indeed leads to a significant 
reduction in macrophage numbers in the spleen of mice on a western type diet 
compared to control vaccinated mice. Next to this systemic effect, the cellularity 
of atherosclerotic plaques from CD127 vaccinated mice was reduced after 
vaccination indicating a reduction in the number of viable macrophages within 
the plaque. 
We therefore conclude that CD127 is induced by macrophages in a pro-
atherogenic situation. This upregulation can have several functions. IL-7 
signaling is in T cells  a potent inducer of anti-apoptotic survival factors such as 
bcl-2 and its family members32. It may be speculated that macrophages need 
survival signals to cope with the pro-apoptotic and toxic environment of the 
atherosclerotic plaque with high levels of oxidized lipoproteins and reactive 
oxygen species. The resulting upregulation of CD127 will result in the removal 
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of these cells via CD8+ cells in mice vaccinated against CD127. To further 
investigate this hypothesis we stained plaques from control and CD127 
vaccinated mice for apoptosis using an anti-TUNEL antibody. As expected, 
plaques from CD127 vaccinated mice showed increased apoptosis, even when 
corrected for the increased plaque area.  
 
Induction of macrophage apoptosis in the atherosclerotic plaque due to the 
vaccination possibly has a direct impact on plaque growth. In literature, it is 
however shown by several authors that specific induction of macrophage 
apoptosis during lesion formation does not induce, but reduces or does not affect 
lesion formation. Among others this was shown by selective induction of 
macrophage apoptosis by using Diphtheria toxin receptor (DTr) transgenic bone 
marrow transplantation which resulted in decreased lesion formation33. Bone 
marrow transplantation using Bax deficient donors resulted in increased lesion 
formation34. This is in concordance with the DTr experiment, as Bax is a pro-
apoptotic factor and deletion of this factor will reduce macrophage apoptosis. No 
effect was observed on plaque growth in apoE mice overexpresing the pro-
apoptotic factor p5335. These studies indicate that in our experiments, an 
additional effect is most likely responsible for the vast induction on lesion 
formation. 
 
Next to this surprising effect on the macrophage population we evaluated the 
number and phenotype of the lymphocyte population after vaccination in our 
model for atherosclerosis. Extensive studies have shown the importance of IL-7 
for the maintenance of the lymphocyte population in both humans and mice. 
Most of this research however, concentrates on the role of this molecule in early 
life. We show that the relative number of both CD4 and CD8 positive cells in 
spleen and lymph nodes is not altered after vaccination against CD127. This is in 
line with studies that show IL-7 acts predominantly as a thymopoietic molecule 
in the development of the immune system36.  
Farrar et al. however have proposed that the activation STAT-5 via IL-7/CD127 
signaling is important in the development of CD4+CD25+ T cells37. Next to this, 
IL-7 is essential for the survival of these regulatory T cells15. Our data clearly 
show that vaccination against CD127 led to a significant reduction in 
CD4+CD25+ regulatory T cells in the draining lymph nodes of the aorta. Several 
recent publications have shown the protective effect of these CD4+CD25+ 
regulatory T cells in atherosclerosis38,39. The decrease we observe in this 
important T cell population could possibly explain the vast increase in plaque 
formation in the carotid artery of mice vaccinated against CD127. 
 
CD127 is shared by the TSLP receptor, so besides modulating IL-7 signaling, it is 
possible that the signaling of TSLP is influenced as well. TSLP is an IL-7 like 
cytokine that supports the activation of immature dendritic cells (DC’s) and it 
might be an early trigger for DC-mediated allergic inflammation40. TSLP is also 
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produced in the thymus where it instructs thymic DC’s to induce auto-reactive 
T cells to become CD4+CD25+FOXP3+ regulatory T cells41. Furthermore, TSLP is 
associated with Th2 induction via OX40L42. These findings indicate that TSLP is 
associated with an athero-protective function via the induction of regulatory T 
cell function and the production of Th2 cytokines with anti-atherogenic 
properties42. Vaccination against CD127 would lead to decreased TSLP function, 
and, based on its athero-protective properties described above, to an increased 
atherogenesis. We show that vaccination against CD127 indeed leads to 
accelerated lesion formation, including TSLP as a possible target cytokine of our 
vaccination.  
 
In general we conclude that macrophages upregulate CD127 in response to 
oxLDL and that the expression of CD127 is increased in atherosclerotic plaques 
compared to healthy vascular tissue. Vaccination against CD127 leads to severely 
increased atherosclerotic plaque formation, by reducing the number of 
regulatory T cells in draining lymph nodes and by increasing macrophage 
apoptosis. Based on the results presented here, CD127 signaling is providing an 
anti-atherogenic stimulus to both macrophages and regulatory T cells and 
further research is necessary to fully understand the regulation of this multi-
functional and pleiotropic signaling route in vascular biology. 
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Summary and Perspectives 
 













Despite impressive progress in the treatment of cardiovascular disease by 
widespread statin administration and reduction of other risk factors, 
atherosclerosis derived clinical events are still the major cause of death in the 
Western hemisphere. As established in the last decade, atherosclerosis is a lipid 
associated inflammatory disease of the larger and medium sized arteries1-5. 
Although the beneficial effects of statins are partially due to their pleiotropic 
anti-inflammatory effects, no therapy is available that specifically reduces the 
inflammation associated with atherogenesis. In this thesis, several approaches 
are presented that offer therapeutic immuno-modulatory possibilities for 
atherosclerosis.  At present, therapy is provided to patients that already show 
clinical cardiovascular symptoms or have elevated cholesterol levels. This 
implies that lesion formation in these patients can only be targeted at an already 
advanced stage. Since atherosclerosis is a disease that starts at a very young age, 
identification of new targets during the initiation of the atherosclerotic process 
will be highly relevant. There is however, little knowledge on the mechanisms 





Differential gene regulation during initial atherogenesis 
 
To get insight in the initial vascular changes preceding lesion formation, the 
transcriptional regulation within the vessel wall was monitored in an animal 
model for atherosclerosis, the LDL receptor deficient mouse. In this model, 
atherosclerosis develops upon Western type diet administration as a 
consequence of an increase in serum VLDL/LDL resembling a more “human” 
like pro-atherogenic lipoprotein profile6. As gene regulation is mostly exerted 
group-wise by means of transcription factors, we searched for transcription 
factors that potentially are involved in the regulation of genes associated with 
very early changes in atherogenesis. It appears that FOXO1 mediated 
transcription is enhanced already after 1.5 weeks during Western type diet 
feeding, and that this is maintained throughout the administration of the diet. 
This was further substantiated by the significant upregulation of the FOXO1 
downstream gene HMG-CoA reductase. Interestingly, HMGCoA reductase is the 
target enzyme of statins that specifically inhibit this enzyme and the subsequent 
synthesis of cholesterol.  
 
Infiltration of leukocytes into the vessel wall is one of the hallmarks of 
atherosclerosis. Attraction of leukocytes is mediated not only by the 
upregulation of adhesion molecules and chemokines by the vessel wall, but by 
the activation of leukocytes as well. Therefore, the reaction of the spleen in 
response to the diet was monitored during atherosclerotic lesion formation.  
High fat diet administration resulted in profound upregulation of established 
pro-inflammatory cytokines such as IFNγ, IL-1β, CD40 and CCL5. Interestingly, 
this response showed a sharp peak at 6 weeks of diet administration.  A number 
of T cell activation markers from the TNF receptor superfamily were vastly 
upregulated at this time point as well. As upregulation of these molecules 
reflected a specific activation of T cells, the response of CD4+ cells was 
investigated on mRNA level by using micro-arrays. This cell type is identified as 
the predominant T cell type in atherosclerosis7, 8. The transcription of the CD4+ 
cells revealed a different time dependent regulation pattern. At 6 weeks of diet 
feeding no upregulation of immune response related activation markers was 
observed, but after 12 weeks the expression of TNFRSF members, adhesion 
molecules and Th1/Th2 differentiation was increased. The only upregulated 
gene set associated with immune responses that was present at both 6 and 12 
weeks was the CCR5 pathway. This indicates that the observed pattern in the 
spleen is possible a primary (innate) response to the high fat diet feeding. Only 
after a longer period of time (possibly 9 weeks), the activation of the adaptive T 
helper cells is initiated. 
 
After the identification of several genes and pathways that are clearly 
differentially regulated during atherogenesis, some of these targets were verified 
in a model for atherosclerotic plaque formation.  
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Inhibition of leukocyte migration in atherogenesis 
 
Our microarray studies indicated that the CCR5 pathway was associated with 
plaque formation as upregulation of CCR5 in the vessel wall coincided with an 
enrichment of the CCR5 pathway on T cells during initial lesion formation. This 
chemokine receptor has a prominent role in the attraction of leukocytes, 
predominantly Th1 cells, to sites of inflammation9. As atherosclerotic plaque 
formation is enhanced by the activation and subsequent release of Th1 
cytokines, it could be speculated that inhibition of CCR5 signaling would lead to 
attenuated plaque formation. To specifically target the migration of these Th1 
cells we used the HIV entry inhibitor TAK-779. This molecule is a potent 
antagonist for both CCR5 and CXCR3, a chemokine receptor that is also 
predominantly expressed on Th1 cells10. Treatment with TAK-779 resulted in a 
vast decrease in lesion formation. This decrease was due to reduced migration of 
Th1 cells which led to a 98% reduction in the expression of the pro-atherogenic 
Th1 cytokine IFNγ. TAK-779 is an HIV entry inhibitor and can be used in HIV-
positive patients to repress HIV replication. Current treatment of these patients 
with protease inhibitors has been associated with increased evidence of 
cardiovascular events and increased levels of atherogenic lipoproteins such as 
LDL and VLDL11. Our study shows that TAK-779, besides blocking HIV entry, 
also reduces atherosclerotic lesion formation and in this way has potential 
benefits for the growing population of young HIV positive patients.  
 
After we established the protective effects of a CCR5/CXCR3 antagonist, we 
focused our attention on CXCR3 itself. CXCR3 is a chemokine receptor that is 
mostly expressed on Th1 effector cells12. CXCR3 positive T cells have been 
shown to aggravate several immune diseases and we anticipated that the specific 
inhibition of CXCR3 by the CXCR3 antagonist NBI-74330 would lead to a 
reduction of plaque formation. We indeed observed a significant reduction in 
lesion formation upon treatment with NBI-74330. CXCR3 is expressed on 
effector T cells that drive the inflammation. We assessed the balance between 
activated effector cells and regulatory cells and found that treatment with a 
CXCR3 antagonist beneficially increased the number of regulatory T cells.  
 
The trans-endothelial migration of leukocytes to the atherosclerotic plaque is 
facilitated via adhesion molecules expressed in the endothelial junction and this 
process is named diapedesis. Blockade of this transmigration route provides an 
attractive way to inhibit atherosclerotic plaque formation. Previously it was 
shown that mice deficient in PECAM-1 or JAM-1, two proteins that facilitate 
diapedesis, develop less atherosclerosis than control mice13, 14. When an 
additional member of the junctional adhesion molecules was identified, CD99, a 
pro-atherogenic role for this molecule could be suggested. In order to elucidate 
the function of CD99 during atherosclerotic lesion formation, a DNA vaccine 
that encoded the extracellular part of CD99 was constructed and attenuated 
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Salmonella transformed with the CD99 plasmid was used to induce cellular 
immunity against cells that express CD99. This vaccination strategy induces a 
CD8+ mediated cytotoxic response against cells that express CD99. Vaccination 
against CD99 resulted in a vast decrease in lesion formation and this decrease 
was accompanied by decreased expression of CD99 on leukocytes. By using a fast 
and flexible vaccination strategy, we identified CD99 as a pro-atherogenic 
molecule. However, more research is needed to delineate the exact mechanism 
by which CD99 induces lesion formation. 
 
Not only chemokines and adhesion molecules contribute to the migration of 
leukocytes to the plaque, but some interleukins also display chemotactic 
properties. IL-16 is one of these signaling molecules, and based on this property 
it was originally named Leukocyte Chemotactic Factor (LCF)15-17. It attracts 
CD4+ cells and was implicated as pro-inflammatory in several auto-immune 
diseases. Based on the pro-inflammatory properties described in literature, we 
anticipated that IL-16 would attract leukocytes to the atherosclerotic plaque, 
and that by blocking IL-16 signaling would inhibit atherosclerotic lesion 
formation. Surprisingly, in chapter 7 it is described that IL-16 has anti-
atherogenic properties. Vaccination against this interleukin results in 
accelerated lesion formation, especially after prolonged periods of diet feeding. 
IL-16 is sythesized as a precursor that needs to be cleaved by caspase 3 in order 
to be secreted. Caspase 3 is a rate limiting enzyme in the apoptosis cascade, and 
it was shown that apoptotic cells spontaneously released IL-16. Apoptosis is a 
phenomena predominantly associated with more advanced stages of 
atherosclerosis, indicating why IL-16 vaccination would be more detrimental in 
late stage atherogenesis. Possibly IL-16 mediates a migration signal for CD4+ T 
cells with regulatory phenotype, as IL-16 induces CD25 expression on T cells. 
When IL-16 signaling is blocked, lesion formation is accelerated by the reduced 
attraction of regulatory T cells. 
 
 
Inhibition of leukocyte activation in atherogenesis 
 
Next to the migration of leukocytes, the activation of immune cells provides 
another interesting signaling cascade associated with atherosclerotic lesion 
formation. It was shown that the activation of Th1 cells and NKT cells leads to 
aggravation of atherogenesis18-20. As shown in chapter 3, T cell co-activation 
markers from the TNF receptor superfamily are upregulated after Western type 
diet feeding and subsequent atherosclerotic lesion formation. For OX40, a 
member of this superfamily, a relation was found between the expression of this 
molecule on T cells, and the severity of several auto-immune diseases such as RA 
and EAE21, 22. We therefore monitored the expression of OX40 on T cells during 
lesion formation and found a significant upregulation of this molecule during 
atherogenesis providing a rationale for therapeutic blocking of this pathway 
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during atherogenesis. The antibody mediated blockade of the ligand of OX40 
(OX40L) that is expressed by APC’s is described in chapter 8. Blockade of 
OX40/OX40 ligand signaling results in reduced lesion formation, however not 
by modulating the expression of Th1 cytokines such as IFNγ or the migration of 
effector cells to the atherosclerotic plaque. This was rather puzzling, as the 
reduction in lesion formation was quite prominent. OX40 was however not only 
described as a potent inducer of Th1 responses, but could induce Th2 activation 
as well. We therefore determined the concentration of oxLDL specific antibody 
isotypes IgG1, IgG2a and IgM. The production of antigen specific IgG is 
mediated by the activation of B cells by specific subsets of T helper cells. Th1 
cells induce isotype switching to IgG2a, and Th2 cells induce production of IgG1 
antibodies.  It appears that Th2 mediated isotype switching was reduced due to 
decreased production of IL-4, and this led to decreased levels of IgG1 oxLDL 
specific antibodies. Because isotype switching was inhibited, B cells continued to 
produce the more aspecific IgM antibodies.  Binder et al however showed that 
IgM antibodies are produced in response to IL-5, which is a Th2 associated 
interleukin. We showed that IL-5 levels indeed were increased upon OX40L 
antibody administration. The discrepancy between decreased IL-4 levels and 
increased IL-5 levels was rather unexpected, as these interleukins are mainly 
regulated in a similar way. More research is necessary to determine the exact 
role of these Th2 cytokines in atherogenesis. 
 
As described in the introduction, T cell homeostasis is essential in the immune 
response during atherogenesis. IL-7 is an interleukin that has major functions in 
the regulation of T cell survival and differentiation23. We therefore were 
interested in the function of IL-7 during atherosclerotic lesion formation. A 
vector that contained the coding region for IL-7 receptor (CD127) was designed 
and used to create a DNA vaccine. Vaccinated LDL receptor deficient mice was 
performed and the effect of the vaccination on lesion formation was determined. 
Vaccination against this receptor for IL-7 severely increases the lesion burden in 
LDLr-/- mice by 300%. Lesions from vaccinated mice showed increased 
macrophage apoptosis and reduced numbers of regulatory T cells were found in 
the lymph nodes draining from the aortic arch. The increase in macrophage 
apoptosis was rather unexpected, as CD127 expression was mostly reported on T 
cells. We however showed that exposure of macrophages to oxLDL greatly 
increases the expression of CD127. As our vaccination strategy selectively targets 





Concluding remarks and future perspectives 
 
Upon review of the various aspects of this thesis, the question raises which 
therapeutic field will eventually become most promising for use in a clinical 
setting. The research in this thesis provides tools for inhibition of leukocyte 
migration, and interference with leukocyte activation. Both fields have their 
own pros and cons and this paragraph will discuss some of these considerations.  
 
Inhibition of leukocyte migration has been shown to be very effective in the 
attenuation of atherosclerosis. It must however be stated that leukocyte egress is 
essential in almost all inflammatory processes. Non selective inhibition of 
leukocyte migration will most likely interfere with essential defense 
mechanisms such as the clearance of pathogens. This especially is a problem 
when the treatment can not reversed, which is evedent with vaccinations. 
Vaccination against CD99 non selectively impairs leukocyte migration, and 
therefore its application may lead to clinical inflammatory complications. Ewing 
sarcoma’s however highly express CD99, have a very bad clinical outcome and 
are predominantly seen in very young children. In this patient population, 
vaccination against CD99 would be very beneficial and probably life saving. 
Inhibition of migration of a leukocyte subset, instead of the total population 
would erase some of the above stated risks. The inhibition of migration of 
CXCR3 and/or CCR5 positive cells potently decreased the formation of 
atherosclerotic plaques. These receptors are predominantly expressed on a small 
subset of T cells that have a clear pro-atherogenic effect. It was shown in 
literature that bacterial infections and viral infections in mice deficient for both 
receptors did not result in increased lethality24-27. This indicates that no large 
scale systemic immune suppression is reached during treatment with 
CCR5/CXCR3 antagonists. It was already mentioned that an additional property 
of CCR5/CXCR3 antagonists is their inhibitory effects on HIV replication. 
Treating HIV positive patients with these antagonists will therefore be hitting 
two birds with one stone28. The replication of the virus will be attenuated, but at 
the same time, severe cardiovascular side effects that are the result of the 
currently used protease inhibitors will be counteracted. 
This thesis has clearly shown that inhibition of the migratory properties of a 
specific subset of T cells can also have adverse effects. Vaccination against the 
CD4+ T cell migration factor IL-16 severely increased the lesion burden in later 
stages of atherosclerosis. However, no effects were visible during initial lesion 
formation. This shows that intervention in a signaling cascade can have 
differential effects at different time points of lesion formation. It implies that a 
drug or vaccination with significant beneficial effects on initial lesions can lead 
to destabilization of advanced plaques or the other way around. Evidently, 
plaque formation in humans is not a linear process, and plaques of different 
stages are present at the same time.  It is therefore of the utmost importance to 
identify the exact role of a molecule in initial as well as advanced lesions.  
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Not only minimizing migration of pro-atherogenic cells can provide protection 
against atherogenesis, inhibition of activated T cell signaling and co-stimulation 
can lead to attenuated lesion formation as well.  This was shown by antibody 
treatment against OX40 ligand. OX40L is expressed on antigen presenting cells, 
and binds to OX40 on activated T cells. Targeting OX40 positive T cells has a 
clear advantage above general immune-suppression since these cells are mainly 
associated with auto-inflammatory disorders. The selective suppression of the 
activation and proliferation of this subset has clinically relevant properties for 
atherosclerosis and other auto-immune diseases. Repression of co-stimulation 
may be preferred above stimulation of suppressive T cell subsets, as was shown 
by the administration of a CD28 antibody designed to boost T cell activation and 
the expansion of regulatory T cells.  Due to the lack of well designed pro-clinical 
experiments, 6 healthy volunteers that received this antibody developed severe 
clinical symptoms associated with major release of T cell cytokines and 
subsequent multiple organ failure29.  
 
Next to the specific de-activation of T cells, we determined the role of IL-7 
signaling in atherosclerosis. For this purpose, we developed a vaccination 
strategy to remove cells that expressed high levels of IL-7 receptor (CD127).  We 
designed this study to remove activated T cells and presumably to decrease 
lesion formation in this way. However, we found that macrophages show 
increased expression of this receptor as well, especially in the context of high 
levels of oxidized LDL. This was not documented yet, and the increase in lesion 
formation after vaccination against CD127 was at least partially due to increased 
macrophage apoptosis. This shows that a signaling pathway can be very well 
documented in a certain subset of cells, but completely ignored in the analysis of 
other relevant cell types.  
 
In conclusion, modulation of leukocyte activation and migration provides an   
attractive possibility for future drug design in the field of atherosclerosis. 
However, due to the complexity of immunological signaling cascades, extensive 
pre-clinical characterization is needed before these potential new drug 
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Hart en vaatziekten zijn de meest voorkomende doodsoorzaak in de westerse 
wereld.  De onderliggende oorzaak van infarcten en beroertes is voornamelijk 
het dichtslibben van de grote slagaders door middel van de vorming van een 
atherosclerotische plak, ook wel aderverkalking genoemd. De klinische 
manifestaties van atherosclerose zijn het gevolg van volledige blokkade van de 
bloeddoorvoer van het vat. Dit kan gebeuren doordat de plaque het volledige vat 
afsluit, maar ook na een eventuele scheuring van de plaque waardoor een 
blokkerend bloedstolsel ontstaat. In beide gevallen blijft achterliggende weefsel 
verstoken van voedingsstoffen en het meest desastreus, zuurstofrijk bloed. Op 
deze manier kan atherosclerose in de vaten in het hart leiden tot een myocard 
infarct, en een vernauwing van de vaten in de hersenen zorgen voor een 
beroerte. 
 
In de laatste 20 jaar is in kaart gebracht welke risicofactoren bijdragen aan het 
ontstaan van atherosclerose, en de meest belangrijke daarvan zijn verhoogde 
cholesterol waarden in het bloed, roken, hoge bloeddruk en weinig 
lichaamsbeweging. De huidige therapieën spitsen zich dan ook vooral toe op het 
verlagen van deze risicofactoren. Zo wordt een te hoog cholesterol gehalte in het 
bloed behandeld met statines, en wordt mensen aangeraden minimaal 30 
minuten per dag te bewegen. Dankzij grootschalige behandeling is de incidentie 
van hart en vaatziekten sterk gedaald, maar nog steeds vormen zij de 
belangrijkste doodsoorzaak in Nederland en in andere Westerse landen. 
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In de afgelopen tien jaar is het duidelijk geworden dat niet alleen hoge 
cholesterol waarden en roken een rol spelen in atherosclerose. Ook het immuun 
systeem blijkt betrokken te zijn bij de vorming van atherosclerotische plaques. 
De algemeen geaccepteerde theorie op dit moment is dat de binnenwand van het 
vat geactiveerd raakt door bijvoorbeeld roken, een hoge bloedruk, genetische 
aanleg of andere risicofactoren. De initiële activatie van de vaatwand zorgt 
ervoor dat de cholesterolvervoerende deeltjes in het lichaam, de lipoproteïnen, 
door de vaatwand heen kunnen migreren. Eenmaal binnenin de vaatwand 
aangekomen, worden deze deeltjes gemodificeerd. Daarnaast zorgt het 
geactiveerde bloedvat ervoor dat er immuuncellen worden aangetrokken om de 
beschadiging te verhelpen. Deze immuuncellen, in het bijzonder macrofagen 
zijn bijzonder geschikt voor het opruimen van allerlei ongewenste deeltjes, zoals 
bacteriën en dode cellen, maar ook de gemodificeerde lipoproteïnen. Naast 
macrofagen zijn ook T cellen betrokken in deze fase van atherosclerose. Deze 
cellen scheiden moleculen uit die het immunologische proces kunnen 
beïnvloeden. Er bestaan T cellen die remmend werken, maar ook T cellen die 
ervoor zorgen dat er meer ontstekingscellen worden aangetrokken, die 
vervolgens bijdragen tot de groei van de atherosclerotische plaque.  
 
In dit proefschrift worden verschillende experimenten beschreven waarin het 
ontstekingsproces dat plaatsvindt tijdens atherosclerose beïnvloed wordt. In 
hoofdstuk 1 worden de componenten van het immuunsysteem beschreven die 
een rol spelen bij atherosclerose. Er wordt eerst aandacht besteed aan moleculen 
die de aantrekking van immuuncellen (leukocyten) reguleren, de zogenaamde 
chemokines. Daarnaast worden moleculen besproken die een immunologische 
reactie kunnen versterken of afremmen, de zogenaamde interleukines. Als 
laatste wordt aandacht besteed aan de oppervlakte markers op leukocyten die 
gebruikt kunnen worden bij de activatie van de deze cellen.  
 
Omdat het proces dat leidt tot de vorming van atherosclerotische plaques nog 
lang niet volledig bekend is, hebben wij in hoofdstuk 2 dit (gedeeltelijk) in kaart 
gebracht en eventuele nieuwe eiwitten geïdentificeerd die als target kunnen 
dienen voor de toekomstige behandeling. Hiervoor werd een genetisch 
gemodificeerd muismodel gebruikt dat door middel van een Westers dieet dat 
hoog is aan vetten en cholesterol atherosclerose ontwikkeld. In deze muis is de 
receptor voor LDL, een pro-atherogeen lipoproteïne weggehaald, en op dit dieet 
ontwikkelt deze muis een menselijk lipoproteïnen profiel. De genregulatie in de 
vaatwand van deze muis is geanalyseerd op verschillende tijdspunten gedurende 
het vette dieet en vergelijken dit vervolgens met de genexpressie in de vaatwand 
van gezonde muizen.  
 
Niet alleen de vaatwand speelt een rol bij het ontstaan van atherosclerose maar 
ook de activatie en migratie van immuuncellen is hierbij betrokken. Naast de 
regulatie van de genexpressie in de vaatwand, wordt in hoofdstuk 3 de 
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genregulatie van T cellen gedurende een vetrijk dieet bestudeerd. Hierbij 
worden nieuwe moleculen en receptoren ontdekt die een eventuele rol spelen in 
de immunologische activatie gedurende het ontstaan van atherosclerose.  
 
Nadat in hoofdstuk 2 en 3 een inventarisatie is gemaakt van de mechanismen die 
betrokken zijn bij dieet geïnduceerde laesie vorming, hebben we in de volgende 
hoofdstukken verschillende therapeutische benaderingen geëxploreerd om de 
immunologische reactie te beïnvloeden. 
 
In hoofdstuk 4 wordt het effect van de toediening van een antagonist voor de 
chemokine receptoren CCR5 en CXCR3 beschreven. Deze receptoren bevinden 
zich hoofdzakelijk op de atherosclerose bevorderende T helper 1 cellen en zijn 
betrokken bij de migratie van deze cellen in de richting van een ontsteking. Het 
blokkeren van deze Th1 migratie leidde tot een vermindering in plaquevorming 
in LDL receptor deficiënte muizen. Deze vermindering wordt veroorzaakt 
doordat de migratie van de Th1 cellen naar de plaque volledig geblokkeerd is. 
Dit is onder andere aangetoond door een bijna totale afwezigheid van het pro-
atherogene Th1 cytokine interferon gamma in de plaques van de behandelde 
muizen.  
Een vergelijkbaar experiment is uitgevoerd met een specifieke antagonist van 
CXCR3. De resultaten van dit onderzoek zijn beschreven in hoofdstuk 5. Ook 
hier was duidelijk te zien dat een blokkade van CXCR3 het ontstaan van 
atherosclerotische plaques remt. Deze vermindering in plaque formatie blijkt het 
gevolg van een toename in lokaal aanwezige regulatoire T cellen. Deze T cellen 
zijn bijzonder efficiënt in het onderdrukken van een immuunrespons door het 
uitscheiden van anti-inflammatoire cytokines. De aanwezigheid van één van 
deze cytokines, TGFβ, was significant verhoogd in plaques van therapeutisch 
behandelde muizen. 
 
In hoofdstuk 6 beschrijven we voor de eerste keer de pro-atherogene rol van het 
onlangs geïdentificeerde molecuul CD99. CD99 is een receptor die zowel tot 
expressie komt op leukocyten als op het endotheel, de cellaag die de binnenkant 
van een bloedvat bekleedt. Interactie tussen CD99 op de immuun-cel met CD99 
op het endotheel is nodig voor de migratie van leukocyten naar de plaque. Een 
vetrijk dieet activeert het endotheel waardoor de expressie van CD99 verhoogd. 
De rol van CD99 in atherosclerose is vervolgens bestudeerd door een vaccin te 
genereren dat specifiek cellen met een hoge expressie van CD99 wegvangt. 
Wanneer LDLr deficiënte muizen gevaccineerd worden tegen CD99 
ontwikkelen ze 70 procent minder atherosclerose en daarnaast is de celdichtheid 
van deze plaques ook lager. 
 
In dit proefschrift wordt ook een vaccinatie beschreven tegen interleukine-16 
(IL-16) waarvan de resultaten zijn weergegeven in hoofdstuk 7. Dit molecuul 
induceert de migratie van een specifiek type T cel, de CD4 positieve T helper 
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cel. Omdat er in verschillende ziektemodellen een pro-inflammatoire werking 
voor IL-16 werd aangetoond, is een vaccinatieprotocol ontwikkeld om de functie 
van IL-16 te blokkeren in de LDL receptor deficiënte muis. Verrassend genoeg 
resulteert vaccinatie tegen IL-16 in een vermeerdering van atherosclerose, 
vooral in de verder gevorderde stadia van atherosclerose. De onverwachte anti-
atherogene rol voor IL-16 is mogelijk het gevolg van de late IL-16 gemedieerde 
aantrekking van regulatoire T cellen. Actief IL-16 kan namelijk alleen vrij 
komen nadat de pro-vorm door caspase-3 wordt geknipt. Dit enzym is essentieel 
in het aanzetten tot geprogrammeerde celdood, ook wel apoptose genoemd. Dit 
proces vindt hoofdzakelijk plaats in meer ontwikkelde atherosclerotische 
plaques. 
 
Niet alleen de migratie van leukocyten speelt een belangrijke rol in de vorming 
atherosclerotische plaques. Ook de activatie van deze cellen heeft invloed op de 
lokale immunologische respons. In dit proefschrift worden twee studies 
beschreven die de hypothese testen dat de activatie van pro-atherogene T cellen 
bijdraagt aan het atherosclerotische proces.  
Een van de moleculen die betrokken is bij de activatie van T cellen is OX40. Dit 
molecuul wordt tot expressie gebracht ongeveer 3 dagen na de initiële activatie 
van T cellen, en heeft een co-stimulatoire functie. In hoofstuk 8 wordt de 
blokkade van de interactie van OX40 met haar ligand OX40L dat voorkomt op 
antigen-presenterende cellen zoals B cellen en macrofagen beschreven. 
Toepassing van een selectief antilichaam tegen OX40 ligand leidt tot een 
reductie in atherosclerose in LDL receptor deficiënte muizen. Deze reductie 
wordt veroorzaakt doordat de interactie tussen geactiveerde Th2 cellen en B 
cellen niet meer functioneert. Deze B cellen blijven daardoor beschermende IgM 
antilichamen tegen geoxideerd LDL aanmaken wat resulteert in verminderde 
atherosclerose. 
 
IL-7 is een interleukine dat bijdraagt aan de activatie en differentiatie van T 
cellen. Omdat de rol van IL-7 in het proces van atherosclerose nog niet 
onderzocht is, hebben wij een vaccinatie ontwikkeld tegen de receptor van IL-7, 
CD127 (IL7R). De resultaten van deze experimenten staan beschreven in 
hoofdstuk 9. Expressie van de IL-7 receptor was beschreven op T cellen, en de 
vaccinatie was zo ontworpen dat deze zou moeten leiden tot de verwijdering 
van T cellen met een hoge expressie van IL-7R. Uit onze experimenten bleek dat 
niet alleen T cellen, maar ook macrofagen een zeer hoge expressie hebben van 
CD127, vooral nadat ze worden blootgesteld aan geoxideerd LDL. Deze 
blootstelling aan geoxideerd LDL zal in het bijzonder het geval kunnen zijn in 
de atherosclerotische plaque. Vaccinatie tegen IL-7R resulteerde dan ook in 
verhoogde apoptose van macrofagen in de plaque, en een toegenomen 
plaquegroei in LDL receptor deficiënte muizen. Daarnaast was ook het aantal 
regulatoire T cellen in de buurt van de plaque verlaagd, wat nog verder bijdraagt 




Het onderzoek dat beschreven staat in dit proefschrift heeft verschillende 
nieuwe targets opgeleverd die een aanknopingspunt kunnen vormen voor de 
ontwikkeling van nieuwe medicijnen tegen atherosclerose. Naast deze nieuwe 
targets is ook aangetoond dat door middel van vaccinaties, eenvoudig en snel de 
rol van een nieuw molecuul of receptor in het proces van atherosclerose 
onderzocht kan worden. De resultaten dragen bij aan een beter inzicht in de 
gecompliceerde processen die ten grondslag liggen aan de vorming van een 
atherosclerotische plaque, en met name in de immunologische component 
hiervan. Het toegenomen inzicht in de interactie tussen verschillende 
immunologisch actieve cellen in atherosclerose zoals beschreven in dit 
proefschrift, zal leiden tot een meer doelgerichte therapeutische utilisatie van 
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Appendix 1: List of PCR primers 
GENE REVERSE  PRIMER FORWARD  PRIMER 
36B4 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 
ABCB10 CAGAAACGTGCACTTCACATACC GATGGAAAGACTGAAATCCTGGA 
CCL8 AGCTACGAGAGAATCAACAATATCCA CAGAGAGACATACCCTGCTTGGT 
CCR2 CCTTGGGAATGAGTAACTGTGTGA TGGAGAGATACCTTCGGAACTTCT 
CCR3 TGCAGGTGACTGAGGTGATTG CGGAACCTCTCACCAACAAAG 
CCR5 GACTGTCAGCAGGAAGTGAGCAT CTTGACGCCAGCTGAGCAA 
CD 4 GTGAGCTGGAGAACAGGAAAGAG GGCTGGTACCCGGACTGA 
CD127 TACCGTGAGCGACAAAGATG GCTGAATCATTGGGTCACCT 
CD134 GCCTTCAAAGAACTACCTAGGGACTATG GCTCTCCTGGTTTTCTTTGCA 
CD25 GGAGCCGCAAGCTAAAAGC TGCCTTCGTGCCCACTGT 
CD28 AGACTCCTTCAAGTGACTACCATGAAC GGGCTGGTAAGGCTTTCGA 
CD40 GGTAAGATGGCTTTTGTGGGTAAA GAAGTCCCAGGGATCAAAATCA 
CD68 CCTCCACCCTCGCCTAGTC TTGGGTATAGGATTCGGATTTGA 
CD69 AAAGCACGAGCGATCCAGTTA AGAAAAT AATTCGTTCCTCACCAACTA 
CD99 GCCGCTGCATCAGTGATG TTGTGAGTGGAGGTTATGATGTCA 
CTLA-4 GGACCACAAAGGGCTTGATC CGAGGTCCTGCACCAACTG 
CXCL10 GGATGGCTGTCCTAGCTCTGTAC CCTGGGCATGGCACATG 
CXCR3 GCTGCTGTCCAGTGGGTTTT AGTTGATGTTGAACAAGGCGC 
FOXP3 GGAGCCGCAAGCTAAAAGC TGCCTTCGTGCCCACTGT 
GITR GCCCTATGGCTGCCTTTCTC GCTAAACGTGGTGCTCTTGGT 
HMGcoAred. TCTGGCAGTCAGTGGGAACTATT CCTCGTCCTTCGATCCAATTT 
HPRT TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 
IFNγ ATAACTATTTTAACTCAAGTGGCATAGATG T TCT GGC TCT GCA GGA TTT TCA 
Il-10 TCTTACTGACTGGCATGAGGATCA GTCCGCAGCTCTAGGAGCAT 
Il-12 GACCAAAGGGACTATGAGAAGTATTCA CTGCTGCCGTGCTTCCA 
IL-16 AGGCAACGAGGTTCTTTCCA CCGAGCTTGGCGAAGGATA 
IL-17 CCAGGGAGAGCTTCATCTGTGT AAGTCCTTGGCCTCAGTGTTTG 
Il-1β TGG TGT GTG ACG TTC CCA TTA AGGTGGAGAGCTTTCAGCTCATAT 
IL-2 TGCCAATTCGATGATGAGTCA GGCTTGTTGAGATGATGCTTTG 
IL-4 ACTTGAGAGAGATCATCGGCATTT AGCACCTTGGAAGCCCTACAG 
IL-6 GAAGAATTTCTAAAAGTCACTTTGAGATCTA CAC AGT GAG GAA TGT CCA CAA AC 
Il-9 CCGTGCTACAGGGAGGGA TGGAAAACAGGCAAGAGTCTTG 
MCP-1 GCATCTGCCCTAAGGTCTTCA TTCACTGTCACACTGGTCACTCCTA 
MIP-1α CCAGGGTTCTCAGCACCAAT CTTCTCTGGGTTGGCACACA 
RANTES GCAAGTGCTCCAATCTTGCA CTTCTCTGGGTTGGCACACA 
TGFβ AGGGCTACCATGCCAACTTCT GCAAGGACCTTGCTGTACTGTGT 
TNFα GCCAGCCGATGGGTTGTA AGGTTGACTTTCTCCTGGTATGAG A 





Appendix 2: Abbreviations 
 
36B4  acidic ribosomal phosphoprotein PO 
Ab   antibody 
ABC  ATP binding casette 
APC   antigen presenting cell 
apoE/apoB   apolipoprotein E/apolipoprotein B 
CCR/CXCR   CC/CXC chemokine receptor 
CCL/CXCL   chemokine ligand 
CD    cluster of differentiation 
CMV    Cytomegalovirus 
CTLA    cytotoxic T-lymphocyte antigen 
CVD    cardiovascular disease 
DC    dendritic cell 
EAE    experimental acquired encephalomyelitis 
FABP  fatty acid binding protein 
FACS    fluorescent-activated cell sorting 
FMLP  formyl-met-leu-phe 
Foxp3    forkhead box p3 
GFP    green-fluorescent protein 
GSEA  gene set enrichment analysis 
HDL    high-density lipoprotein 
HMG-coA 3-hydroxy-3-methylglutaryl coenzyme A 
HPRT  hypoxanthine-guanine phophoribosyltransferase 
ICE  interleukin-1β converting enzyme 
i.p.    intraperitoneal 
i.v.   intravenous 
ICAM-1   intercellular adhesion molecule-1 
IFN    interferon 
Ig    immunoglobulin 
IL    interleukin 
IP-10  interferon γ inducible protein 
ITAC  interferon γ inducible T cell α-chemoattractant 
(ox)LDL   (oxidized) low-density lipoprotein 
LDLr    low-density lipoprotein receptor 
LPS    lipopolysaccharide 
MCP-1    monocyte chemotactic protein 
MHC    major histocompatibility complex 
MIG  monokine induced by interferon γ 
MIP-1  macrophage inflammatory protein-1 
MMP   matrix metalloproteinase 
NFAT  nuclear factor of activated T cells 
NF-κB    nuclear factor κB 
NK    natural killer 
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NKT cell  natural killer T cell 
oxLDL    oxidized low-density lipoprotein 
PBS   phophate buffered saline 
PPAR  peroxisome proliferators-activated receptor 
RANTES regulated on activation, normal T cell expressed and secreted 
SMC    smooth muscle cell 
SR    scavenger receptor 
TCR    T cell receptor 
TGFβ   transforming growth factor β 
Th1/Th2   T helper 1/T helper 2 
TNF    tumor necrosis factor 
Tr1    regulatory T cell type 1 
Treg    regulatory T cell 
TUNEL  terminal deoxynucleotidyl transferase end-labeling 
VCAM-1   vascular cell adhesion molecule-1 
VLDL    very low-density lipoprotein 
 
 
